text stringlengths 65 123k | url stringlengths 25 420 | crawl_date timestamp[us, tz=UTC]date 2022-04-01 01:00:57 2022-09-19 04:34:04 |
|---|---|---|
A new international study estimates that from January 1, 2020, to May, 1, 2022, nearly 8 million kids age 18 and under lost a parent or primary caregiver to a pandemic-related cause. When the researchers included the deaths of secondary caregivers like grandparents or other older relatives, the number of kids affected rose to 10.5 million.
That's a big jump from the prior estimate of 5.2 million children who lost a parent or caregiver to COVID-19 from the start of the pandemic until Oct 31, 2021.
The findings are "heartbreaking and disturbing," says Susan Hillis, the main author of the new study, and a co-chair of the Global Reference Group on Children Affected by COVID-19 and Crisis, an international team that's been tracking the indirect toll of the pandemic on children.
Some nations are beginning to address these catastrophic losses with new programs that offer support to the bereaved families – although the U.S. lags in this effort.
Why have estimates gone up?
Asked why the numbers are far higher than previously thought, Hillis answers: "Part of the increases are because we just have more accurate death data on which to model our estimates. And of course, the other aspect of the increases is that deaths have continued."
The study, published in JAMA Pediatrics, also found that the greatest numbers of kids affected by these losses were in Africa and Southeast Asia. India has seen the most suffering, with 3.5 million children grieving the loss of a parent or primary/secondary caregiver. However, Bolivia and Peru have the highest rates of kids affected, with 1 out of every 50 children in both countries losing caregivers during the pandemic.
These children face potentially devastating consequences. The emotional toll may be what people think of first but the impact hits many areas of a child's life.
"This enormous bereavement is an economic loss," explains Lorraine Sherr, a psychologist at the University College London, and a member of the Global Reference Group, who wasn't involved in the latest estimates.
That's especially true when the parent or primary caregiver who died was the main breadwinner in the family. A family's loss of income can put kids at a higher risk of food and housing insecurity.
If a child moves to a new community or family because of the death of a parent, "it's a separation," she says. "And then there's disengagement at school and then disengagement with friendships, with things previously that made them happy or helped them learn. So you have this kind of huge cascade of losses."
Bereavement is one of the top predictors of poor outcomes at school, says psychologist Julie Kaplow, executive vice president of trauma and grief programs at the Meadows Mental Health Policy Institute.
Studies also point to the lasting mental and physical health impacts from losing a parent or caregiver.
"It increases the risk of mental health problems, suicide, prolonged grief complications, sexual exploitation and abuse, even physical abuse of children," says Hillis.
Finding ways to help bereaved children
Many countries and organizations are finally recognizing the urgent need to help children and families deal with this loss, says Sherr.
"Some efforts are being put in place, especially in South Africa, in Eswatini and Kenya and Botswana," says Joel-Pascal Ntwali N'konzi, a co-author of the new study and a researcher at the African Institute for Mathematical Sciences in Kigali, Rwanda. In South Africa and Eswatini, 1 in 100 children have lost a parent or caregiver.
Sometimes the solution is in the form of cash aid.
Providing cash payments to such families can ensure that families can afford school fees in countries where education comes with a price tag. N'konzi and his co-authors are hopeful that other countries will join these efforts.
The World Bank is also looking into providing countries with funding for "cash plus care initiative," says Sherr.
"That means that you provide the family with a stipend or a small cash injection, but you twin that with care — some kind of social support services, linking to school and education."
These kinds of support programs would also connect bereaved families with grassroots organizations or nonprofits that can provide mental health care and psychological support to children and the surviving parent or caregivers.
Past research on children orphaned by the HIV-AIDS epidemic shows that such efforts can buffer the impact of the trauma on kids, says Sherr, who has done research on this topic.
"We looked at educational risk, things like missing school, dropping school year achievement," she explains. "We looked at emotional outcomes such as depression, stress, identity, anxiety, trauma. We also looked at positive outcomes like coping and resilience."
She says projects that included cash transfer plus connection to community-based supports and services improved these outcomes among grieving children.
However, there have been no federal efforts to address the crisis here in the United States, notes Rachel Kidman, a social epidemiologist who has studied the long-term impacts of the HIV-AIDS epidemic on children. The new study found that more than 250,000 American children had lost a parent or caregiver due to the pandemic as of May 1, 2022.
And yet, says Kidman, who was not involved in the new research: "I'm not seeing any concerted efforts or even a lead by the federal government" to address the needs of these children."
Copyright 2022 NPR. To see more, visit https://www.npr.org. | https://www.wyomingpublicmedia.org/2022-09-06/nearly-8-million-kids-lost-a-parent-or-primary-caregiver-to-the-pandemic | 2022-09-07T10:42:28Z |
Skateboarders in Philadelphia claimed a prize from a park in New York City: a green bench known among skaters for its smooth parabolic curve.
Copyright 2022 NPR
Skateboarders in Philadelphia claimed a prize from a park in New York City: a green bench known among skaters for its smooth parabolic curve.
Copyright 2022 NPR | https://www.wyomingpublicmedia.org/2022-09-07/a-bench-perfect-for-skateboarding-moves-across-the-country-frequently | 2022-09-07T10:42:37Z |
Eebbers was the oldest working dog in the agency and was assigned to the Minneapolis-Saint Paul International Airport. He recently won first place in the TSA's cutest K9 contest.
Copyright 2022 NPR
Eebbers was the oldest working dog in the agency and was assigned to the Minneapolis-Saint Paul International Airport. He recently won first place in the TSA's cutest K9 contest.
Copyright 2022 NPR | https://www.wyomingpublicmedia.org/2022-09-07/after-10-years-as-an-explosive-detection-dog-for-the-tsa-eebbers-is-retiring | 2022-09-07T10:42:43Z |
The strain on the power grid is leading to outages in some parts of the state and is putting vulnerable residents at risk. Other western states are also baking under the historic heat.
Copyright 2022 NPR
The strain on the power grid is leading to outages in some parts of the state and is putting vulnerable residents at risk. Other western states are also baking under the historic heat.
Copyright 2022 NPR | https://www.wyomingpublicmedia.org/2022-09-07/an-intense-heat-wave-in-california-is-stressing-the-states-power-grid | 2022-09-07T10:42:50Z |
The puss caterpillar bears a striking resemblance to Cousin Itt from the Addams Family, a fuzzy little bug that one can't help but want to touch. However, beneath its hairy surface are poisonous barbs that pack a powerful sting, which can result in days and even weeks of pain.
One of the most venomous caterpillars in the U.S., the puss can be found feasting on foliage in states between New Jersey and Florida and as far west as Texas. Most encounters typically occur when the caterpillar accidentally falls out of a tree or when people are removing leaves from around their home.
A puss caterpillar stung the manager of Virginia Tech's Insect ID Lab, Eric Day, when he accidentally brushed up against a tree while mowing his lawn in rural Virginia. He said it resulted in a burning sensation and a blister about an inch long at the sting site.
"The burning sensation went away in a day or so, but that blister and then subsequent kind of irritated area was visible for several weeks," he recalled.
The caterpillar can grow to a little over 1 inch long and is covered in gray and orange hairs, which have venom glands at the base, according to the University of Florida's Institute of Food and Agricultural Sciences. It's commonly found in Florida but is most abundant in Dallas and southern parts of Texas.
The level of pain caused by the caterpillar's sting varies from person to person, but entomologist Molly Keck of the Texas A&M AgriLife Extension Service said the venom can be dangerous to individuals who suffer from extreme reactions to insect bites.
"Some may just have localized discomfort that lasts for just a short period of time. Others could have something as severe as anaphylaxis or needing to seek medical attention," Keck told NPR.
She said the caterpillars can be found most often in the fall and spring, when people are spending time outdoors.
If you happen to get stung by the caterpillar, the National Capital Poison Center recommends using tape to remove the hairs and then gently washing the area with soap and water. If the sting site begins to itch, use hydrocortisone cream or a baking soda and water paste for relief.
If the pain worsens, seek out medical attention, Keck said. The sting has been known to cause anaphylaxis in rare instances, which can be life threatening.
Copyright 2022 NPR. To see more, visit https://www.npr.org. | https://www.wyomingpublicmedia.org/2022-09-07/despite-its-innocently-furry-appearance-the-puss-caterpillars-sting-is-brutal | 2022-09-07T10:42:56Z |
The 2022 Venice Film Festival started a little over a week ago, and one film has dominated much of the conversation — not because of its cinematography, editing or script, but because of reported behind-the-scenes drama that's stolen the spotlight.
Don't Worry Darling is director Olivia Wilde's second feature film, following her 2019 debut, Booksmart. The movie, which stars Florence Pugh, Harry Styles, Chris Pine, Gemma Chan and Wilde herself, premiered on Monday at the festival and is scheduled for wide release on Sept. 23.
The film is a psychological thriller set in the 1950s, in the fictional town of Victory, Calif. Pugh and Styles play Alice and Jack, a married couple who live in the town, which was built by the company Jack works for. As Alice tries to learn more about her community, tensions begin to arise between her and her new neighbors.
Reportedly, the production of the film had also been filled with tension, and interactions between the stars at Venice left the internet to speculate wildly.
"Some aspects of the unfolding interpersonal drama definitely appear like an unwieldy mess," Nicholas Baer, Assistant Professor of Media, Arts & Society at Utrecht University, told NPR. "So although it's always tricky to gauge intentionality, I'd imagine it's a combination of 'authentic' drama and savvy image manipulation."
The memes begin at the Venice Film Festival
On Monday morning ahead of the premiere, Wilde and the film's stars participated in a press conference — most of them, that is. Absent from the panel was Pugh, who flew to Italy from Budapest where she had been filming the sequel to Dune. Festival representatives told Variety that her nonattendance was because her flight to Italy wouldn't land until after the presser had taken place.
Pugh has not spoken much about the film on social media or to press since it finished filming, which has led to speculation that she did not enjoy her time on set.
The press had many questions for Wilde regarding her working relationship with Pugh and, in response, the director praised the actress for her work. "I can't say how honored I am to have her as our lead. She's amazing."
When asked about working on the film, Harry Styles — who is dating Wilde — gave a response that the internet is still trying to understand: "The thing I like about the movie is that it feels like a movie." Chris Pine's reaction to this moment birthed memes that would pave the way for many more to come.
“i wanna goooooo hooooooooooooommmmeeee”
— Andy Dandy Shitpost (@ANDYdrewME) September 5, 2022
pic.twitter.com/s1DLcRVkUX
somebody get chris pine outta there #Venezia79 pic.twitter.com/zmYxmvpbka
— bethany (@fiImgal) September 5, 2022
Florence Pugh toasts the internet
Pugh later arrived at the festival in time for the film's red carpet premiere. In a video originally posted to Instagram, Pugh was seen toasting the camera while carrying an Aperol Spritz in a purple Valentino ensemble — a carefree look that sparked yet more buzz.
florence pugh avoiding the conference and its drama at the venice film festival and enjoying a spritz. this is what i call iconic behaviour, no one is doing it like her pic.twitter.com/G7iPdXp45N
— fra🍂🫧 | #1 kit connor protector (@goldenheartvhes) September 5, 2022
Across the great divide on the red carpet
The night of the film's premiere began relatively lightheartedly, with Chris Pine taking pictures of Florence Pugh on the red carpet.
Chris Pine being supportive and taking photos of Florence Pugh on the ‘Don't Worry Darling’ red carpet at the 79th Venice International Film Festival. (September 5th, 2022)
— Chris Pine Daily (@cpinedaily) September 5, 2022
📸: Daniele Venturelli#ChrisPine #FlorencePugh #DontWorryDarling #Venezia79 pic.twitter.com/bcbiyGc6N1
But then, as the cast began getting ready for a group photo on the red carpet, it appeared that Pugh, Wilde and Styles were strategically separated by fellow actors Pine, Chan, Sydney Chandler and Nick Kroll.
Additional photos of the cast and director at the ‘Don't Worry Darling’ red carpet at the 79th Venice International Film Festival (September 5th, 2022)
— Chris Pine Daily (@cpinedaily) September 5, 2022
📸: Kate Green & Daniele Venturelli#ChrisPine #FlorencePugh #HarryStyles #GemmaChan #OliviaWilde #Venezia79 pic.twitter.com/R7pjpNLIjN
Could all of this be a PR stunt? Experts weigh in
Internet speculation didn't stop once the cast went into the theater. The actors were placed in a seating arrangement closely resembling the cast photo, and Chris Pine once again continued his run at the top of the meme leaderboard as he put on his sunglasses just as the lights went down in the theater.
chris pine putting on his sunglasses as the lights cut… oh that man is taking a nap https://t.co/e1fN4EXFfs
— mirrorball 🛋 (@tracesofswift) September 5, 2022
This brings us to a hotly debated moment between Harry Styles and Chris Pine. In a video circulated on social media, Styles approached his seat next to Pine and appeared to lean slightly over, with his lips moving in a puckering motion—then, a moment where Pine stopped clapping, looked down at his lap and laughed. The suspicious movement around Styles' mouth made some wonder: Did Harry Styles spit on Chris Pine?
Although Pine's publicist told People that such claims are "complete fabrication," the video regardless sent the internet into an uproar of jokes, takes and slo-mo'ed video. Analyzing the videos of #Spittake, as some users have put it, has become the Zapruder film of Twitter.
Analyzing that video of Harry Styles and Chris Pine like it's the zapruder film
— Dana Schwartz (@DanaSchwartzzz) September 6, 2022
The film has generally not been well received by critics, and there continues to be heavy speculation online that all of this press has been drummed up to help create a buzz for the film.
Olivia Wilde’s “Don’t Worry Darling” is currently receiving bad reviews with Florence Pugh and Harry Styles receiving praise for their performance. pic.twitter.com/OQETYES6vd
— Pop Tingz (@ThePopTingz) September 5, 2022
"As a communications guy, my gut reaction to this kind of thing when it is on an international stage is that it is all about getting attention," says film and media historian Chris Yogerst. "Of course, we learned there was more to the story with the notorious Oscars slap. That may be the case here as well, but because there were many smiles all around, my guess is that this is a PR move or an inside joke of some kind."
A lot of speculation and confusion surrounds what is really going on behind the scenes in the movie, which runs parallel with themes seen in the film, Baer said —"a focus on polished appearances and the cracks in attractive facades."
Copyright 2022 NPR. To see more, visit https://www.npr.org. | https://www.wyomingpublicmedia.org/2022-09-07/does-controversy-sell-movie-tickets-the-cast-of-dont-worry-darling-might-find-out | 2022-09-07T10:43:03Z |
It's a move seen as retaliation by the Kremlin for western sanctions on Russia over its invasion of Ukraine. The energy crisis is not limited to Europe as other countries are also feeling the impact.
Copyright 2022 NPR
It's a move seen as retaliation by the Kremlin for western sanctions on Russia over its invasion of Ukraine. The energy crisis is not limited to Europe as other countries are also feeling the impact.
Copyright 2022 NPR | https://www.wyomingpublicmedia.org/2022-09-07/european-energy-prices-soar-after-russia-cuts-off-a-natural-gas-pipeline-to-germany | 2022-09-07T10:43:09Z |
Across the Midwest, farmland prices more than doubled over the past two years — making it difficult for young farmers to grow their businesses.
Copyright 2022 Iowa Public Radio
Across the Midwest, farmland prices more than doubled over the past two years — making it difficult for young farmers to grow their businesses.
Copyright 2022 Iowa Public Radio | https://www.wyomingpublicmedia.org/2022-09-07/farmland-prices-are-up-sharply-how-did-it-get-so-expensive | 2022-09-07T10:43:16Z |
NPR's A Martinez talks to Ronnye Stidvent, head of the Center for Women in Law in Texas, about voter registration rising among women after the Supreme Court decision to roll back abortion rights.
Copyright 2022 NPR
NPR's A Martinez talks to Ronnye Stidvent, head of the Center for Women in Law in Texas, about voter registration rising among women after the Supreme Court decision to roll back abortion rights.
Copyright 2022 NPR | https://www.wyomingpublicmedia.org/2022-09-07/more-women-are-registering-to-vote-how-could-that-affect-midterms | 2022-09-07T10:43:22Z |
The latest on a Russian-controlled nuclear power plant in Ukraine. The Western U.S. bakes under historic heat wave. On Brazil's Independence Day, President Bolsonaro plans to flaunt his military ties.
Copyright 2022 NPR
The latest on a Russian-controlled nuclear power plant in Ukraine. The Western U.S. bakes under historic heat wave. On Brazil's Independence Day, President Bolsonaro plans to flaunt his military ties.
Copyright 2022 NPR | https://www.wyomingpublicmedia.org/2022-09-07/morning-news-brief | 2022-09-07T10:43:29Z |
President Bolsonaro is urging supporters to take to the streets for Independence Day. This may be a precursor to more verbal attacks on democratic institutions ahead of next month's elections.
Copyright 2022 NPR
President Bolsonaro is urging supporters to take to the streets for Independence Day. This may be a precursor to more verbal attacks on democratic institutions ahead of next month's elections.
Copyright 2022 NPR | https://www.wyomingpublicmedia.org/2022-09-07/on-independence-day-brazils-president-plans-to-flaunt-his-military-ties | 2022-09-07T10:43:35Z |
Netta is an international pop star. She won the Eurovision Song Contest for her home country of Israel back in 2018, and she's become known for her eye-catching outfits and quirky dance moves.
Copyright 2022 NPR
Netta is an international pop star. She won the Eurovision Song Contest for her home country of Israel back in 2018, and she's become known for her eye-catching outfits and quirky dance moves.
Copyright 2022 NPR | https://www.wyomingpublicmedia.org/2022-09-07/playground-politica-is-an-ode-to-popstar-nettas-childhood-in-nigeria | 2022-09-07T10:43:41Z |
LEON, Mexico — I'm at a concert in Leon, the largest city in the Mexican state of Guanajuato — a region with a rich, but tragic history. The land surrounding this concert was once the epicenter of global silver production in the 18th century, when tens of thousands of Indigenous families were forced to toil in its deadly mines.
Fast forward a couple of centuries, and the descendants of those people that kept the global economy churning for so long are now gathering to be entertained by a musical legend.
The Puerto Rican rapper, Residente, is recognized for being a groundbreaking, genre-bending artist. But he's also known as a leader in Latin American political thought who is well versed in the region's history.
"He has a little bit of everything: Fun lyrics and a more political side, but he's able to combine them very well," says long-time fan Abraham Morales at the concert.
Residente has been making hits for more than 15 years; first as the vocalist for the hip hop group Calle 13, and now as a solo artist. He's sold millions of albums and holds the record for most Latin Grammy Awards with 27.
At concerts like this one in Leon, Residente's fans sing along to every song, from the biggest hits to the most obscure, middle-of-the-album songs. His cult-like following keeps him on the concert trail, even though he hasn't dropped an album since his solo debut in 2017. I asked Residente where he sees himself right now.
"I'm writing for fun," Residente tells me. "I'm tired of touring. I like the people. I hate flying."
"Sometimes I enjoy the concerts and sometimes I don't enjoy them at all."
Residente, 44, says he's reached a reflective point in his life. This shines through in his 2020 single "René." In it, he discusses the killing of his childhood best friend at the hands of Puerto Rican police, his struggles with depression and alcohol, and his recent divorce.
"Nobody believed that it was going to be a hit because it's eight minutes," Residente says. "And it went viral and everyone liked it and everyone was listening to it, and it's eight minutes — and it's just me over a piano."
"René" became a surprise smash for Residente – its music video has more than 260 million views on YouTube. It was supposed to be the first song off of his new album, but then the pandemic hit, and things got delayed. As of now, he's hoping to release this new album by the end of the year, and to do a proper tour in 2023.
While some of Residente's recent music is autobiographical, he has also begun battling rival rappers in highly publicized duels.
"But then I learned, man, I'm not going to be all my life answering to all these people," Residente says.
But he isn't following his own advice. Just last week, he responded to a diss track by fellow Puerto Rican rapper, Cosculluela, by releasing his response two days later. At time of publication, "Cosquillita" has nearly 8 million listens on YouTube, just three days after the song was released.
Although battling rappers is a scuffle that Residente thoroughly enjoys, most of his energy has been expended on much larger opponents — social phenomena in Latin America, particularly economic inequities, political persecution, and the often hostile role that the United States has played in the region.
"This is Not America" continues in this tradition by questioning the United States' adoption of the word "American."
"Everyone is American on this continent," Residente says. "And it's how they took the word and made it for them," he adds. "It's like another way of colonization."
The video for "This is Not America" gorily depicts the violence inflicted by U.S.-backed regimes in Argentina, Chile, and Colombia, as well as the CIA-directed death squads who massacred entire communities throughout Central America.
Note: This music video includes graphic depictions of violence that some might find objectionable.
"All the things I'm presenting are the collateral damages that the U.S. created in Latin America," Residente says.
Puerto Rico, a U.S. territory and Residente's home country, is always at the forefront of his mind when he writes and performs. As a result, he says he's received death threats and that he was even banned from performing on the island.
"I know I opened a door for artists to say things," Residente states. "I said to Luis Fortuno, 'He's a motherf*****,'" Residente asserts, speaking of Puerto Rico's former governor. "I got censored for four years. (Bad Bunny) said the same thing a week or two ago, and he was a hero. But at the time that I said it, maybe people weren't ready for that."
Today, it appears that Puerto Rico is ready. After decades of registering just 5% or less of gubernatorial votes, the two independence-minded parties on the island combined to reach nearly a third of votes in the 2020 general election.
And if recent viral videos of protests on the island are any indication, the nationalist movement only seems to be gaining momentum. I asked Residente whether he thinks he'll see the day when Puerto Rico is an independent country, something he's yearned for throughout his adult life.
"I think so," Residente says. "Now more than ever, it's right there, knocking at the door."
Whether or not that day does come, Residente seems determined to keep pushing for it. In the meantime, his fans will continue to sing along.
Copyright 2022 NPR. To see more, visit https://www.npr.org. | https://www.wyomingpublicmedia.org/2022-09-07/puerto-rican-rapper-residente-is-challenging-the-definition-of-america | 2022-09-07T10:43:48Z |
The morning of November 14, 1960, a little girl named Ruby Bridges got dressed and left for school.
At just six years old, Ruby became the first Black child to desegregate the all-white William Frantz Elementary School in New Orleans.
Federal marshals had to escort Ruby, as she was faced with throngs of angry white protestors restrained by barricades.
Today, she is a civil rights activist and author, with her most recent children's release, I Am Ruby Bridges: How one six-year-old girl's march to school changed the world, telling the story of that day, with illustrations by Nikkolas Smith.
She joined All Things Considered to share more about her experience, and what today's children can learn from what she endured.
This interview has been lightly edited for clarity and length.
Interview Highlights
On what she knew that day in 1960
Well, not much. I had already attended an all-Black school for kindergarten and thought I knew enough about school to sort of understand that I was merely going to a new school.
I had no idea that it was going to be a white school. It wasn't something that my parents explained to me. As a matter of fact, the only thing they said is, "Ruby, you're going to go to the school today and you better behave." I have to say that that's what I was concentrating on, right? Not behaving, being on my best behavior.
I did not have a clue [about why people were yelling]. But I have to say, living in New Orleans all my life and even then, I was accustomed to Mardi Gras. And that's exactly what it looked like to me. White people, Black people all lined up together, shouting and waving their hands and throwing things. And so I actually thought we would see a parade.
On her experiences at William Frantz Elementary, including being the only child in her class
When I arrived on the first day, the mob of people standing outside rushed inside of the building behind me. I was escorted to the principal's office where I sat the whole day with my mom, waiting to be assigned to a classroom. But that did not happen because every one of those parents rushed in behind me, went into every classroom, and they pulled out every child. I watched them parade right past me out of the school building. And so by the time I got there on the second day, the school was totally empty.
I think part of the story that lots of people are not aware of is that there were some white parents who actually tried to cross that same picket line, that same mob, during that year, to bring their kids to school with me. But even when that happened, it was only a handful, maybe five, six kids. And the principal would take them and she would hide them so that they would never see me and I would never see them. So needless to say, I spent the entire year in an empty classroom with my teacher, Mrs. Henry, who was white. She had come from Boston to teach me. But those other kids were hidden away and we never really came in contact with each other.
I remember hearing voices, but I never saw kids and it kept me wondering where the voices were coming from. If they were real at all. What I did not know is that every time I would mention it to Mrs. Henry, she would go to the principal and advocate for me. She was saying, "The law's changed and kids can be together now, but you're hiding them from Ruby. If you don't allow them to come together, I'm going to report you to the superintendent." And that forced them to allow Mrs. Henry to take me to where they were being hidden. And that was near the end of the year.
On understanding why others treated her differently
When Mrs. Henry took me to this other classroom and opened the door, and lo and behold, there they were four or five kids sitting there playing, I was so excited. It didn't matter to me what they looked like. I just wanted someone my own age to play with, so I was excited to find them finally.
I have to say that that was the day that I realized that everything was about me and the color of my skin, because a little boy said, "I can't play with you. My mom said not to play with you." And he called me the N-word. And that's when I had my "Aha" moment. The reason why there were no kids here was because of me and the color of my skin. He actually made it make sense. I did not realize what was going on around me until he told me. And that was my first encounter with racism. He introduced it to me.
On passing down her lessons to future generations
You know what I've found in the past 25 years, visiting schools and talking to kids and working with them? I think that they relate to the loneliness. They relate to someone not wanting to play with you, for no real good reason, not giving you a chance. It resonates with them and they don't quite understand why someone would do that, why someone would treat another person like that.
What I find is that kids always say, "They didn't want to play with me" and, "I wasn't invited to the party," because of whatever the reason may be. So there are some things in the book that I think they connect to, and I think that they feel like, "You know what? Why don't we give each other a chance, try to get to know each other?"
Everyone at that age wants a friend to play with. And I think that's part of what they resonate with, the fact that it's also explaining a time in history when we couldn't be together. It touches on some of the things that I truly want them to understand, that racism just does not make any sense. And they get that. Once this book is closed and I know that they've gotten that, then I feel like part of my work is done.
Copyright 2022 NPR. To see more, visit https://www.npr.org. | https://www.wyomingpublicmedia.org/2022-09-07/ruby-was-the-first-black-child-to-desegregate-her-school-this-is-what-she-learned | 2022-09-07T10:43:54Z |
The water in Jackson, Miss., is still not safe to drink. NPR's A Martinez talks to Mayor Chokwe Antar Lumumba about the the city's water infrastructure which is deficient.
Copyright 2022 NPR
The water in Jackson, Miss., is still not safe to drink. NPR's A Martinez talks to Mayor Chokwe Antar Lumumba about the the city's water infrastructure which is deficient.
Copyright 2022 NPR | https://www.wyomingpublicmedia.org/2022-09-07/running-water-is-restored-to-jackson-but-when-will-the-boil-order-be-lifted | 2022-09-07T10:44:01Z |
More than 70 years ago a rebellion broke out in South Korea, which at the time was under American military rule. Tens of thousands were killed in the subsequent crackdown, now survivors seek answers.
Copyright 2022 NPR
More than 70 years ago a rebellion broke out in South Korea, which at the time was under American military rule. Tens of thousands were killed in the subsequent crackdown, now survivors seek answers.
Copyright 2022 NPR | https://www.wyomingpublicmedia.org/2022-09-07/survivors-of-a-massacre-in-south-korea-are-still-seeking-an-apology-from-the-u-s | 2022-09-07T10:44:08Z |
NPR's Rachel Martin talks to poet in residence Kwame Alexander, who shares his latest community crowd-sourced poem about the goals that teachers, parents and students have set for themselves.
Copyright 2022 NPR
NPR's Rachel Martin talks to poet in residence Kwame Alexander, who shares his latest community crowd-sourced poem about the goals that teachers, parents and students have set for themselves.
Copyright 2022 NPR | https://www.wyomingpublicmedia.org/2022-09-07/the-latest-crowd-sourced-poem-is-about-hope-for-the-new-school-year | 2022-09-07T10:44:14Z |
Electronic cigarette maker Juul has agreed to a multi-state settlement. The states allege the company marketed aggressively to teenagers. It's the latest blow to a company under fire.
Copyright 2022 NPR
Electronic cigarette maker Juul has agreed to a multi-state settlement. The states allege the company marketed aggressively to teenagers. It's the latest blow to a company under fire.
Copyright 2022 NPR | https://www.wyomingpublicmedia.org/2022-09-07/to-settle-state-probes-into-teen-vaping-juul-will-pay-nearly-440-million | 2022-09-07T10:44:20Z |
The Seattle Storm superstar played her last basketball game Tuesday. The Storm were eliminated from the playoffs by the Las Vegas Aces, ending what Sue Bird promised was her last season.
Copyright 2022 NPR
The Seattle Storm superstar played her last basketball game Tuesday. The Storm were eliminated from the playoffs by the Las Vegas Aces, ending what Sue Bird promised was her last season.
Copyright 2022 NPR | https://www.wyomingpublicmedia.org/2022-09-07/wnba-legend-sue-bird-is-heading-for-retirement | 2022-09-07T10:44:27Z |
A new international study estimates that from January 1, 2020, to May, 1, 2022, nearly 8 million kids age 18 and under lost a parent or primary caregiver to a pandemic-related cause. When the researchers included the deaths of secondary caregivers like grandparents or other older relatives, the number of kids affected rose to 10.5 million.
That's a big jump from the prior estimate of 5.2 million children who lost a parent or caregiver to COVID-19 from the start of the pandemic until Oct 31, 2021.
The findings are "heartbreaking and disturbing," says Susan Hillis, the main author of the new study, and a co-chair of the Global Reference Group on Children Affected by COVID-19 and Crisis, an international team that's been tracking the indirect toll of the pandemic on children.
Some nations are beginning to address these catastrophic losses with new programs that offer support to the bereaved families – although the U.S. lags in this effort.
Why have estimates gone up?
Asked why the numbers are far higher than previously thought, Hillis answers: "Part of the increases are because we just have more accurate death data on which to model our estimates. And of course, the other aspect of the increases is that deaths have continued."
The study, published in JAMA Pediatrics, also found that the greatest numbers of kids affected by these losses were in Africa and Southeast Asia. India has seen the most suffering, with 3.5 million children grieving the loss of a parent or primary/secondary caregiver. However, Bolivia and Peru have the highest rates of kids affected, with 1 out of every 50 children in both countries losing caregivers during the pandemic.
These children face potentially devastating consequences. The emotional toll may be what people think of first but the impact hits many areas of a child's life.
"This enormous bereavement is an economic loss," explains Lorraine Sherr, a psychologist at the University College London, and a member of the Global Reference Group, who wasn't involved in the latest estimates.
That's especially true when the parent or primary caregiver who died was the main breadwinner in the family. A family's loss of income can put kids at a higher risk of food and housing insecurity.
If a child moves to a new community or family because of the death of a parent, "it's a separation," she says. "And then there's disengagement at school and then disengagement with friendships, with things previously that made them happy or helped them learn. So you have this kind of huge cascade of losses."
Bereavement is one of the top predictors of poor outcomes at school, says psychologist Julie Kaplow, executive vice president of trauma and grief programs at the Meadows Mental Health Policy Institute.
Studies also point to the lasting mental and physical health impacts from losing a parent or caregiver.
"It increases the risk of mental health problems, suicide, prolonged grief complications, sexual exploitation and abuse, even physical abuse of children," says Hillis.
Finding ways to help bereaved children
Many countries and organizations are finally recognizing the urgent need to help children and families deal with this loss, says Sherr.
"Some efforts are being put in place, especially in South Africa, in Eswatini and Kenya and Botswana," says Joel-Pascal Ntwali N'konzi, a co-author of the new study and a researcher at the African Institute for Mathematical Sciences in Kigali, Rwanda. In South Africa and Eswatini, 1 in 100 children have lost a parent or caregiver.
Sometimes the solution is in the form of cash aid.
Providing cash payments to such families can ensure that families can afford school fees in countries where education comes with a price tag. N'konzi and his co-authors are hopeful that other countries will join these efforts.
The World Bank is also looking into providing countries with funding for "cash plus care initiative," says Sherr.
"That means that you provide the family with a stipend or a small cash injection, but you twin that with care — some kind of social support services, linking to school and education."
These kinds of support programs would also connect bereaved families with grassroots organizations or nonprofits that can provide mental health care and psychological support to children and the surviving parent or caregivers.
Past research on children orphaned by the HIV-AIDS epidemic shows that such efforts can buffer the impact of the trauma on kids, says Sherr, who has done research on this topic.
"We looked at educational risk, things like missing school, dropping school year achievement," she explains. "We looked at emotional outcomes such as depression, stress, identity, anxiety, trauma. We also looked at positive outcomes like coping and resilience."
She says projects that included cash transfer plus connection to community-based supports and services improved these outcomes among grieving children.
However, there have been no federal efforts to address the crisis here in the United States, notes Rachel Kidman, a social epidemiologist who has studied the long-term impacts of the HIV-AIDS epidemic on children. The new study found that more than 250,000 American children had lost a parent or caregiver due to the pandemic as of May 1, 2022.
And yet, says Kidman, who was not involved in the new research: "I'm not seeing any concerted efforts or even a lead by the federal government" to address the needs of these children."
Copyright 2022 NPR. To see more, visit https://www.npr.org. | https://www.keranews.org/2022-09-06/nearly-8-million-kids-lost-a-parent-or-primary-caregiver-to-the-pandemic | 2022-09-07T10:51:50Z |
A bench, perfect for skateboarding, moves across the country frequently Published September 7, 2022 at 4:10 AM CDT Facebook Twitter LinkedIn Email Listen • 1:33 Skateboarders in Philadelphia claimed a prize from a park in New York City: a green bench known among skaters for its smooth parabolic curve. Copyright 2022 NPR | https://www.keranews.org/2022-09-07/a-bench-perfect-for-skateboarding-moves-across-the-country-frequently | 2022-09-07T10:51:56Z |
Eebbers was the oldest working dog in the agency and was assigned to the Minneapolis-Saint Paul International Airport. He recently won first place in the TSA's cutest K9 contest.
Copyright 2022 NPR
Eebbers was the oldest working dog in the agency and was assigned to the Minneapolis-Saint Paul International Airport. He recently won first place in the TSA's cutest K9 contest.
Copyright 2022 NPR | https://www.keranews.org/2022-09-07/after-10-years-as-an-explosive-detection-dog-for-the-tsa-eebbers-is-retiring | 2022-09-07T10:52:02Z |
The strain on the power grid is leading to outages in some parts of the state and is putting vulnerable residents at risk. Other western states are also baking under the historic heat.
Copyright 2022 NPR
The strain on the power grid is leading to outages in some parts of the state and is putting vulnerable residents at risk. Other western states are also baking under the historic heat.
Copyright 2022 NPR | https://www.keranews.org/2022-09-07/an-intense-heat-wave-in-california-is-stressing-the-states-power-grid | 2022-09-07T10:52:08Z |
It's a move seen as retaliation by the Kremlin for western sanctions on Russia over its invasion of Ukraine. The energy crisis is not limited to Europe as other countries are also feeling the impact.
Copyright 2022 NPR
It's a move seen as retaliation by the Kremlin for western sanctions on Russia over its invasion of Ukraine. The energy crisis is not limited to Europe as other countries are also feeling the impact.
Copyright 2022 NPR | https://www.keranews.org/2022-09-07/european-energy-prices-soar-after-russia-cuts-off-a-natural-gas-pipeline-to-germany | 2022-09-07T10:52:14Z |
Across the Midwest, farmland prices more than doubled over the past two years — making it difficult for young farmers to grow their businesses.
Copyright 2022 Iowa Public Radio
Across the Midwest, farmland prices more than doubled over the past two years — making it difficult for young farmers to grow their businesses.
Copyright 2022 Iowa Public Radio | https://www.keranews.org/2022-09-07/farmland-prices-are-up-sharply-how-did-it-get-so-expensive | 2022-09-07T10:52:20Z |
NPR's A Martinez talks to Ronnye Stidvent, head of the Center for Women in Law in Texas, about voter registration rising among women after the Supreme Court decision to roll back abortion rights.
Copyright 2022 NPR
NPR's A Martinez talks to Ronnye Stidvent, head of the Center for Women in Law in Texas, about voter registration rising among women after the Supreme Court decision to roll back abortion rights.
Copyright 2022 NPR | https://www.keranews.org/2022-09-07/more-women-are-registering-to-vote-how-could-that-affect-midterms | 2022-09-07T10:52:26Z |
The latest on a Russian-controlled nuclear power plant in Ukraine. The Western U.S. bakes under historic heat wave. On Brazil's Independence Day, President Bolsonaro plans to flaunt his military ties.
Copyright 2022 NPR
The latest on a Russian-controlled nuclear power plant in Ukraine. The Western U.S. bakes under historic heat wave. On Brazil's Independence Day, President Bolsonaro plans to flaunt his military ties.
Copyright 2022 NPR | https://www.keranews.org/2022-09-07/morning-news-brief | 2022-09-07T10:52:32Z |
President Bolsonaro is urging supporters to take to the streets for Independence Day. This may be a precursor to more verbal attacks on democratic institutions ahead of next month's elections.
Copyright 2022 NPR
President Bolsonaro is urging supporters to take to the streets for Independence Day. This may be a precursor to more verbal attacks on democratic institutions ahead of next month's elections.
Copyright 2022 NPR | https://www.keranews.org/2022-09-07/on-independence-day-brazils-president-plans-to-flaunt-his-military-ties | 2022-09-07T10:52:39Z |
Netta is an international pop star. She won the Eurovision Song Contest for her home country of Israel back in 2018, and she's become known for her eye-catching outfits and quirky dance moves.
Copyright 2022 NPR
Netta is an international pop star. She won the Eurovision Song Contest for her home country of Israel back in 2018, and she's become known for her eye-catching outfits and quirky dance moves.
Copyright 2022 NPR | https://www.keranews.org/2022-09-07/playground-politica-is-an-ode-to-popstar-nettas-childhood-in-nigeria | 2022-09-07T10:52:45Z |
The water in Jackson, Miss., is still not safe to drink. NPR's A Martinez talks to Mayor Chokwe Antar Lumumba about the the city's water infrastructure which is deficient.
Copyright 2022 NPR
The water in Jackson, Miss., is still not safe to drink. NPR's A Martinez talks to Mayor Chokwe Antar Lumumba about the the city's water infrastructure which is deficient.
Copyright 2022 NPR | https://www.keranews.org/2022-09-07/running-water-is-restored-to-jackson-but-when-will-the-boil-order-be-lifted | 2022-09-07T10:52:51Z |
More than 70 years ago a rebellion broke out in South Korea, which at the time was under American military rule. Tens of thousands were killed in the subsequent crackdown, now survivors seek answers.
Copyright 2022 NPR
More than 70 years ago a rebellion broke out in South Korea, which at the time was under American military rule. Tens of thousands were killed in the subsequent crackdown, now survivors seek answers.
Copyright 2022 NPR | https://www.keranews.org/2022-09-07/survivors-of-a-massacre-in-south-korea-are-still-seeking-an-apology-from-the-u-s | 2022-09-07T10:52:57Z |
NPR's Rachel Martin talks to poet in residence Kwame Alexander, who shares his latest community crowd-sourced poem about the goals that teachers, parents and students have set for themselves.
Copyright 2022 NPR
NPR's Rachel Martin talks to poet in residence Kwame Alexander, who shares his latest community crowd-sourced poem about the goals that teachers, parents and students have set for themselves.
Copyright 2022 NPR | https://www.keranews.org/2022-09-07/the-latest-crowd-sourced-poem-is-about-hope-for-the-new-school-year | 2022-09-07T10:53:03Z |
Help is wanted at many voting sites around the U.S. as the general election season gets underway this month.
In some communities, however, the ongoing COVID pandemic and current political climate are not making it easy to find paid and volunteer poll workers, forcing election officials to count on creative ways to staff up for democracy.
For the 2020 elections, some longtime poll workers dropped out of the ranks because they needed to quarantine or faced higher COVID risks related to their age, according to a report by the U.S. Election Assistance Commission. Special campaigns urging voters to serve at polls that year helped many officials find workers who stepped up.
This year, high school students, military veterans and lawyers are among the potential applicant pools some local and national recruiting efforts are targeting to make sure there's enough staff to check in voters, issue ballots and process votes.
But making a call to serve can be tricky in 2022 with election officials and workers in many parts of the U.S. facing an unprecedented level of scrutiny — along with harassment — driven by election deniers.
"This is an unfortunate factor," said New Jersey Secretary of State Tahesha Way, president of the National Association of Secretaries of State. "After 2020, we are now seeing an increased level of threats towards election officials and workers, which, of course, causes concern and hesitation for those who may want to serve."
For Anil Nathan, though, it's a source of motivation.
The former U.S. Air Force captain co-founded the nonprofit organization We the Veterans, which has started a new project called Vet the Vote to encourage former service members to work at polling sites.
"I think a lot of veterans and military family members would feel the same way about helping to continue to protect and serve the institutions and the process that we wore a uniform to support in our previous lives," Nathan said.
The American Bar Association is also trying to tap into its professional networks by bringing back the Poll Worker, Esq. initiative it used to promote poll working among lawyers and law students for the 2020 elections.
In the suburbs of Washington, D.C., Maryland's Montgomery County Board of Elections has been focused on younger demographic groups. Local teenagers ages 16 and up can serve as poll workers, and kids as young as sixth graders can volunteer as aides to poll workers the night before and on Election Day, when the county's public schools are not in session.
The student aides are part of Future Vote, a program that Gilberto Zelaya, the community engagement and public relations officer for the county's board of elections, started in 2004 in part to help out the workers stationed at polling places.
"They really like the fact that there's this younger generation handing out 'I voted' stickers, making sure that the signs are posted and that the tables are lined up," Zelaya said.
Sometimes, aides get on the floor of polling places with blue painter's tape to lay out arrows pointing voters toward the right direction.
"Our poll workers, especially our older poll workers, they prefer that the students do that as opposed to them because I'm 50 and my knees are starting to crack," Zelaya added.
Sixteen-year-old Danny Dominguez, though, had something else in mind when applying to be an election worker — a more exciting way to rack up community service hours for a graduation requirement in Maryland.
"I've always been interested in how the election process works. And so for the 25 hours, I get to see how people come in, sign up for the elections and vote," said Dominguez, who recently stopped by a recruiting table at a back-to-school fair held inside a mall parking garage.
At the same event, Adaobi Oniwinde filled out an application herself and guided one of her sons toward one as well.
"Honey, I really want you to do this. This is the most important thing," Oniwinde said, eying 16-year-old Layi with a clipboard in hand.
This year's midterms will be the first U.S. general election Oniwinde's children will experience while in the country, after years of living abroad.
"The beauty about the system here is the fact that you really can get involved at any level," Oniwinde said. "People are going out with their kids. I love the way the system here allows everybody to be involved."
Copyright 2022 NPR. To see more, visit https://www.npr.org. | https://www.keranews.org/2022-09-07/the-midterm-elections-need-workers-teens-veterans-and-lawyers-are-stepping-up | 2022-09-07T10:53:09Z |
Electronic cigarette maker Juul has agreed to a multi-state settlement. The states allege the company marketed aggressively to teenagers. It's the latest blow to a company under fire.
Copyright 2022 NPR
Electronic cigarette maker Juul has agreed to a multi-state settlement. The states allege the company marketed aggressively to teenagers. It's the latest blow to a company under fire.
Copyright 2022 NPR | https://www.keranews.org/2022-09-07/to-settle-state-probes-into-teen-vaping-juul-will-pay-nearly-440-million | 2022-09-07T10:53:15Z |
The Seattle Storm superstar played her last basketball game Tuesday. The Storm were eliminated from the playoffs by the Las Vegas Aces, ending what Sue Bird promised was her last season.
Copyright 2022 NPR
The Seattle Storm superstar played her last basketball game Tuesday. The Storm were eliminated from the playoffs by the Las Vegas Aces, ending what Sue Bird promised was her last season.
Copyright 2022 NPR | https://www.keranews.org/2022-09-07/wnba-legend-sue-bird-is-heading-for-retirement | 2022-09-07T10:53:21Z |
The story of Dallas County’s health is, in many ways, a story of unequal distribution of chronic diseases. The last major health assessment of the county showed Parkland Health patients south of I-30 had a far higher count of cases of diabetes and hypertension than those north of the highway.
“The two chronic conditions that we focus on, that are paramount, are diabetes and hypertension," said Jessica Hernandez, Vice President for Community Integrated Health at Parkland. It serves as the public health system for Dallas County.
Similar disparities existed for other ailments, like asthma, cancer, chronic heart failure, and chronic kidney disease.
So how was the community’s struggle with chronic disease affected by the pandemic, a time when health care workers were rushing to help people through a totally new disease? A new report for Dallas County that’s nearing completion may have those answers.
Community outreach
At the Marillac Community Center in West Dallas, you can dance at a birthday party and get a blood pressure reading on the same day.
Parkland Health has a weekly clinic in a quiet room. They take blood pressure readings and perform blood sugar tests for whoever wants one. Everyone is welcome — even walk-ins.
After his visit late last month, Arturo De La Sancha of Oak Cliff said he was surprised his glucose reading was high.
“Pues, no me siento mal. Yo no se porque. Estoy alterado de azucar pero no se por que,” De La Sancha said in Spanish. “Well, I don’t feel bad. My sugar is high, but I don’t know why.”
So now he needs to see a doctor to get to the bottom of it. That’s what the weekly clinic is for: giving people information and guidance about health issues they might not be aware of.
“Si no hubiera venido aquí, no me hubiera dar cuenta,” he said. “If I hadn’t come here, I wouldn’t have realized.” He said if he hadn’t come to the clinic, he wouldn’t have realized he needed to look into it.
Leonela Gonzalez, a senior community health worker at Parkland, said many patients mentioned that during the pandemic they were “not consistent with their blood pressure or their glucose because they were afraid to go see their doctor.”
The event at Marillac is an example of the kind of community outreach for chronic diseases that temporarily stopped in 2020, as fear of the pandemic took hold.
“It was months before our own internal infection prevention department and others would consider the possibility of us going out into the community in the way that we wanted to,” Hernandez said.
Measuring progress
Hernandez said while these events were on pause — and staff scrambled to respond to the testing and treatment demands of COVID — the hospital refined how it would track and follow up with patients.
Outreach like this was part of the plan Parkland laid out to combat chronic diseases among its patients three years ago. That plan, called the Community Health Needs Assessment, is a requirement of the Affordable Care Act, passed by Congress over a decade ago. Tax-exempt organizations that operate hospitals must perform one every three years.
The 2022 Assessment is expected to be released this month.
In a presentation to its board, Parkland said it achieved some of the goals it set in 2019 for blood pressure and diabetes among its patients. But they failed to achieve others.
For example, Parkland surpassed its goal for the number of its patients in six targeted zip codes who received high blood pressure screenings over the past three fiscal years. During those same years, though, it didn’t hit targets for the percentage of patients with diabetes from those zip codes who had “adequately controlled” blood pressure.
Hernandez noted the metrics Parkland established were for their patients, not the county as a whole.
“That will come,” she said. She argued that three years is a very short time when you’re trying to improve the health of the community.
“I would love to see where we are ten years from now. Because really, it sometimes takes a generation to really see some of those improvements when you talk about population health,” she said.
And the responsibility to improve the county’s overall health also lies with private hospitals — mostly located in the Northern half of the county — and the state of Texas. The state is one of only twelve which haven't expanded Medicaid.
“Medicaid expansion would put a quarter of a million of your neighbors here in Dallas County in coverage that currently don’t have it,” Dallas County Judge Clay Jenkins said last week, noting that the “vast majority” of those uninsured people have jobs.
Dallas County has the highest uninsured rate of Texas’ largest six counties.
Primary care
Treating chronic disease takes consistent monitoring, like the screening De La Sancha had at the community center. And a primary care provider — be it a doctor or other medical professional — is key to that monitoring.
“If you’re taking care of your car, getting it maintained, taking care of your apartment and your home, you can take care of yourself,” said Joyce Tapley, CEO of the federally funded Foremost Family Health Clinics. “The best maintenance is going to a primary care doctor.”
At the Agape Clinic in Old East Dallas, which delivers primary care to people without insurance, medical assistant Guadalupe Delgadillo says the baseline health of her patients likely got worse during COVID-19.
“Because most of them, either they were too afraid to come here, or go to another clinic, or another place to get help due to the pandemic,” Delgadillo said. “They probably didn’t want to get COVID or something.”
Parkland, which serves a much higher percentage of the county’s uninsured at its hospital than all hospitals in the county, opened two primary care clinics in recent years, in the Red Bird area and Jubilee Park.
But nonprofit, community-based clinics like Foremost and Agape would like to see Parkland work with them more closely to connect people with primary care and reduce inefficiencies.
Executive Director Paul Hoffman notes the majority of Agape’s patients live in the zip codes Parkland identified as having high percentages of chronic diseases. To improve how people get the care they need, he wants his doctors to be able to refer directly to Parkland specialists.
“What’ll happen is, they end up repeating all of the preliminary primary care work that we do before they even refer to a specialist,” he said.
And Tapley said she’d like to see Parkland refer people who come to the emergency room to her primary care clinic if they don’t really need to be in the ER.
“I have asked them as part of my contribution to the discussion that we formalize and be more consistent with how they’re referring patients to the most appropriate place,” she said.
Those ideas are on the table, Hernandez said, although they are working on how to communicate any care plan a specialist might devise for a patient back to that primary care doctor.
“Certainly, duplication is not what we’re after,” she said.
Got a tip? Email Bret Jaspers at bjaspers@kera.org. You can follow Bret on Twitter @bretjaspers.
KERA News is made possible through the generosity of our members. If you find this reporting valuable, consider making a tax-deductible gift today. Thank you. | https://www.keranews.org/health-wellness/2022-09-07/covid-remains-but-dallas-county-providers-refocus-attention-on-diabetes-and-hypertension | 2022-09-07T10:53:28Z |
Shelling goes on near Ukraine nuclear plant, despite risks
KYIV, Ukraine (AP) — Russian renewed its shelling in the area of Ukraine’s Zaporizhzhia nuclear power plant, a local official said Wednesday, a day after the U.N. atomic watchdog agency pressed for the warring sides to carve out a safe zone there to protect against a possible catastrophe.
The city of Nikopol, located on the opposite bank of the Dnieper River from Europe’s largest nuclear power plant, was fired on with rockets and heavy artillery, regional governor Valentyn Reznichenko said.
The reports of nearby shelling, which couldn’t be independently verified, have caused international alarm. The head of the International Atomic Energy Agency, Rafael Grossi, warned the U.N. Security Council on Tuesday that “something very, very catastrophic could take place” at Zaporizhzhia.
“There are fires, blackouts and other things at the (plant) that force us to prepare the local population for the consequences of the nuclear danger,” Reznichenko said.
The potential peril led the U.N. atomic watchdog agency to urge Russia and Ukraine to establish a “nuclear safety and security protection zone” around the plant.
There are fears the fighting could trigger a catastrophe on the scale of the Chernobyl disaster in 1986. The plant was built during the Soviet era and is one of the 10 biggest in the world.
Neither Moscow nor Kiev officials would immediately commit to the idea of a safety zone, saying more details of the proposal were needed.
Russian President Vladimir Putin defied pressure to halt the war, saying Wednesday that Moscow will forge ahead with its military offensive in Ukraine until it achieves its goals. He also mocked Western attempts to stop Russia with sanctions.
The eastern city of Sloviansk came under Russian fire on Wednesday morning, damaging a school and another building, according to the head of the city administration Vadym Lyakh.
Firefighters in the city dug deep into the still-smoldering rubble of an apartment building and removed at least one body bag.
Chunks of bricks, masonry and concrete lay among the torn branches of nearby trees, mixed with broken glass and roof tiles. Metal doors, buckled by the force of the blast, hung off their hinges.
The strike came at around 4 a.m., said local resident Raisa Smelkova, 75, who lives in another part of the building. She and her husband were unhurt.
Smelkova and her husband lived through the previous war in Ukraine in 2014, when Russia annexed the Crimea region. But this time, she said, things are much worse.
“What is happening now is not just scary, it’s gruesome,” she said. “There is more destruction. Everything is worse. Just everything.”
Three civilians were killed in Russian shelling in the Donetsk region, the Ukrainian presidential office said. Kharkiv city was hit by rockets twice during the night.
But Ukrainian forces have taken control of an unspecified number of towns in the Kherson region, according to Nataliya Humenyuk, a spokesperson for the southern military command. She said details would come later from the military leadership.
The U.K. defense ministry said there had been heavy fighting on three fronts: in the north, near Kharkiv; in the east in the Donbas; and in the south in Kherson Oblast.
Amid a Ukrainian counterattack in the east, “multiple concurrent threats spread across 500 kilometers (310 miles) will test Russia’s ability to coordinate operational design and reallocate resources across multiple groupings of forces,” the ministry said Wednesday.
The Russian military held large-scale military drills that began last week and ended Wednesday in the country’s east that involved forces from China. It was seen as another show of increasingly close ties between Moscow and Beijing amid tensions with the West over the military action in Ukraine.
___
Elena Becatoros in Sloviansk contributed to this report.
___
Follow the AP’s coverage of the war at https://apnews.com/hub/russia-ukraine
Copyright 2022 The Associated Press. All rights reserved. | https://www.whsv.com/2022/09/07/shelling-goes-near-ukraine-nuclear-plant-despite-risks/ | 2022-09-07T11:50:53Z |
Fuel Your Football - or Fútbol - by purchasing participating products at 7-Eleven, Speedway and Stripes stores
IRVING, Texas, Sept. 7, 2022 /PRNewswire/ -- 7-Eleven, Inc., is here to assume its role once again as the destination for sports fandom by helping customers fuel their game days all season long. As fans gear up for a big season of both football and fútbol – 7-Eleven®, Speedway® and Stripes® stores are here to help customers curate an iconic tailgate spread…and so much more. The Fuel Your Football™ promotion will reward customers with the chance of winning exciting prizes and a one-of-a-kind experience inspired by their love of the game – or games.
One game a week just isn't enough. That's why 7-Eleven is giving fans the chance to win the ultimate "football" experience – an all-expense paid trip for two to attend seven games in 11 days across the U.S. One lucky winner will hand pick their itinerary filled with 7 games of either football, soccer or a hybrid of both to attend next year. To be entered to win, customers can purchase select items through Speedy Rewards® and 7Rewards® loyalty programs, found in the Speedway and 7-Eleven apps, or via 7NOW® delivery. Participating products include fan favorites such as Big Gulp® fountain beverages, Slurpee® drinks, pizza and all varieties of Red Bull, Lays, and Monster*.
"Our customers are some of football and soccer's most passionate fans – over the years, we've seen them take their love for the game from 10… to ELEVEN," said Marissa Jarratt, 7-Eleven Executive Vice President and Chief Marketing Officer. "7-Eleven is proud to provide our customers with the highest level of convenience as they fuel up for all their tailgate, game and celebration needs. We hope these exclusive prizes give football, soccer and all sports fans another reason to celebrate this fall as they cheer on their favorite teams."
But the festivities don't stop there. Customers can also have the chance to win one-of-a-kind 'homegate' kits to help them throw the ultimate watch party. Kits will be given away weekly and include a 65-inch Smart TV, access to a sports streaming service, and a variety of supplies and snacks to enhance your game day (think tents, coolers and tailgate games!). Rewards members who purchase participating products in-store or via 7NOW delivery will be entered to win*.
And an at-home tailgate won't be complete without some swag! 7-Eleven stans looking to show off their brand love while they cheer on their favorite teams should look no further than 7Collection. The retailer's online merchandise shop will feature a special Fuel Your Football drop, available this month, with 7-Eleven branded items perfect for an at-home tailgate like a football, cornhole set and more.
The perfect at-home tailgate should also be paired with an equally awesome cup. Sports fans are encouraged to head in store and purchase either a football or soccer collectable cup and dress it up in its turf koozie for some epic Big Gulp or Slurpee drink sipping. What's more, when customers scan their 7Rewards or Speedy Rewards loyalty app with purchase of the cup, they'll score 250 bonus points.
Need help with the perfect tailgate spread? Consider hot-and-ready snacks like pizza, wings, taquitos and Big Bite® hot dogs that can be delivered directly via the 7NOW delivery app. 7Rewards and Speedy Rewards members can stock up on 8 boneless wings for just $2.99** or $5 whole cheese or pepperoni pizzas*** to wow their guests even more than the game winning goal… or touchdown.
The 7NOW delivery app can be downloaded from the App Store or Google Play, or by visiting 7Rewards.com or 7now.com.
*NO PURCHASE NECESSARY TO ENTER OR WIN. Begins 9/7/22 at 12:00:01am ET & ends 1/10/23 at 11:59:59pm ET. Open to legal US residents physically residing in 50 United States or DC who are 13+ years old (minors must have parental consent to participate). Odds of winning depend on # of eligible entries. Sponsor: 7-Eleven, Inc. For full rules, free and other methods of entry, full prize details, and restrictions, see Official Rules at https://bit.ly/7E-FB22.
**Valid through 1/3/23. Available while supplies last. Offer good at participating U.S. 7–Eleven® stores, excludes Hawaii. Offer not valid with any other coupon of discount. No cash value. Consumer pays applicable fees & sales tax.
***Item must be added to cart for discount to apply. One offer per order. While supplies last. Small basket fee may apply if min purchase is not met. Delivery charges may apply. Consumer pays applicable fees & taxes. 7–Eleven, Inc. reserves the right to modify, change, or cancel this offer at any time.
7-Eleven, Inc. is the premier name in the convenience-retailing industry. Based in Irving, Texas, 7-Eleven operates, franchises and/or licenses more than 13,000 stores in the U.S. and Canada. In addition to 7-Eleven® stores, 7-Eleven, Inc. operates and franchises Speedway®, Stripes®, Laredo Taco Company® and Raise the Roost® Chicken and Biscuits locations. Known for its iconic brands such as Slurpee®, Big Bite® and Big Gulp®, 7-Eleven has expanded into high-quality sandwiches, salads, side dishes, cut fruit and protein boxes, as well as pizza, chicken wings and mini beef tacos. 7-Eleven offers customers industry-leading private brand products under the 7-Select™ brand including healthy options, decadent treats and everyday favorites at an outstanding value. Customers can earn and redeem points on various items in stores nationwide through its 7Rewards® loyalty program with more than 50 million members, place an order in the 7NOW® delivery app in over 2,000 cities, or rely on 7-Eleven for bill payment service, self-service lockers and other convenient services. Find out more online at www.7-Eleven.com.
View original content to download multimedia:
SOURCE 7-Eleven, Inc. | https://www.whsv.com/prnewswire/2022/09/07/7-eleven-gives-fans-chance-score-tickets-7-games-11-days/ | 2022-09-07T11:50:59Z |
Accuray Will Anchor Hub That Will Unite Companies From the MedTech, Pharma and Biosciences Sectors, Physicians and Scientists
SUNNYVALE, Calif., Sept. 7, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the company is joining forces with Genolier Innovation Hub, a fully-owned subsidiary of AEVIS VICTORIA SA (SWX: AEVS), in support of a unique new approach to improving patient care. Genolier Innovation Hub will unite companies from the medtech, pharma and biosciences sectors, physicians and scientists, under one roof, with the goal of bringing medical and technological advances to patients faster. The Hub is expected to open in early 2024.
Genolier Innovation Hub will be located in the heart of the Genolier Healthcare Campus in Genolier, Switzerland. The facility will offer different workspaces to meet the varied requirements of the participants including operating rooms to support simulation-based training, bunkers with radiation therapy systems for training, R&D and demonstration, and meeting rooms equipped with the most advanced technologies to host seminars, workshops and events. Accuray will leverage the Hub as a global training center where customers will have the opportunity to obtain hands-on training and learn about advanced radiation therapy techniques – using its CyberKnife® and Radixact® Systems – from renowned faculty.
The CyberKnife and Radixact Systems are radiation therapy devices that have been proven to deliver highly effective treatments for a broad range of tumors almost anywhere in the body. The systems include advanced functionality that make it easier and more efficient to administer extremely precise radiation treatments, even to targets that move, providing the medical care team with options for managing the full spectrum of cancer cases, from routine to complex and initial treatment to retreatment, and neurologic disorders. The two systems are successfully being used at the Clinique Générale-Beaulieu in Geneva, and the Radixact System will also be used at the Clinique de Genolier, both being flagship clinics of the Swiss Medical Network, AEVIS's main shareholding.
"We are proud to lead the radiation therapy industry as an anchor for Genolier Innovation Hub. Our involvement is consistent with our focus on advancing patient care through investments in innovation in all aspects of our business, from our technology to clinical support and education," said Suzanne Winter, president and chief executive officer of Accuray. "We look forward to partnering with Genolier Innovation Hub to usher in a new level of collaboration that speeds the progress made in patient-centric care. This is a long-term commitment for both companies."
"Our philosophy is to put the patient at the heart of everything we do. This viewpoint is a key driver behind the new Genolier Innovation Hub which is designed to provide a forum for creating cross-sector relationships that drive unprecedented improvements in care," said Antoine Hubert, Chairman of the Board of Genolier Innovation Hub and Delegate of the Board of Directors of AEVIS Victoria SA. "Accuray shares our vision and I am confident that by working together we can create a model that sets a new standard in the healthcare industry."
AEVIS invests in healthcare, hospitality & lifestyle and infrastructure. AEVIS′s main shareholdings are Swiss Medical Network SA (90%, directly and indirectly), a Swiss private network of 21 hospitals present in the country's three main language regions, Victoria-Jungfrau AG, a luxury hotel group managing ten luxury hotels in Switzerland and abroad, Infracore SA (30%, directly and indirectly), a real estate company dedicated to healthcare-related infrastructure which is the owner of Genolier Innovation Hub building (to learn more, visit www.infracore.ch), Swiss Hotel Properties SA, a hospitality real estate division, and NESCENS SA, a brand dedicated to better aging. AEVIS is listed on the Swiss Reporting Standard of the SIX Swiss Exchange (AEVS.SW). To learn more, visit www.aevis.com or follow us on LinkedIn.
Genolier Innovation Hub is a scientific and medical platform of more than 25'000 m² open to international health stakeholders in the fields of medtech, pharma, digital technologies and biosciences. Focusing on translational research, development and presentation of innovations and education, this Hub aims to be a central location for physicians, researchers, startups in the launch phase, companies specialized in medtech, pharma and biosciences, hospitals, clinics and educational institutions. This significant project is taking form, with the beginning of the construction in June 2021 and the grand opening scheduled for early 2024. To follow the progress of the construction site, there is a live-webcam available. Here is the video of the Genolier Innovation Hub, which is also available on the website and LinkedIn.
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Sunnyvale, California, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, Twitter, and YouTube.
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications and results; patient experiences and outcomes; and expectations regarding the first patient treatments and the training facility discussed in this press release. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products; the company's ability to develop new products or improve existing products to meet customers' needs; the company's limited long-term clinical data supporting the safety and efficacy of its products and such other risks identified under the heading "Risk Factors" in the company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 17, 2022, and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Media Contact
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
View original content to download multimedia:
SOURCE Accuray Incorporated | https://www.whsv.com/prnewswire/2022/09/07/accuray-partners-with-swiss-based-genolier-innovation-hub-bring-medical-technological-advances-patients-faster/ | 2022-09-07T11:51:05Z |
- AMPLY Power, the electric vehicle (EV) fleet charging and energy management solutions provider acquired by bp in 2021, will now operate under the name bp pulse.
- Under bp's global electrification brand, AMPLY's innovative products and services will expand to new regions globally.
- The rebranding introduces bp pulse to the US and wider Americas, following a successful launch in the United Kingdom in 2020.
- The AMPLY leadership team including founder and CEO, Vic Shao, remains with the business leading bp pulse's fleet projects in the U.S.
HOUSTON, Sept. 7, 2022 /PRNewswire/ -- AMPLY Power is becoming part of bp's global electrification brand, bp pulse.
bp acquired the fleet EV charging and energy management provider in December 2021. AMPLY Power has seen continued growth as it helps fleets accelerate the transition to EVs. This success lays the foundation for bp pulse's expansion in the fleet electrification sector in the Americas and beyond.
The decision to roll-out the bp pulse brand follows the successful brand launch in the United Kingdom in 2020. In Germany, bp's charging solutions business operates as Aral pulse. Worldwide, bp pulse operates around 16,000 charge points with an ambition to install 100,000 by 2030.
AMPLY was built on the idea of making EV adoption easy for fleets that operate trucks, transit and school buses, vans and light-duty vehicles through proprietary charge management software and its charging-as-a-service model. AMPLY's founder and CEO, Vic Shao will become president of bp pulse's fleet division in the Americas.
Dave Lawler, chairman and president of bp America, said: "We are committed to growing our next-generation mobility business in the US and this is a significant step. Introducing the bp pulse brand will bring continued investment across America to help bp and the nation make forward progress on electrification."
Richard Bartlett, senior vice president for bp pulse said: "AMPLY is one of the most important acquisitions we've made as we scale up our EV charging solutions, products & services globally. We are already integrating Vic and the team with the bp pulse global team and they will bring so much thanks to their incredible expertise in fleet, software, and charge management.
"bp pulse is one of bp's priority growth areas that will deliver and symbolize bp's transition to an integrated energy company as we continue our journey to net zero by 2050."
The bp pulse team, now including AMPLY's expertise, is setting its sights on introducing AMPLY's Omega charge management software and charging-as-a-service (CaaS) model to new geographies. By using Omega and CaaS, fleets can optimize EV charging costs and vehicle utilization, improving the fleet's overall resilience and reliability. In addition, the team is looking to bring bp pulse's expertise in public charging from Europe to North America.
Vic Shao, founder of AMPLY Power and president of bp pulse's fleet division, said: "As the founder of AMPLY Power, I'm enormously proud of my team's journey from the seedling of an idea to becoming a key facilitator in bp's overall global electrification goals and seeing our rebrand to bp pulse."
"There's a fantastic mission here accelerating the decarbonization of mobility at scale as quickly as we can. Managing a fleet's charging operations is critical to the success of any electric fleet. Joining the bp pulse brand will unlock our full potential to support and accelerate electrification in the US and beyond."
In addition to its ambition to install 100,000 charge points by 2030, bp pulse has announced ambitions to install charging infrastructure across Europe as well as Australia and New Zealand. A £1 billion commitment to the United Kingdom and a €1 billion joint venture with Iberdrola in Spain and Portugal were announced earlier this year. The company is in a joint venture with ride hailing company Didi in China and is part of a joint venture, Jio-bp, in India.
About bp
bp's ambition is to become a net zero company by 2050 or sooner, and to help the world get to net zero. bp has a larger economic footprint in the United States than anywhere else in the world, investing more than $130 billion in the economy and supporting about 245,000 jobs. For more information on bp in the US, visit www.bp.com/us.
bp pulse is bp's EV charging business, rolling out fast, reliable charge points to consumers and commercial fleets around the world. Entering into the Americas, bp pulse focuses on providing EV charging and energy management to fleets that operate heavy-, medium- and light-duty vehicles. Key offerings for these fleets include intelligent charge management software, Omega, and a Charging-as-a-Service solution–allowing bp pulse to manage the charging of an EV fleet from start to finish, while optimizing energy costs and vehicle utilization. Globally, bp pulse is one of the United Kingdom's leading rapid and ultra-fast public EV charging networks. It also operates the largest number of sites with ultra-fast charging in Germany, with a growing charging point footprint in China and the Netherlands. The company aims to increase its network of public EV charging points by 2030 to over 100,000 worldwide.
Further information
bp press office, United States
uspress@bp.com
Cautionary statement
In order to utilize the 'safe harbor' provisions of the United States Private Securities Litigation Reform Act of 1995 (the 'PSLRA'), bp is providing the following cautionary statement. This press release contains certain forecasts, projections and other forward-looking statements – that is, statements related to future, not past, events and circumstances which may relate to one or more of the financial condition, results of operations and businesses of bp and certain of the plans and objectives of bp with respect to these items. These statements are generally, but not always, identified by the use of words such as 'will', 'expects', 'is expected to', 'aims', 'should', 'may', 'objective', 'is likely to', 'intends', 'believes', 'anticipates', 'plans', 'we see' or similar expressions. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will or may occur in the future and are outside the control of bp. Actual results may differ from those expressed in such statements, depending on a variety of factors including the risk factors set forth in our most recent Annual Report and Form 20-F under 'Risk factors'.
Our most recent Annual Report and Form 20-F is available on our website at www.bp.com, or can be obtained from the SEC by calling 1-800-SEC-0330 or on its website at www.sec.gov
View original content to download multimedia:
SOURCE bp America | https://www.whsv.com/prnewswire/2022/09/07/amply-power-rebrands-bp-pulse-sets-sights-global-expansion/ | 2022-09-07T11:51:11Z |
ALPHARETTA, Ga., Sept. 7, 2022 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Joe Woody, chief executive officer, and Michael Greiner, senior vice president and chief financial officer, will present and participate in an analyst-led fireside chat at the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 14 at approximately 1:30 p.m., ET.
A webcast of the conference presentation will be available on the Investors section of the Avanos Medical website and will be archived on that site.
About Avanos Medical:
Avanos Medical (NYSE: AVNS) is a medical technology company focused on delivering clinically superior breakthrough medical device solutions to improve patients' quality of life. Headquartered in Alpharetta, Georgia, Avanos is committed to addressing some of today's most important healthcare needs, such as reducing the use of opioids while helping patients move from surgery to recovery. Avanos develops, manufactures and markets its recognized brands in more than 90 countries. For more information, visit www.avanos.com and follow Avanos Medical on Twitter (@AvanosMedical), LinkedIn and Facebook.
View original content to download multimedia:
SOURCE Avanos Medical, Inc. | https://www.whsv.com/prnewswire/2022/09/07/avanos-medical-inc-present-morgan-stanley-20th-annual-global-healthcare-conference/ | 2022-09-07T11:51:18Z |
Platform Will Support Growing Demand for New, Sustainable Infrastructure Across the Country
BATON ROUGE, La., Sept. 7, 2022 /PRNewswire/ -- Bernhard Capital Partners Management, LP ("Bernhard Capital"), a services and infrastructure-focused private equity management firm, today announced the launch of a dedicated architecture, engineering, and construction (AEC) platform with an investment in Grace Hebert Curtis Architecture ("GHC"). GHC will continue to be led by CEO Jerry Hebert and its current management team, which will retain a significant stake in the business. Financial terms of the transaction were not disclosed.
Founded in Baton Rouge and with locations in Dallas, New Orleans, Lake Charles, and Lafayette, GHC and its team of talented, client-focused architects have delivered innovative, functional, and personal projects for thousands of customers. Its holistic, immersive design project management approach prioritizes transparency, client engagement, and customer satisfaction throughout every step of the development process. The company currently serves clients in designing and developing properties across distinct asset classes and industries, including education (higher ed and K-12), commercial office, industrial, and healthcare.
Bernhard Capital will support the ongoing growth of GHC and build on the company's recent momentum. The firm plans to leverage its critical infrastructure services expertise with this platform to partner with the best-in-class businesses supporting the growing demand for modern, sustainable infrastructure.
"We continue to see a number of tailwinds within the broader AEC market as businesses, institutions, and local and federal governments dedicate more resources to the development of critical and civic infrastructure, particularly K-12 schools and healthcare," said Jeff Koonce, Partner at Bernhard Capital. "GHC has established a reputation for delivering the highest quality architecture and design services to bring new, sustainable properties to life and will be well positioned for long-term success. We look forward to building a platform that will serve as a one-stop offering for customers across the country."
"We have spent over five decades exceeding our clients' expectations and serving as the conduit for their vision. Our team's commitment to excellence and creating engaging spaces that embrace and celebrate our clients' mission and culture has created unique opportunities to partner with premier businesses, organizations, and civic and educational institutions," said Mr. Hebert. "The exceptional team at Bernhard Capital shares our vision for growth while maintaining our focus on designing buildings and infrastructures that support and improve the communities and businesses they serve. We are excited to work together to build on our track-record of success, expand our capabilities to better serve our clients and lay the groundwork for a leading, full-service national AEC platform."
Bernhard Capital Partners is an operationally focused private equity firm investing in middle-market businesses that provide essential services for critical infrastructure in North America. Bernhard Capital Partners was established in 2013 and has deployed capital across four funds representing approximately $2.9 billion of gross assets under management and is ranked as one of Private Equity International's 300 largest private equity firms worldwide. Bernhard Capital Partners seeks to create sustainable value by leveraging its experience in acquiring, operating, and growing services and infrastructure businesses. For more information, visit www.bernhardcapital.com.
Contacts
Media
Ed Trissel / Kate Thompson / Erik Carlson
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449
View original content:
SOURCE Bernhard Capital Partners Management, LP | https://www.whsv.com/prnewswire/2022/09/07/bernhard-capital-launches-aec-platform-with-investment-grace-hebert-curtis/ | 2022-09-07T11:51:24Z |
The funding round led by JVP poised to reduce cultivate meat production costs by 300% making it more affordable
Erel Margalit JVP Chairman: "Biobetter has the key to scale up production of cultivated meat, make it accessible to consumers globally and protect our planet"
KIRYAT SHEMONA, Israel, Sept. 7, 2022 /PRNewswire/ -- FoodTech start-up BioBetter, Ltd., has secured USD10M in its A –round funding. The round was led by Jerusalem Venture Partners (JVP), with additional investment from Milk and Honey Investments, LLC, and the Israeli Innovation Authority (IIA). This significant injection of capital will be instrumental in accelerating cell-cultured meat closer to its ambitions for broad scale production.
BioBetter harnesses the inherent advantages of tobacco plants as bioreactors for creating the growth factors necessary for the cellular development of cultivated meat. This landmark botanical development could significantly reduce the cost of cultured meat and help rapidly advance its commercialization. The start-up is on a mission to relieve one of the biggest bottlenecks in this emerging industry: the steep costs and limited availability of growth factors that play a critical role in multiplying cultured meat cells.
BioBetter has pioneered a unique protein manufacturing platform for producing growth factors (GFs) using tobacco plants (Nicotiana tabacum) as natural, self-sustaining, animal-free bioreactors. The field-grown tobacco plants offer a new, sustainable, efficient, and flexible response to the market need for more competitively priced GFs, specifically insulin, transferrin, and FGF2. These compounds are necessary to make cultivated meat commercially viable.
"Biobetter has the key to scale up production of cultivated meat, make it accessible to consumers globally and protect our planet," declares Erel Margalit, Founder & Executive Chairman of JVP & Margalit Startup City. "This is not only because of the sheer volumes of GFs it can produce but also by virtue of its ability to substantially reduce their cost." Growth factors form the key building blocks for cell-cultured proteins. But costs currently run anywhere from USD50,000 to USD500,000 per gram of FGF2, for example. BioBetter's technology has the potential to bring these costs down to just one US dollar per gram
BioBetter will expand to a larger pilot plant within the Tel Hai Industrial Park in the Upper Galilee Region of Israel. The establishment of the new site will substantially increase its tobacco plant-processing capacity, enabling it to meet its current pool of commissions emanating from cell-based meat cultivators globally. The new funding also will be applied to broaden BioBetter's product portfolio of growth factors. BioBetter currently is recruiting sufficient new talent to double its workforce.
"Biobetter has the potential to create global and regional impact," enthuses Nisan Zeevi, Director of JVP and VP of Margalit Startup City Galil. "Closer to home, this venture will create a significant new source of income for local farmers. As cellular agricultural expands, we will dedicate some 500 acres here in the galilee of tobacco plantations to support the industry. This also helps growers find new purpose in the burgeoning alternative protein scene following a reduction in smoking over the last decade that has left many tobacco fields idle and tobacco farmers suffering financial loss."
"World population growth, combined with dwindling natural resources, are going to put incredible strain on meat supply—and the already fragile environment—in the coming decades," explains Amit Yaari, PhD, CEO of BioBetter. "Cultivated meat offers a promising solution to these problems and can ensure a more resilient supply chain with better economic and environmental returns.
"Thanks to the Biobetter platform, tobacco is set to make a pivotal comeback as a catalyst for bringing better food security," adds Dana Yarden, MD, co-founder of BioBetter. "As a result of this funding round, we can scale up production in 2023 and expect to go commercial with our tobacco plant-derived, food-grade GF portfolio by 2024."
Biobetter is one of the dozens of food-tech start-ups that work under the umbrella of the new the international foodtech center of Margalit Start-up City Galil launched last year by the globally renowned VC. The new ecosystem was established as part of a strategic move to transform Israel's Galilee region into a new nerve center for Agri-food tech innovation and to engender fruitful collaboration between the network of academic institutions and businesses rooted in these fields that exist in the region.
About BioBetter
BioBetter was founded by Oded Shoseyov, PhD, a serial entrepreneur and researcher at The Hebrew University in Jerusalem; Dana Yarden MD, MBA, a biotech business expert; and Avi Tzur, an industrialist with an avid vision to put tobacco plant to positive use and the first investor in the technology. BioBetter pioneers novel protein expression platforms to address the fast-growing demand for complex recombinant proteins.
The new technology will alleviate one of the biggest bottlenecks in advancing cultured meat to mass production. The start-up previously raised USD5M for its growth factor production platform from private investors, including Institutional VC and Alpha Capital Anstalt. The company participates in the Israel Innovation Authority program and the Good Food Institute, which also helps support the company's financing.
About JVP
JVP, founded in 1993 by Dr. Erel Margalit, is an internationally renowned VC fund. It is among the pioneering firms of the Israeli VC industry and has raised over $1.6bn. Over the years, JVP has built over 160 companies and has been listed numerous times by Preqin, as one of the top-ten consistently performing VC firms worldwide. JVP has been instrumental in building some of the world's largest companies to emerge, facilitating 12 IPOs on NASDAQ, including CyberArk Software ($4.7 billion mkt. cap.), QLIK Technologies ($4 billion mkt. cap.) as well as many large industry sales. Over the past decade, JVP has spearheaded the creation of international Centers of Excellence, including the AI and Media center in Jerusalem, the Cyber center in Beer Sheva, the FoodTech center in the Galilee, and the International Cyber and FinTech center in NYC, in partnership with NYC/EDC and the leading universities of the city. https://www.jvpvc.com.
Company contact
BioBetter
Dana Yarden, Co-Founder
E-mail: info@biobetter.bio
Web: www.biobetter.bio
Press contact
NutriPR
Liat Simha
Tel: +972-9-9742893
E-mail: liat@nutripr.com
Twitter: @LiatSimha
Web: www.nutripr.com
Photo - https://mma.prnewswire.com/media/1892505/BioBetter_and_JVC_annonce_A_round_investment.jpg
View original content to download multimedia:
SOURCE BioBetter | https://www.whsv.com/prnewswire/2022/09/07/biobetter-lands-usd10m-funding-relieve-cultivated-meats-bottleneck-using-tobacco-plants/ | 2022-09-07T11:51:31Z |
ROSEVILLE, Minn., Sept. 7, 2022 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced that Michael A. Carr, President and Chief Executive Officer, and Bill Koschak, Chief Financial Officer, will present at the H.C Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022.
H.C. Wainwright 24th Annual Global Investment Conference
Date: Tuesday, September 13, 2022
Time: 2:30 p.m. ET
Webcast: https://journey.ct.events/view/89f76b34-90f0-4836-b94b-90b001e47b2a
Management is also available for 1:1 meetings during the conference. Conference attendees should reach out to the event organizers or investors@calyxt.com to schedule.
The presentation will be available for viewing and replay from the Investors section of Calyxt's website at www.calyxt.com.
Calyxt (Nasdaq: CLXT) is a plant-based synthetic biology company. The Company leverages its proprietary PlantSpring™ technology platform to engineer plant metabolism to produce innovative high value plant-based chemistries for use in customers' materials and products. As plant-based solutions, the Company's synthetic biology products can be used in helping customers meet their sustainability targets and financial goals. Calyxt's diversified offerings are primarily delivered through its proprietary BioFactory™ production system. For more information, visit www.calyxt.com.
PlantSpring, BioFactory, Plant Cell Matrix™, and the Calyxt logo are trademarks of Calyxt, Inc. Any other trademarks belong to their respective owners.
Contacts:
View original content to download multimedia:
SOURCE Calyxt, Inc. | https://www.whsv.com/prnewswire/2022/09/07/calyxt-present-hc-wainwright-24th-annual-global-investment-conference/ | 2022-09-07T11:51:37Z |
SAN FRANCISCO BAY AREA, Calif., Sept. 7, 2022 /PRNewswire/ -- Rondo Therapeutics, a privately-held biotechnology company advancing next-generation immuno-oncology platforms, announces the addition of Carolyn Bertozzi, Ph.D., to its Scientific Advisory Board. Dr. Bertozzi is a Professor of Chemistry and Director of the Sarafan ChEM-H institute at Stanford University and is a world leader in the field of glycobiology, generating new insights regarding disease-associated changes in cell surface glycosylation patterns. Jessica Stark, Ph.D., an American Cancer Society postdoctoral fellow in the Bertozzi Research Group, is also joining Rondo as a scientific consultant. Dr. Stark has pioneered new approaches in understanding the role of glycobiology in the functioning of the innate immune system.
Dr. Bertozzi has been recognized with many honors and awards for both her research and teaching accomplishments. She is an elected member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the German Academy of Sciences Leopoldina. Recent awards of note include the Welch Award in Chemistry (2022); The Dickson Prize in Medicine, University of Pittsburgh (2022); Dr H.P. Heineken Prize for Biochemistry and Biophysics (2022); Wolf Prize (2022); AAAS Lifetime Mentor Award (2022). Dr. Bertozzi is also an accomplished entrepreneur, having founded several biotech companies including Palleon Pharma and Lycia Therapeutics.
"We are excited and privileged to be working with both Carolyn and Jessica in an exciting new area of biology," said Nathan Trinklein, Ph.D., co-founder and President of Rondo Therapeutics. "By combining their deep biological knowledge with Rondo's unique ability to rapidly develop bispecific antibodies, we are aiming to create a new class of biologics with a unique mechanism of action."
"We are thrilled to be working with the Rondo team to take on glycobiology as an emerging frontier for immunotherapy," said Jessica Stark, Ph.D., American Cancer Society postdoctoral fellow at Stanford University. "Through development of a novel class of bispecifics, we hope to make a difference for patients in multiple solid tumor indications."
Dr. Bertozzi is joining a group of highly distinguished scientists and clinicians on Rondo's Scientific Advisory Board: James Ford, M.D., Professor of Medicine, Stanford University; Alessandra Cesano, CMO, ESSA Pharmaceuticals; and Leonard Presta, Ph.D., renowned Protein Engineer.
Rondo Therapeutics is a biopharmaceutical company exploring new frontiers in cancer therapy. Rondo is committed to advancing the field of immuno-oncology, with a focus on treating solid tumors that fail to respond to current therapies. Our solution is to create a new class of bispecific antibodies that safely engage the immune system to initiate and sustain a robust anti-tumor response and overcome the suppressive tumor microenvironment.
Learn more at: www.rondotx.com.
View original content:
SOURCE Rondo Therapeutics | https://www.whsv.com/prnewswire/2022/09/07/carolyn-bertozzi-professor-director-sarafan-chem-h-institute-stanford-university-joins-rondo-therapeutics-scientific-advisory-board/ | 2022-09-07T11:51:45Z |
ROCKVILLE, Md. and LUND, Sweden, Sept. 7, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, and BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced the first-patient-in in China Phase 1 dose-escalation and expansion study of BI-1206, a first-in-class fully human monoclonal antibody (mAb) that targets FcγRIIB, in combination with rituximab in patients with relapsed/refractory Non-Hodgkin's Lymphoma (NHL). The study design is to assess the safety, tolerability, pharmacology, and clinical activity of BI-1206. The patient was enrolled at Henan Cancer Hospital.
Wei-Wu He, Ph.D., CASI's Chairman, and Chief Executive Officer, commented, "We are excited to dose the first patient in the continued evaluation of BI-1206. BI-1206 has previously shown encouraging early signs of efficacy in Phase 1, a tolerable safety profile, and the potential to be used with multiple therapeutic mAbs that rely on ADCC/CDC* for efficacy. This Phase 1 trial in China will generate valuable information and has the potential to provide early evidence of clinical activity in the treatment of relapsed or refractory Non-Hodgkin's Lymphoma."
Martin Welschof, CEO of BioInvent, said: "The initiation of this Phase I trial in China is an important milestone for BioInvent as it marks the expansion of the clinical program of our lead drug candidate, BI-1206. The clinical results have been very promising, and we are looking forward to generating additional data together with our partner CASI Pharmaceuticals with the aim of improving treatment for patients with NHL and addressing this significant unmet medical need."
The National Medical Products Administration (NMPA) granted BI-1206 Clinical Trial Application (CTA) approval in December 2021. Ethics committee approval from a leading investigational site was granted in January 2022. BI-1206 is currently being investigated outside of China in two Phase 1/2 trials. One is evaluating the BI-1206 combination with rituximab for the treatment of non-Hodgkin lymphoma (NHL), which includes patients with follicular lymphoma (FL), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL) who have relapsed or are refractory to rituximab. A second Phase 1/2 trial is investigating BI-1206 in combination with anti-PD1 therapy Keytruda® (pembrolizumab) in solid tumors. Earlier this year, the U.S. FDA granted Orphan Drug Designation, for BI-1206, for the treatment of follicular lymphoma, the most common form of slow-growing non-Hodgkin lymphoma.
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering. The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com
CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the Greater China market, leveraging the Company's China-based regulatory and commercial competencies and its global drug development expertise. The Company's operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd., located in Beijing, China. The Company has built a commercial team of more than 100 hematology and oncology sales and marketing specialists based in China. More information on CASI is available at www.casipharmaceuticals.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, revenue growth, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and we assume no duty to update forward-looking statements. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Actual results could differ materially from those currently anticipated due to a number of factors.
The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.
For further information, please contact:
CASI Pharmaceuticals, Inc.
Rui Zhang
Phone: 240.864.2643
Email: ir@casipharmaceuticals.com
BioInvent International AB (publ)
Cecilia Hofvander, Senior Director Investor Relations
Phone: +46 (0)46 286 85 50
Email: cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
View original content to download multimedia:
SOURCE CASI Pharmaceuticals, Inc. | https://www.whsv.com/prnewswire/2022/09/07/casi-pharmaceuticals-bioinvent-announce-dosing-first-patient-bi-1206-phase-1-clinical-trial-treatment-relapsedrefractory-non-hodgkins-lymphoma-china/ | 2022-09-07T11:51:52Z |
LONDON, Sept. 7, 2022 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, announced today that Jonathan Gear, Chief Executive Officer, and Jonathan Collins, Executive Vice President and Chief Financial Officer, will present at the following investor conferences in September 2022.
- Barclays Global Financial Services Conference on Monday, September 12, 2022 at 9:00 am Eastern Time. The live webcast can be accessed at https://event.webcasts.com/starthere.jsp?ei=1569249&tp_key=f56825be66&tp_special=8 and will be available for replay.
- Goldman Sachs Communacopia + Technology Conference on Thursday, September 15, 2022 at 11:30 am Pacific Time (2:30 pm Eastern Time) at https://event.webcasts.com/starthere.jsp?ei=1569224&tp_key=0b52f79e6f&tp_special=8 and will be available for replay.
Clarivate™ is a global leader in providing solutions to accelerate the pace of innovation. Our bold mission is to help customers solve some of the world's most complex problems by providing actionable information and insights that reduce the time from new ideas to life-changing inventions in the areas of Academia & Government, Life Sciences & Healthcare, Professional Services and Consumer Goods, Manufacturing & Technology. We help customers discover, protect and commercialize their inventions using our trusted subscription and technology-based solutions coupled with deep domain expertise. For more information, please visit clarivate.com.
Category: Webcast
Source: Clarivate Plc
View original content to download multimedia:
SOURCE Clarivate Plc | https://www.whsv.com/prnewswire/2022/09/07/clarivate-present-upcoming-investor-conferences-september-2022/ | 2022-09-07T11:51:58Z |
Mostow to Play Integral Role in CodeMettle's Continued Strategic Growth
ATLANTA, Sept. 7, 2022 /PRNewswire/ -- CodeMettle, an innovative developer of NetOps software from the edge to the enterprise, today announced Mike Mostow as its first chief operating officer. Mostow brings more than 25 years of experience in operations and sales leadership, along with a proven track record of building and scaling teams in fast-growing enterprise software and technology companies.
"We welcome Mike Mostow as our first-ever COO to guide our continued growth," said Richard Graham, CEO of CodeMettle. "Mike will play an integral role in that growth by leading business development, sales, marketing and operations. He will support our customers with the successful deployment and use of our products, including our new revolutionary Terminus 2.0, a first-of-its-kind product in the NetOps industry."
Mostow will continue to drive the use of sophisticated DevSecOps engineering practices as a competitive advantage, solving complex customer problems in bold and innovative ways. He will ensure operational excellence across the product sales and delivery lifecycle, providing our customers the best performing, most reliable, and highest quality NetOps solutions.
"It's a once-in-a-lifetime opportunity to join the CodeMettle team at this exciting time," said Mostow. "The company's customers, people, culture and technology are unmatched in the market. CodeMettle's dedication to exceeding customer requirements, to include those of our nation's Warfighters, is also a true company differentiator."
Previously, Mostow served in executive roles at Everbridge Inc. and Leidos. He brings two-plus decades of prior experience in sales leadership and general management, along with demonstrated success in scaling commercial and government enterprise software and technology businesses. Mostow will prioritize operational excellence as CodeMettle prepares for both for the upcoming Army Unified Network Operations program and the application of CodeMettle's products across the government and commercial markets.
CodeMettle was established in 2009 to simplify the management of the most complex networks for defense, government and commercial customers. Our intuitive software products consolidate fragmented data, processes and operations into one common operating picture. Edge to enterprise, simplified. Learn more.
Joyce Bosc
On behalf of CodeMettle
(301) 717-9529
jbosc@boscobel.com
View original content:
SOURCE CodeMettle | https://www.whsv.com/prnewswire/2022/09/07/codemettle-announces-industry-veteran-mike-mostow-first-coo/ | 2022-09-07T11:52:05Z |
WASHINGTON, Sept. 7, 2022 /PRNewswire/ -- Cogent Communications Holdings, Inc. (NASDAQ: CCOI) ("Cogent") announced today that it has entered into a definitive agreement to acquire T-Mobile's Wireline Business. Cogent's commitment to serving the Wireline Business customers it is acquiring through this transaction will cement the future for this strong legacy business as T-Mobile continues its strategic focus on providing wireless solutions to consumers and enterprises as the core of its future growth.
For Cogent, acquisition of T-Mobile's Wireline Business is expected to be an ideal strategic fit with its existing business. The Wireline Business offers the legacy Sprint U.S. long-haul network that provides an owned network asset to complement and eventually replace Cogent's current leased network and provides the ability to expand its product set, including the sales of optical wave transport services to new and existing customers. It also has a current customer base who are a fit for Cogent's products and services, and a group of experienced employees with the knowledge and capabilities to execute the company's strategy.
As part of the agreement, in addition to the fiber network and related assets and customers, Cogent will acquire certain liabilities associated with the business. In addition, at the closing of the acquisition, the parties will enter into a separate agreement pursuant to which Cogent will offer IP transit services to T-Mobile for 54 months following the closing date and T-Mobile will pay Cogent $700 million for such services, with $350 million due in equal payments over the first 12 months after closing and $350 million due in equal payments over the remaining 42 months.
Cogent expects to offer customers the ability to migrate from their legacy MPLS VPN solutions to modern Ethernet / VPLS or SD-WAN / DIA solutions for their corporate needs. Cogent also expects to facilitate the migration of netcentric internet access customers from the T-Mobile Wireline Business (legacy Sprint) AS1239 to Cogent's AS174.
A newly formed direct subsidiary of Cogent will consummate the acquisition. Cogent does not plan to issue new debt or equity in order to finance the acquisition, and the transaction is not expected to be dilutive to Cogent's existing stockholders. Cogent plans to maintain its current dividend per share, which is expected to continue to increase over time.
The transaction is subject to receipt of regulatory approvals and other customary closing conditions and is expected to close in the second half of 2023.
Morgan Stanley & Co. LLC served as exclusive financial advisor for Cogent, and Latham & Watkins LLP acted as legal advisor.
Houlihan Lokey served as the exclusive financial advisor to T-Mobile and T-Mobile was represented by Joseph Alexander, Nancy Victory, Marc Samuel and Jason Juall from DLA Piper.
Cogent will host a conference call with investors to discuss the announcement at 8:00 a.m. EDT. To join via phone, participants must register for the call here.
Once registered, participants will receive the dial in number along with a unique PIN. Each individual caller will require their own unique PIN. To ensure timely access, participants should register promptly and dial in approximately 5 minutes before the call starts. A listen only webcast is accessible under "Events" in the "About" section of Cogent's website at https://www.cogentco.com/events and will remain available through September 21, 2022. A presentation about the announcement can be found at Cogent's website here.
Cogent (NASDAQ: CCOI) is a facilities-based provider of low cost, high speed Internet access and private network services to bandwidth intensive businesses. Cogent's facilities-based, all-optical IP network provides services in over 219 markets across 51 countries.
Cogent is headquartered at 2450 N Street, NW, Washington, D.C. 20037. For more information, visit www.cogentco.com. Cogent can be reached in the United States at (202) 295-4200 or via email at info@cogentco.com.
Except for historical information and discussion contained herein, statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. These forward-looking statements include, but are not limited to, statements regarding benefits of the proposed acquisition, integration plans and expected synergies and anticipated future financial and operating performance and results, including estimates for growth. The statements in this release are based upon the current beliefs and expectations of Cogent's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including risks related to the acquisition of T-Mobile's Wireline Business by Cogent and related transactions, such as the expected timing and likelihood of completion of the pending acquisition, including the timing, receipt and terms and conditions of any required governmental and regulatory approvals of the pending merger that could reduce anticipated benefits; the ability to successfully integrate the businesses; the occurrence of any event, change or other circumstance that could give rise to the termination of the acquisition agreement; the risk that the parties may not be able to satisfy the conditions to the proposed transaction in a timely manner or at all; risks related to disruption of management time from ongoing business operations due to the proposed transaction; the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of Cogent's common stock; the risk that the proposed transaction and its announcement could have an adverse effect on the ability of Cogent and T-Mobile to retain customers, to retain and hire key personnel or to maintain relationships with their suppliers and customers and on their operating results and businesses generally; the risk that problems may arise in successfully integrating the businesses of the companies, which may result in the combined company not operating as effectively and efficiently as expected; the risk that the combined company may be unable to achieve cost-cutting synergies or that it may take longer than expected to achieve those synergies and other factors; and other risks discussed from time to time in Cogent's filings with the Securities and Exchange Commission, including, without limitation, Cogent's Annual Report on Form 10-K for the year ended December 31, 2021 and Quarterly Reports on Form 10-Q for the quarters ended March 31, 2022 and June 30, 2022. Cogent undertakes no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.
View original content to download multimedia:
SOURCE Cogent Communications Holdings, Inc. | https://www.whsv.com/prnewswire/2022/09/07/cogent-announces-definitive-agreement-acquire-t-mobiles-wireline-business/ | 2022-09-07T11:52:13Z |
- YaronTurpaz, Ph.D., SVP and Senior Advisor, Computational Discovery, Compugen to participate in a panel discussion on leveraging artificial intelligence and machine learning to advance discovery and accelerate drug development.
HOLON, Israel, Sept. 7, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today, that Yaron Turpaz, Ph.D., Senior Vice President and Senior Advisor, Computational Discovery at Compugen will participate in a panel at the Fierce Biotech Summit taking place from 20 to 21 September 2022, in Boston, United States.
Event: Fierce Biotech Summit
Date: Tuesday, September 20, 2022
Speaker: Yaron Turpaz, Senior Vice President and Senior Advisor, Computational Discovery, Compugen
Panel: Leverage AI and ML to Advance Discovery and Accelerate Drug Development
More details about the event can be found on link
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class monoclonal antibody targeting TIGIT for the treatment of solid tumors. Partnered programs include bapotulimab, an antibody targeting ILDR2, in Phase 1 development, licensed to Bayer under a research and discovery collaboration and license agreement, and a TIGIT/PD-1 bispecific derived from COM902 (AZD2936) in Phase 1/2 development by AstraZeneca through a license agreement for the development of bispecific and multi-specific antibodies. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets. The most advanced program, a high affinity antibody, COM503 with first-in-class potential is about to enter pre-IND enabling studies. COM503 targets a soluble immune checkpoint upregulated in the tumor microenvironment in response to IFN-γ. Compugen is headquartered in Israel, with offices in South San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.
Company contact:
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:
SOURCE Compugen Ltd. | https://www.whsv.com/prnewswire/2022/09/07/compugen-participate-upcoming-fierce-biotech-summit/ | 2022-09-07T11:52:19Z |
CHICAGO, Sept. 7, 2022 /PRNewswire/ -- COUR Pharmaceuticals, a clinical-stage biotechnology company developing novel immune-modifying nanoparticles (COUR NanoParticles or CNPs) designed to reprogram the immune system in treating autoimmune disorders, announced the closing of a $30 million financing led by Alpha Wave Ventures.
The proceeds from the financing will be used to expand COUR's CNP platform technology and advance the Company's two human proof-of-concept studies in Primary Biliary Cholangitis and Peanut allergy, as well as development programs in Myasthenia Gravis and Type 1 Diabetes. In addition to autoimmune and allergic disorders, COUR's platform technology has application in gene therapy to induce immune tolerance, with the potential to improve durability and enable repeat dosing.
"As COUR set out to pursue its first institutional financing round in the Company's history, we were very fortunate to find a likeminded investor in Alpha Wave, which appreciates our innovation-driven culture and mission-critical approach to taking on big ideas in therapeutic areas where there are no or few therapies" said CEO and Founder, John J. Puisis, adding "The ability to secure a financing in these turbulent market conditions is a true testament to the tremendous capabilities of COUR's team, technology and results to date. With this important infusion of capital, we look forward to rapidly advancing our revolutionary drug candidates aimed to reprogram the immune system for people suffering from immune disorders."
As part of the financing, Chris Dimitropoulos, Managing Director, Biotechnology at Alpha Wave Global, will join COUR's Board of Directors.
"With multiple validating partnerships, an independent clinical development pipeline and the first known clinical study in humans demonstrating antigen-specific tolerance, we strongly believe COUR is well positioned to be the leader in bringing to market multiple first-in-class antigen-specific therapies to drive a paradigm shift in the treatment of autoimmune disorders away from immune suppressive approaches and towards true immune reprogramming." said Chris Dimitropoulos. "We look forward to working collaboratively with the COUR team to advance this important technology."
SVB Securities acted as the placement agent to the Company in connection with the financing. Cooley LLP served as legal advisor to COUR Pharmaceuticals and Kirkland and Ellis LLP served as legal counsel to Alpha Wave Ventures.
COUR Pharmaceuticals is developing first-in-class therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease. COUR's platform of immune-modifying nanoparticles focus on treating the root cause of immune disease, unlike traditional approaches, which only minimize symptoms using toxic immune suppression. COUR's lead product for celiac disease, partnered with Takeda Pharmaceutical Company, is the first demonstration of induction of antigen-specific immune tolerance in any autoimmune disease. Data from clinical and preclinical settings demonstrate the potential opportunity for the COUR nanoparticle platform to address a wide range of immune and inflammatory conditions. The underlying technology was acquired from Northwestern University and draws from more than 30 years of research in immune tolerance. For more information, please visit www.courpharma.com.
Alpha Wave is a global investment company with offices in New York, Miami, London, Abu Dhabi, Tel Aviv, Bangalore, Jakarta, and Sydney. Its flagship global venture and growth fund, Alpha Wave Ventures, aims to invest in best-in-class venture and growth-stage companies and endeavors to be helpful long-term partners to the founders and management teams. Alpha Wave manages a variety of investment partnerships that cover several asset classes, themes, and geographies. For more information, please visit www.alphawaveglobal.com.
Investor Relations & Media Contact:
Brian C. Bock
Chief Financial Officer
bbock@courpharma.com
View original content to download multimedia:
SOURCE COUR Pharmaceuticals | https://www.whsv.com/prnewswire/2022/09/07/cour-pharmaceuticals-announces-30m-financing-led-by-alpha-wave-ventures/ | 2022-09-07T11:52:26Z |
MISSISSAUGA, ON, Sept. 7, 2022 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF) an advanced medical technologies company, today is pleased to announce that the Company's Board of Directors has approved the grant of stock options (the "Options") exercisable for a total of 437,500 common shares ("Common Shares") to certain of its employees. All Options were granted pursuant to the Company's amended and restated stock option plan and are subject to the terms of the applicable grant agreements and the requirements of the TSX Venture Exchange.
The Options were granted at an exercise price of $2.50, being equal to the volume weighted average trading price of the Common Shares on the TSX Venture Exchange for the five (5) trading days immediately preceding the day on which the Option is granted. The Options shall vest 34% on the first anniversary following the date of the grant, 33% on the second anniversary following the date of the grant and 33% on the third anniversary following the date of grant. The Options shall expire on the date that is five (5) years from the initial grant date.
Covalon Technologies Ltd. is a researcher, developer, manufacturer, and marketer of patent-protected medical products that improve patient outcomes and save lives in the areas of advanced wound care, infection management and surgical procedures. Covalon leverages its patented medical technology platforms and expertise in two ways: (i) by developing products that are sold under Covalon's name; and (ii) by developing and commercializing medical products for other medical companies under development and license contracts. The Company is listed on the TSX Venture Exchange, having the symbol COV and trades on the OTQX Market under the symbol CVALF. To learn more about Covalon, visit our website at www.covalon.com.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management's expectations, estimates and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the "Risks and Uncertainties" section of our management's discussion and analysis of financial condition and results of operations for the three and nine months ended June 30, 2022, which is available on the Company's profile at www.sedar.com, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events or otherwise, except as required by law.
View original content to download multimedia:
SOURCE Covalon Technologies Ltd. | https://www.whsv.com/prnewswire/2022/09/07/covalon-announces-issuance-stock-options/ | 2022-09-07T11:52:32Z |
For the first time, OEMs and their suppliers can have full visibility and manage vulnerabilities for all components within a single platform
DETROIT, Sept. 7, 2022 /PRNewswire/ -- Cybellum, a leading provider of the Product Security Platform for automotive manufacturers, announced today at the 6th Annual Auto-ISAC Summit, a first-of-its-kind solution for greater visibility and vulnerability analysis and management of AUTOSAR based ECUs. This enables greater insight for OEMs and their suppliers, of all of their components, from one platform, to provide more secure vehicles and to comply faster with emerging regulations.
The AUTOSAR platform is well-established for providing deeply embedded electronic control units (ECUs). As vehicles have evolved over the last number of decades from simpler electronic units to software defined machines, AUTOSAR has provided OEMs and suppliers a stable foundation to build their distributed software systems. By using a layered software architecture with a compatible methodology, the AUTOSAR Platform supports all kinds of microcontroller-based ECUs, from engine control units to life-saving ADAS features.
To comply with current and emerging regulations and to ensure that the vehicles are safe from a cyber security standpoint, automobile manufacturers must have visibility into the software and module compositions of AUTOSAR ECUs. With this release by Cybellum, OEMs are able to receive full visibility with vulnerability management from one comprehensive platform.
"We are excited with this release and expanded support for AUTOSAR that provides OEMs and their suppliers with the most complete offering available for uncovering and managing vulnerabilities for all vehicle components," said Eran Rosenberg, VP of Product Management at Cybellum. "Our team continuously works to expand Cybellum's platform, providing more expanded vulnerability monitoring, threat detection, and remediation solutions for the automotive sector. AUTOSAR is another example of the additional capabilities we are adding to our product security platform to enable manufacturers to rapidly comply with regulations and ensure that their vehicles are free of cyber threats."
The new capability enables automobile manufacturers to rapidly meet compliance requirements for AUTOSAR ECUs with full visibility and by identifying and analyzing vulnerabilities and threats in components, modules, and software. This is especially crucial in a time where manufacturers are working to reduce time to market while maneuvering through an unprecedented hostile cybersecurity environment.
About Cybellum
Cybellum enables automotive OEMs and suppliers to keep the products they build secure and compliant, every single moment of their life. Industry leaders use Cybellum's product security platform to fuse security into every phase of the product lifecycle. Powered by Cyber Digital Twins™ technology -- a live digital replica of every software component inside your devices – Cybellum allows product security teams to manage cyber risk continuously, whatever new threat arises. From living SBOMs to automated vulnerability management and continuous monitoring, teams can ensure their product portfolio is secure from design to post-production and beyond. www.cybellum.com
Cybellum media contact:
Annette Habani
Marketing Manager
Cybellum
annette@cybellum.com
View original content:
SOURCE Cybellum | https://www.whsv.com/prnewswire/2022/09/07/cybellum-announces-solution-autosar-providing-oems-their-suppliers-with-component-visibility-risk-vulnerability-management/ | 2022-09-07T11:52:39Z |
PRINCETON, N.J., Sept. 7, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that Dr. Phillip Chan, Chief Executive Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022. An on-demand webcast of the presentation will be accessible via the following Link. Company management will also meet with investors in 1x1 meetings throughout the conference.
An archived recording of CytoSorbents' presentation at the conference will be available under the Investor Relations portion of the Company's website at Events & Presentations - Cytosorbents, and will be available for 90 days.
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood purification. Its lead product, CytoSorb®, is approved in the European Union and distributed in more than 70 countries worldwide. It is an extracorporeal cytokine adsorber that reduces "cytokine storm" or "cytokine release syndrome" in common critical illnesses that can lead to massive inflammation, organ failure and patient death. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments. CytoSorb is also used during and after cardiothoracic surgery to remove inflammatory mediators that can lead to postoperative complications, including multiple organ failure. As of June 30, 2022, more than 179,000 CytoSorb devices have been used cumulatively. CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure. The DrugSorb™-ATR antithrombotic removal system, based on the same polymer technology as CytoSorb, also received two FDA Breakthrough Device Designations, one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic procedures. The company has initiated two FDA-approved pivotal studies to support FDA marketing approval of DrugSorb-ATR in the United States. The first is the randomized, controlled STAR-T (Safe and Timely Antithrombotic Removal-Ticagrelor) study of 120 patients at 30 centers to evaluate whether intraoperative use of DrugSorb-ATR can reduce the perioperative risk of bleeding in patients receiving ticagrelor and undergoing cardiothoracic surgery. The second study is the STAR‑D (Safe and Timely Antithrombotic Removal-Direct Oral Anticoagulants) randomized, controlled trial of 120 patients at 30 centers evaluating the intraoperative use of DrugSorb-ATR to reduce perioperative bleeding risk in patients undergoing cardiothoracic surgery and taking direct oral anticoagulants, including apixaban and rivaroxaban.
CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other body fluids through pore entrapment and surface adsorption. The company's technologies have received more than $39.5 million in non-dilutive grants, contracts and other non-dilutive funding from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), the National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF/AFMC) and others. The company has numerous marketed and in-development products based on this unique blood purification technology protected by numerous issued U.S. and international patents and registered trademarks, as well as several pending patent applications, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, DrugSorb™-ATR, ContrastSorb and others. For more information, please visit the company's websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter.
Forward-looking statements
This press release contains forward-looking statements that fall within the safe harbor of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding our plans, objectives, future goals and prospects for our business, expectations regarding the future impact of COVID-19 or the ongoing conflict between Russia and Ukraine, representations and assertions, and are not historical facts and are generally identified by the use of words such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar terms, although some forward-looking statements are worded differently. You should be aware that the forward-looking statements in this press release reflect management's current beliefs and expectations, but that our actual results, events and performance may differ materially from those in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the risks disclosed in our Annual Report on Form 10-K filed with the SEC on March 10, 2022, our Quarterly Reports on Form 10-Q and the press releases and other communications to stockholders that we issue from time to time seeking to inform interested parties of the risks and factors that may affect our business. We caution you not to place undue reliance on such forward-looking statements. We are under no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by federal securities laws.
Please Click to Follow Us on Facebook and Twitter
CytoSorbents Contact:
Amy Vogel
(732) 398-5394
avogel@cytosorbents.com
Public Relations Contact:
Eric Kim
Rubenstein Public Relations
212-805-3052
ekim@rubensteinpr.com
View original content to download multimedia:
SOURCE CytoSorbents Corporation | https://www.whsv.com/prnewswire/2022/09/07/cytosorbents-present-hc-wainwright-24th-annual-global-investment-conference/ | 2022-09-07T11:52:46Z |
New book by the KickCharge® Creative president and leading authority on disruptive marketing for service businesses provides invaluable blueprint for driving growth with branding
WASHINGTON, N.J., Sept. 7, 2022 /PRNewswire/ -- Dan Antonelli, creative director and president of KickCharge® Creative and a pioneer in disruptive branding for the home service industry, shares critical insights that help small service business owners grow in his new best-selling book, "Branded Not Blanded: KickCharge™ Your Home Service Brand."
Antonelli has created more than 2,000 brand designs in his career, establishing him as the leading authority on successful branding for service companies. "Branded Not Blanded," available now for pre-order on the Amazon website, leverages his experience to offer business owners a blueprint for creating a killer home service brand.
"This book is the ultimate guide to creative branding that helps businesses stand out from the competition, attract the right clients and employees, and win the hearts and minds of their ideal customers," Antonelli said. "Complacency and weak branding — or 'blanding' — hold back so many home service companies. But recognizing weak branding is an opportunity to change the direction of your company and improve your culture. There are many weak brands in the service industry, and it's easy to leverage that for your own success. All you have to do is build a better brand."
With real case studies and success stories as well as actionable insights for home service business owners, "Branded Not Blanded" is a valuable resource for small service business owners. Antonelli presents his comprehensive knowledge in accessible language and easily digestible chapters that readers can apply to their own business.
In the book, Antonelli guides readers through essential topics such as:
- Brand Basics: The basics of what branding means for home service companies, and how it's relevant to their success.
- What Is Brand Disruption?: When it comes to branding, disruption means looking at what everyone else is doing and finding a way to be unique and different.
- Branding and the Home Consumer: Your branding needs to speak to skeptical consumers and make potential customers feel something positive about your company.
- Leveraging Your Brand to Win on the Streets: Your vehicles are perhaps the single most important part of your brand efforts — and one of the most cost-effective.
- Launching Your New Brand: Introducing your new brand to the world effectively requires careful planning and implementation.
"Many owners of home service businesses say they can't afford to invest in branding, but the truth is they can't afford not to," Antonelli said. "Companies with effective brands spend less on marketing than complacent, bland brands. It takes less work to get people excited about a company with a compelling, brand story and a strong, memorable visual brand identity. With this book, business owners can learn what branding truly is, why it matters in our industry, and how they can successfully implement a dynamic brand strategy that will drive revenue, support a positive workplace culture and power growth."
To pre-order Dan Antonelli's "Branded Not Blanded," visit https://www.amazon.com/Branded-Not-Blanded-KickChargeTM-Service-ebook/dp/B0BBL1CCJ9.
For more information about KickCharge® Creative, visit https://www.kickcharge.com.
KickCharge® Creative is an award-winning branding agency that has been setting the standard for small business marketing for more than 25 years. We have helped hundreds of startups, small- and mid-sized businesses thrive and grow thanks to our unique understanding of how to create disruptive brands that connect with their customers. At KickCharge Creative, we specialize in branding, logo development, truck wrap design, website design, social media, content writing and everything else related to marketing. We don't just talk the talk. We walk the walk. Our team has the tools and tactics to differentiate you from your competitors. For more information, visit https://www.kickcharge.com.
MEDIA CONTACT:
Heather Ripley
Ripley PR
(865) 977-1973
hripley@ripleypr.com
View original content to download multimedia:
SOURCE KickCharge® Creative | https://www.whsv.com/prnewswire/2022/09/07/dan-antonelli-delivers-key-branding-insights-home-service-companies-best-selling-branded-not-blanded/ | 2022-09-07T11:52:52Z |
ATLANTA, Sept. 7, 2022 /PRNewswire/ -- The government of Costa Rica has selected DEKRA to operate the country's vehicle inspection program. The decision was announced by the President of Costa Rica, Rodrigo Chaves, in a press conference on Wednesday, August 26. DEKRA is expected to begin conducting inspections in late September.
DEKRA will operate the Inspección Técnica Vehicular vehicle inspection program for two years, including management of 13 physical stations and 3 mobile stations across Costa Rica. DEKRA plans to employ approximately 450 local personnel in 2022, in order to conduct an average of 2 million vehicle inspections each year. Inspections are required annually for all vehicles in Costa Rica, including passenger cars, commercial vehicles, taxis, and motorcycles. Required inspections include safety components, such as performance of brakes and shocks, as well as emissions testing.
President Chaves highlighted DEKRA's extensive experience in vehicle inspection and global reputation for excellence as part of its winning bid. Eleven bids from national and international companies were considered in the competitive tender.
"Each day and in every action we take, DEKRA is committed to creating a safer and more sustainable world," said Bert Zoetbrood, President and Chief Regional Officer of DEKRA Americas. "We are proud to be the vehicle inspection partner for the government and people of Costa Rica, making roads safer and air cleaner with each inspection that we conduct."
Costa Rica will be the fifth country in the Americas where DEKRA conducts vehicle inspections, joining existing programs in the United States, Mexico, Chile, and Brazil. In the past 18 months, DEKRA has established new vehicle inspection business in five countries, including three in the Americas, bringing the total to 25 countries globally. DEKRA is the world's leading vehicle inspection company and, with the addition of Costa Rica, will perform nearly 30 million inspections annually.
"DEKRA's technical expertise in the field of periodic vehicle inspection is in demand worldwide and is winning over more and more markets," says Christoph Nolte, who, as Executive Vice President, is responsible for DEKRA's Vehicle Inspection business field. "Technically safe vehicles that are regularly inspected according to recognized standards are a basic prerequisite for road safety."
DEKRA North America protects people, assets, and our community by providing comprehensive testing, inspection, certification and consulting services around the globe. DEKRA NORTH AMERICA is a service unit of DEKRA S.E., a global leader in safety since 1925 with over 47,000 employees in 60 countries across six continents.
View original content:
SOURCE DEKRA North America | https://www.whsv.com/prnewswire/2022/09/07/dekra-awarded-national-vehicle-inspection-program-costa-rica/ | 2022-09-07T11:52:58Z |
NEW YORK, Sept. 7, 2022 /PRNewswire/ --
Key takeaways
- Increasingly, additional responsibilities are falling to the audit committee, including cybersecurity and environmental, social, and governance (ESG) reporting. According to the "Audit Committee Practices Report," a survey conducted by Deloitte and the Center for Audit Quality finds audit committees are being challenged by increased complexity in their core responsibilities as well as scope creep across other areas within their organizations.
- Deloitte has updated, modernized, and digitized its "Audit Committee Guide" to provide up-to-date resources and insights on how audit committee members can perform their duties effectively.
- Deloitte's "Audit Committee Guide" provides access to the latest tools and resources regarding committee requirements, oversight responsibilities and strategies for promoting effectiveness. It also features questions that committees can consider asking to drive candid discussions.
- The guide is useful for veteran and new audit committee members alike, as well as those who work closely with audit committees, CFOs, controllers, chief audit executives, general counsel, corporate secretaries, and independent auditors.
Deloitte launched an enhanced and digitized version of its "Audit Committee Guide" today. Last published in 2018, Deloitte's "Audit Committee Guide" provides a first-hand look at the latest requirements and an explanation of the shifting roles and responsibilities of audit committee members, especially in emerging areas such as environmental, social, and governance issues, including cybersecurity. While the guide is focused on requirements for public companies based in the United States, much of the content can be leveraged by those serving on non-public company audit committees. Each section within the "Audit Committee Guide" also features questions that committees can consider asking to promote constructive dialogue on a variety of topics.
Additional oversight responsibilities are falling to the audit committee. According to a survey conducted by Deloitte and the Center for Audit Quality, audit committees are being challenged by increased complexity in their core responsibilities as well as scope creep across other areas within their organizations.
The enhanced "Audit Committee Guide" can serve as a resource on a multitude of topics of interest to committee members, such as:
- How audit committees can fulfill their responsibilities to oversee the many aspects of financial reporting, risk, internal auditors, independent auditors, and ethics and compliance.
- To what extent committee composition meets the requirements of the SEC, NYSE, and Nasdaq with respect to independence and financial literacy.
- How an audit committee's charter aligns with current listing requirements, especially as the committee's responsibilities may have shifted in recent years.
- Common practices and considerations with respect to performing committee evaluations and self-assessments.
- How committees can improve their overall effectiveness.
"As the role of the audit committee continues to expand, it's important for audit committees to clearly understand their responsibilities and prioritize their agendas. The SEC's disclosure proposals in areas such as cybersecurity and climate are positioned to dramatically increase the volume of information required in corporate reporting, which falls within the audit committee's area of responsibility. The 'Audit Committee Guide' can help audit committees and those who work with them keep pace on these rapidly evolving requirements."
— Krista Parsons, Audit & Assurance managing director, Audit Committee Program leader,
Center for Board Effectiveness, Deloitte & Touche LLP
"Deloitte's Center for Board Effectiveness has updated, digitized and enhanced the 'Audit Committee Guide' to provide audit committees with the latest tools and resources for understanding their requirements and oversight responsibilities. The guide also offers suggestions for enhancing committee effectiveness during this time when regulatory requirements are evolving rapidly. Given the critical role audit committees play in protecting investors and the health of the capital markets, it is important that they stay on top of the latest developments and have the latest tools and resources to operate effectively."
— Maureen Bujno, Audit & Assurance managing director, Audit & Assurance governance leader
Center for Board Effectiveness, Deloitte & Touche LLP
Deloitte's "Audit Committee Guide" and supporting documents will be updated regularly to reflect evolving guidance and leading practices. To access the full guide, please visit HERE.
Deloitte provides industry-leading audit, consulting, tax and advisory services to many of the world's most admired brands, including nearly 90% of the Fortune 500® and more than 7,000 private companies. Our people come together for the greater good and work across the industry sectors that drive and shape today's marketplace — delivering measurable and lasting results that help reinforce public trust in our capital markets, inspire clients to see challenges as opportunities to transform and thrive, and help lead the way toward a stronger economy and a healthier society. Deloitte is proud to be part of the largest global professional services network serving our clients in the markets that are most important to them. Building on more than 175 years of service, our network of member firms spans more than 150 countries and territories. Learn how Deloitte's more than 345,000 people worldwide connect for impact at www.deloitte.com.
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as "Deloitte Global") does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the "Deloitte" name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.
View original content to download multimedia:
SOURCE Deloitte | https://www.whsv.com/prnewswire/2022/09/07/deloitte-updates-audit-committee-guide-meet-evolving-risk-landscape-regulatory-environment/ | 2022-09-07T11:53:05Z |
World renowned design firm Herzog & de Meuron and acclaimed landscape designer Piet Oudolf have conceived a place where art and nature combine for reflection, contemplation, and learning
PHILADELPHIA, Sept. 7, 2022 /PRNewswire/ -- The Board of Trustees of Calder Gardens today unveiled the design for its new site on the Benjamin Franklin Parkway in the heart of downtown Philadelphia. Featuring a building conceived by Pritzker Prize-winning design practice Herzog & de Meuron and gardens by internationally acclaimed Dutch landscape designer Piet Oudolf, the project is dedicated to the art and ideas of Alexander Calder, a native Philadelphian who is considered one of the most innovative and influential artists of the 20th century.
Featuring galleries illuminated by natural light, in a structure ensconced in a flowing landscape of native and flowering species, Calder Gardens will present a rotating selection of masterworks from the Calder Foundation, New York, including mobiles, stabiles, monumental sculptures, and paintings. "The esthetic value of these objects cannot be arrived at by reasoning," Calder wrote in 1933. "Familiarization is necessary." Installed both indoors and outdoors, Calder's art will be in constant dialogue with nature and the changing atmospheres of the seasons. Calder Gardens will provide the public with a singular place for contemplation and reflection, as well as abundant opportunities for learning and community building through a schedule of inclusive public programs and special events.
"Our intention for Calder Gardens is not only to create the ideal environment for the public to encounter my grandfather's work but also to elevate personal contemplation and reflection," said Alexander S. C. Rower, President of the Calder Foundation. "Calder's role as a pioneer of experiential art is essential to his legacy. For viewers who open themselves up to the possibilities of his mobiles and stabiles, the unexpected takes root. His objects continuously unfold in real time."
Calder was born in Philadelphia in 1898, and his connections to the city are grounded in the rich artistic lineage of his family. A trio of iconic installations by three generations of Calders can be found along the Benjamin Franklin Parkway: at the southeast end, atop City Hall, stands the monumental statue William Penn (c. 1886–94) by the artist's grandfather Alexander Milne Calder; at the midpoint sits Swann Memorial Foundation (1924) by his father Alexander Stirling Calder; and at the northwest end is Calder's own 1964 mobile The Ghost, which hangs majestically in the main hall of the Philadelphia Museum of Art. Thus Calder Gardens brings into the 21st century the legacy of a Philadelphia family whose work has defined and enriched the city for over a century.
Crafted specifically for the presentation of Calder's work, the landscape and architecture of Calder Gardens will unfold as a choreographed progression that moves visitors from the quotidian city context to a more contemplative realm beyond the traditional museum experience, allowing them to engage with art as a personal, real-time encounter—as the artist intended.
"This was actually an open-ended process rather than a finished concept based on a fixed program. A kind of conceptual path which made us carve out the ground rather than build forms and volumes above—we were looking for space to present Calder's work in a new and unprecedented way," said Jacques Herzog, founding partner along with Pierre de Meuron of Herzog & de Meuron. "That space in the making eventually grew into a whole sequence of different galleries and also rather unexpected spaces, niches and gardens; such as the apse and the quasi-galleries or open plan gallery, the sunken or vestige gardens. And not only galleries in the classical sense, but every corner and angle, every stair and corridor should be offering itself up as a place to put art."
Discreetly nestled into the landscape, Herzog & de Meuron's almost 18,000 sq ft structure will be sheathed in softly reflective metal cladding that blurs the boundaries between architecture and the natural world—the material and the immaterial.
Departing the busy Parkway, visitors will approach the building along a path that winds through a meadow-like landscape punctuated by trees, arriving at the main entrance on the building's north façade. Beyond the threshold, a sequence of spaces will reveal themselves below ground level as distinct volumes that will house a constantly changing display of Calder's most acclaimed works. Large windows will wash the interiors with natural light and frame both the shifting geometries of Calder's work and views of different gardens conceived as outdoor galleries. A Sunken Garden and Vestige Garden, visible from within the building through expansive glazing that likewise permits visitors outdoors to see into the building's exhibition spaces. Quiet but theatrical, Herzog & de Meuron's design has been conceived to amplify the impact of the artworks—to encourage engagement with their kinetic properties by affording visitors many different vantage points—and catalyze discovery and reflection.
The seamless relationship between the built elements designed by Herzog & de Meuron and the gardens envisioned by Piet Oudolf is central to the philosophy of Calder Gardens. The site will be distinguished by its naturalistic four-season garden, intending to create an entirely different experience than all other cultivated, manicured gardens on the Parkway.
"I see my gardens as living sculptures where change is constant," Oudolf said. "The site is like a canvas to work on, and each plant has a personality that must work with the others. The composition of the garden is variable and will evolve through the seasons. For Calder Gardens, the horticultural design must also serve the works of art. My hope is that people will take the time to stand still and think here, to fully experience these elements together and have an emotional reaction that stays with them long after their visit. It's not about what you see, but what you sense."
The nonprofit Calder Gardens was launched by a group of Philadelphia philanthropists working in collaboration with the Calder Foundation and partnership with the City of Philadelphia and the Commonwealth of Pennsylvania. While governed by its board and curatorial committee, Calder Gardens will be operated by the Barnes Foundation—a renowned cultural and educational institution—to provide administrative, operational, and educational programming support when the new site opens to the public in what constitutes a new model for institutional sustainability and efficiency.
The Calder Gardens Board announced its selection of Herzog & de Meuron as Design Consultants in 2020. Ballinger will be the project's Executive Architects. Presented before the Philadelphia Art Commission this week, the Basel, Switzerland-based firm's design has been developed over the past two and a half years through intensive collaboration with the organization's board, the Calder Foundation, and, since 2021, Piet Oudolf. The shared goal has been to create a place where art and nature merge uniquely: the 1.8-acre Calder Gardens site—situated between 21st and 22nd Streets, across from the Barnes Foundation—will be a sanctuary-like retreat for Philadelphia residents and visitors alike, and a complement to the existing configuration of internationally acclaimed arts institutions that line the Parkway. "Calder Gardens marks a significant step toward realizing a long-held vision to not only create a permanent home for Calder's artistic contributions in his birth city but also to add yet one more jewel to the already culturally rich Parkway," said Joe Neubauer, Founder of the Neubauer Family Foundation and lead funder of the initiative.
In addition to lead funding from the Neubauer Family Foundation, the Calder Gardens project has been brought to fruition by numerous philanthropists and private foundations, including The Pew Charitable Trusts, the Estate of H.F. (Gerry) Lenfest, and an anonymous donor. The project is also supported by the Commonwealth's Redevelopment Assistance Capital Program. The $70 million projected budget for Calder Gardens will include a substantial endowment to provide ongoing operating support and has been raised through the generous contributions of these patrons.
Sue Urahn, president and chief executive officer of The Pew Charitable Trusts, said, "Pew is very pleased to support Calder Gardens and we are excited to see the plans for it begin to take shape. The new public space will be a wonderful addition to the Parkway and enhance Philadelphia's reputation as a world-class city in which to live, work, and visit."
"The Calder family is integral to the history and now the future of Philadelphia. I am grateful for the range of partners that will bring Calder Gardens and the amazing art and ideas to the Parkway," said Jim Kenney, Mayor of Philadelphia. "This will continue to build upon an ever-growing arts and culture presence in our great city, further enhancing the city's cultural experiences for visitors and residents alike."
Marsha Perelman, President of the Board, Calder Gardens, said of the design unveiled today, "To honor Calder's work in a project of this significance, we engaged some of the world's most respected and experienced talents. Herzog & de Meuron and Piet Oudolf are universally admired for their work on cultural sites. They know what it takes to create an unparalleled art experience and to challenge conventions to expand our minds and senses. I am thrilled that Philadelphians will be able to benefit from this unique experience in their own city."
Calder Gardens is scheduled to open in 2024.
The public can learn more about Calder Gardens online at caldergardens.org and on social media @calder_gardens on Instagram and Twitter.
EDITORS NOTES
About Calder
Calder (b. 1898, Lawnton, Pennsylvania–d. 1976, New York City), whose illustrious career spanned much of the twentieth century, is the most acclaimed and influential sculptor of our time. Born in a family of celebrated, though more classically trained artists, Calder utilized his innovative genius to profoundly change the course of modern art. He began in the 1920s by developing a new method of sculpting: by bending and twisting wire, he essentially "drew" three-dimensional figures in space. He is renowned for the invention of the mobile, whose suspended, abstract elements move and balance in changing harmony. From the 1950s onward, Calder increasingly devoted himself to making outdoor sculpture on a grand scale from bolted steel plate. Today, these stately titans grace public plazas in cities throughout the world.
About the Calder Foundation
The Calder Foundation, a nonprofit 501(c)3 organization founded in 1987 by Alexander S. C. Rower and the Calder family, is dedicated to collecting, exhibiting, preserving, and interpreting the art and archives of Alexander Calder. The Foundation's objectives include furthering public knowledge and appreciation for the arts; conducting research in art history and related subjects and presenting those results to the general public; providing facilities and programs to assist the education and development of artists; and preserving Calder's artistic legacy for scholarship, including the physical preservation of his works, archives, homes, and studios. Additionally, the Calder Foundation is dedicated to conserving natural resources and education in agriculture and sustainable environmental practices. The Foundation's projects include collaborating on exhibitions and publications, organizing and maintaining the Calder archives, examining works attributed to Calder, and cataloguing the artist's works. The Foundation also organizes its own exhibitions, lectures, performances, and events on Calder and on contemporary artists supported by the biannual Calder Prize and the Atelier Calder residency program in Saché, France.
Website | Instagram | Facebook | Twitter
About the Neubauer Family Foundation
The Neubauer Family Foundation (NFF) invests in people and data-driven, evidence-based initiatives intended to achieve transformational impact. Philanthropic initiatives include strategic investments in Philadelphia's school system, violent crime prevention, innovative leadership of arts & cultural organizations, institutions of higher learning and advancing new opportunities for Israeli-Arabs to participate in Israel's high prestige, high income scientific revolution.
About the Barnes Foundation
The Barnes Foundation is a nonprofit cultural and educational institution that shares its unparalleled art collection with the public, organizes special exhibitions, and presents programming that fosters new ways of thinking about human creativity. The Barnes collection is displayed in ensembles that integrate art and objects from across cultures and time periods, overturning traditional hierarchies and revealing universal elements of human expression. Home to one of the world's finest collections of impressionist, post-impressionist, and modern paintings—including the largest groups of paintings by Pierre-Auguste Renoir and Paul Cézanne in existence—the Barnes brings together renowned canvases by Henri Matisse, Pablo Picasso, Amedeo Modigliani, and Vincent van Gogh, alongside African, Asian, ancient, medieval, and Native American art as well as metalwork, furniture, and decorative art.
The Barnes Foundation was established by Dr. Albert C. Barnes in 1922 to "promote the advancement of education and the appreciation of the fine arts and horticulture." A visionary collector and pioneering educator, Dr. Barnes was also a fierce advocate for the civil rights of African Americans, women, and the economically marginalized. Committed to racial equality and social justice, he established a scholarship program to support young Black artists, writers, and musicians who wanted to further their education. Dr. Barnes was deeply interested in African American culture and became actively involved in the Harlem Renaissance, during which he collaborated with philosopher Alain Locke and Charles S. Johnson, the scholar and activist, to promote awareness of the artistic value of African art.
Since moving to Philadelphia in 2012, the Barnes Foundation has expanded its commitment to diversity, inclusion, and social justice, teaching visual literacy in groundbreaking ways; investing in original scholarship relating to its collection; and enhancing accessibility throughout every facet of its programs.
The Barnes Foundation is situated in Lenapehoking, the ancestral homeland of the Lenape people. Read our Land Acknowledgment.
About the Pew Charitable Trusts
The Pew Charitable Trusts is driven by the power of knowledge to solve today's most challenging problems. We are an independent nonprofit organization—the sole beneficiary of seven individual trusts established between 1948 and 1979 by two sons and two daughters of Sun Oil Company founder Joseph N. Pew and his wife, Mary Anderson Pew. Informed by our founders' entrepreneurial and optimistic spirit, Pew has evolved with the challenges and demands of the times while remaining true to the Pew family's enduring interest in research, practical knowledge, and a robust democracy. Today, Pew is a global research and public policy change agent that remains nonpartisan and dedicated to serving the public.
About Herzog & de Meuron
Established in Basel in 1978, Herzog & de Meuron is a partnership led by Jacques Herzog and Pierre de Meuron together with Senior Partners Christine Binswanger, Ascan Mergenthaler, Stefan Marbach, Esther Zumsteg, and Jason Frantzen. An international team of over 500 collaborators including the two Founders, five Senior Partners, ten Partners, and 48 Associates work on projects across Europe, the Americas and Asia. Our main office in Basel is supported by our studios in Germany in Berlin and Munich; in Hong Kong; in the UK in London; and in the USA in New York and San Francisco; and by our site offices in Copenhagen and Paris.
The practice has designed a wide range of projects from the small scale of a private home to the large scale of urban design. Many projects are highly recognized public facilities, such as museums, stadiums, and hospitals, and they have completed distinguished private projects including offices, laboratories and apartment buildings. Awards received include the Pritzker Architecture Prize (USA) in 2001, the RIBA Royal Gold Medal (UK), the Praemium Imperiale (Japan), both in 2007, and the Mies Crown Hall Americas Prize (USA) in 2014.
About Piet Oudolf
Considered a renegade in the landscape industry, the Dutch landscape designer Piet Oudolf (b. 1944) has revolutionized the way perennial gardens are designed and viewed in landscapes today. With a new planting style and meticulous attention to the plants, Oudolf has forged the ability to break the rules when his eye finds it necessary to do so.
Some of Oudolf's most influential works in the United States include The Highline perennial plantings, New York; Lurie Garden, Chicago; Oudolf Garden Detroit; and the perennial plantings at Battery Park, New York. Among the many awards he has received, Oudolf was the recipient of the prestigious Prins Bernhard Culture Prize, an award given by the Prins Bernard Culture Foundation to a person who has made an extraordinary contribution to culture in The Netherlands. Oudolf continues to design perennial gardens while also serving as a guest professor at numerous prestigious universities around the world.
Media Contacts:
Tim Spreitzer
TSpreitzer@tierneyagency.com
215-514-0170
Andrea Schwan
andrea@andreaschwan.com
917-371-5023
View original content to download multimedia:
SOURCE CP2023 | https://www.whsv.com/prnewswire/2022/09/07/design-unveiled-calder-gardens-new-national-international-cultural-destination-heart-downtown-philadelphia-benjamin-franklin-parkway/ | 2022-09-07T11:53:11Z |
—New Funds Intended to Support Analysis of ADNI Databases to Validate and Extend Existing Data Showing AlzoSure® Predict Accurately Identifies Those Individuals Who Will Progress to Alzheimer's Disease Up to 6 Years Before Diagnosis—
PALO ALTO, Calif., Sept. 7, 2022 /PRNewswire/ -- Diadem U.S., Inc., a jointly owned subsidiary of Diadem SpA, a company developing the first blood-based test for the early prediction of Alzheimer's disease (AD), today reported that it has been awarded a Small Business Innovation Research (SBIR) direct to Phase ll grant for an expected total of approximately $2.5 million from the National Institute on Aging (NIA) at the National Institutes of Health (NIH).
The two-year award will allow the company to screen data from the Alzheimer's Disease Neuroimaging Initiative (ADNI), a longitudinal multicenter study designed to enable development of biomarkers for the early detection and tracking of AD. Since its launch more than a decade ago, this landmark public-private partnership has made major contributions to AD research. The new study is designed to make use of all four ADNI patient cohorts to identify participants who were early progressors to AD and to further validate the prognostic ability of Diadem's non-invasive AlzoSure® Predict blood test to accurately identify these patients years before diagnosis.
Paul Kinnon, Chief Executive Officer of Diadem U.S. and a principal investigator of the new study, commented, "Diadem is dedicated to transforming the treatment of AD by developing and commercializing new accurate, affordable and accessible prognostic and diagnostic biomarker tools for early identification of individuals who will or will not progress to AD within six years. With this grant, our team intends to further validate our AlzoSure® Predict prognostic test using the U.S.-based ADNI databases. We have previously published compelling data documenting the accuracy and utility of AlzoSure® Predict using the highly regarded AIBL longitudinal patient cohorts from Australia. We look forward to working with the distinguished group of AD consultants we have assembled to replicate and potentially extend our clinical analyses using the comprehensive and well characterized patient information available through ADNI."
The specific aims of the SBIR AlzoSure® Predict biomarker study include:
- Validate its ability to discriminate the different stages of cognitive decline
- Establish its specificity for AD compared to other dementias
- Confirm its prognostic clinical utility by categorizing patients into disease classes and stages
- Compare its performance against current diagnostic and prognostic AD methods.
Diadem has recruited a group of leading Alzheimer's researchers to participate in the study design and analysis. Analytic support will be provided by the Biomarker Research Laboratory of the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine, University of Pennsylvania.
Alzheimer's disease is a debilitating and life-threatening disease of the nervous system that is among the 10 leading causes of death in the U.S. It affects 50 million patients worldwide with 10 million new cases reported each year. Diadem has developed and validated its revolutionary, minimally invasive, cost-effective blood-based test, AlzoSure® Predict, that requires only 1mL of blood and 4 to 5 days for analysis to detect AD at the asymptomatic and prodromal (early symptomatic) stage, with an accuracy greater than 95% up to at least 6 years in advance of the clinical onset of symptoms. Previous research also demonstrated that AlzoSure® Predict can discriminate between the different kinds of dementia with high accuracy.
The predictive ability of the test may be a breakthrough in the field of AD and dementia research. It may improve patient care by supporting the ability of researchers to successfully develop more effective new treatments by enabling the design of clinical studies that intervene much earlier in the disease process. In addition, it may help clinicians stratify patients by relevant factors, while also supporting more informed decisions regarding prevention and treatment options to maximize patient outcomes and improve their quality of life.
AlzoSure® Predict is a non-invasive biomarker blood test that has demonstrated the ability to identify with high accuracy whether individuals over the age of 50 with signs of cognitive impairment will or will not progress to Alzheimer's disease up to six years before diagnosis. AlzoSure® Predict uses a proprietary antibody (U-p53AZ) to measure blood levels of a conformational variant of the p53 protein that has been implicated in the pathogenesis of AD. Previous studies suggest that this p53 variant has utility as a diagnostic and as a predictive biomarker to identify individuals likely to progress to AD up to six years before symptoms appear.
The utility of AlzoSure® Predict is supported by clinical data from a large longitudinal study that was the basis for AlzoSure® Predict's Breakthrough Device designation from the U.S. Food & Drug Administration and its CE-IVD marking.
The study will be funded by a grant from the NIH (1R44AG078051-01).
About Diadem
Diadem was founded as a spin-out of the University of Brescia (Italy). The company is developing the first blood-based prognostic test for the early detection of dementia, with a focus on Alzheimer's disease. The lack of accurate, accessible and affordable diagnostic tools is a major contributor to the absence of effective treatments for this devastating condition. As a result, patients are not diagnosed until late in the illness, when effective treatment is no longer possible. Diadem's rapid, accurate and cost-effective blood-based prognostic test makes it possible for the first time to identify patients early in the disease process, when effective interventions and better outcomes are far more feasible. The utility of the approach has been demonstrated in longitudinal clinical studies that were the basis for awarding CE-IVD marking in the E.U. and a Breakthrough Device designation in the U.S. Additional retrospective and prospective clinical trials are ongoing to further validate clinical claims and support widespread adoption and use. Diadem is preparing for commercialisation of AlzoSure® Predict in collaboration with global strategic partners. The company is also developing AlzoSure® Confirm, a blood-based diagnostic test for AD that has shown promising results in early studies. For more information, visit diademdx.com/.
View original content:
SOURCE Diadem U.S., Inc. | https://www.whsv.com/prnewswire/2022/09/07/diadem-receives-25-million-nih-sbir-grant-further-validate-prognostic-utility-its-blood-test-early-identification-patients-who-will-progress-alzheimers-disease/ | 2022-09-07T11:53:18Z |
BRISBANE, Australia, Sept. 7, 2022 /PRNewswire/ -- AcuraBio (formerly Luina Bio), a leading Australian biopharmaceutical CDMO, has been acquired by biotech investor Dr. Glenn Haifer and Ampersand Capital Partners, a global healthcare private equity firm.
With more than two decades of experience, AcuraBio is a globally focussed organization bringing innovative therapeutics to market for customers in the biotech, pharmaceutical, and animal health industries. AcuraBio provides recombinant proteins and vaccines, and complex live biotherapeutic products to customers on the leading edge in emerging therapeutics.
The rebranding of the company signifies an innovative new growth phase for AcuraBio. As part of the transaction, Dr. Haifer and Ampersand are bringing significant investment to the company, with a focus on expanding the organization to better serve customers. To fuel additional growth, AcuraBio is planning to increase production facility capacity, and is actively evaluating expansion into new service offerings and technological capabilities.
Dr. Haifer brings a wealth of experience to AcuraBio, as the former company Chairman and investor behind Australian biotech successes such as Agilex Biolabs and Avance Clinical. "We are very excited to be reinventing a company with such deep scientific experience," said Dr. Haifer. "With our deep expertise and commitment to further investment, AcuraBio will be a leader in the APAC region for international biopharma clients attracted by the technology, scientific excellence, and innovation we will bring to the platform. I am excited to leverage Ampersand's industry expertise as we take AcuraBio to the next level."
Based in the US and with more than $3 billion of assets under management, Ampersand is exclusively focused on growth-oriented investments in the healthcare sector. Ampersand has previously partnered with leading CDMOs such as Brammer Bio, ArrantaBio, Vibalogics, and Genezen, and the firm is a highly experienced investor in the emerging therapeutics CDMO industry. David Anderson, General Partner at Ampersand, said "AcuraBio is strategically positioned in Australia to support international biopharma drug development. Australia has a strong reputation for clinical and scientific excellence which is the foundation to success for a company like AcuraBio. We are extremely pleased to be working with Dr. Haifer, who is a proven biotech investor and growth strategist with a real focus on client-centric service innovations."
AcuraBio Pty Ltd is one of Australia's most experienced biopharmaceutical CDMOs, offering trusted, client-focused services to both domestic and international clients for the past 20 years. AcuraBio offers significant quality, cost, and IP assurances for biopharma companies around the world. World-class researchers and proven facilities, a streamlined regulatory framework, generous tax incentives, and government funding make Australia a prime location for biotech research. AcuraBio has the following operating licenses: TGA (Australian FDA equivalent) license for the manufacture of human therapeutic APIs from biological and synthetic sources, APVMA (veterinary equivalent of the TGA) license for manufacture of sterile immunobiological products, OGTR license to produce products from genetically modified organisms, and a DAF facility license for import and use of biologic materials. Additional information about AcuraBio is available at www.acurabio.com.
Founded in 1988, Ampersand is a middle market private equity firm with more than $3 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience in seeking to build value and drive strong long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm's core healthcare sectors. Additional information about Ampersand is available at www.ampersandcapital.com.
Media Contact
Media@AcuraBio.com
View original content to download multimedia:
SOURCE AcuraBio | https://www.whsv.com/prnewswire/2022/09/07/dr-glenn-haifer-ampersand-capital-partners-acquire-australian-biologics-cdmo-luina-bio-rebranding-acurabio/ | 2022-09-07T11:53:25Z |
Drilling at New Afton's East Extension Continues to Deliver High-Grade Mineralization
Published: Sep. 7, 2022 at 7:30 AM EDT|Updated: 23 minutes ago
TORONTO, Sept. 7, 2022 /PRNewswire/ - New Gold Inc. ("New Gold" or the "Company") (TSX: NGD) (NYSE American: NGD) is pleased to provide detailed drill results for the underground exploration program underway at its New Afton Mine and provides an update on additional exploration activities at its operations.
Highlights
The below table provides 2022 assay result highlights for New Afton's upper portion of the East Extension (above 1.75 g/t Au and/or 1.75% Cu and an interval ≥30m). Refer to Table 2 and Table 3 at the end of this news release for full assay results and drill hole collar coordinate
Results to date show continuous mineralization, within an interpreted 1% copper grade shell, averaging 300 x 30 metres in plan and 250 metres down dip with higher gold and copper grades compared with the average grade of the current New Afton Mineral Reserve estimate of 0.67g/t gold and 0.74% copper
Results will be incorporated in the 2022 year-end New Afton Mineral Resource estimate with the potential to add valuable resources at above current Mineral Reserve grades
Geological interpretations show additional targets for higher-grade mineralization down plunge and vertically below the upper portion of East Extension where drilling is ongoing (refer to Figure 1) and both targets have the potential to host additional mineralization similar to the upper portion of the East Extension
Given the lateral proximity to the C-Zone, the East Extension appears to have the potential to bring additional higher-grade reserves at a low development cost into the mine plan in the near-to mid-term
"I am very encouraged by the results to date on New Afton's underground exploration program," stated Renaud Adams, President & CEO. "New Afton's underground exploration program is focused on increasing higher-grade Mineral Resources to enhance the near-term mine plan and extend the mine life. We are focused primarily on three key initiatives. The first involves defining the higher-grade zone within the upper portion of the East Extension. The second is to explore the potential down plunge extension of the higher-grade zone, and the third initiative is to test for additional mineralization beneath the higher-grade zone. The upper portion of the East Extension continues to return gold and copper assay results well above the current Mineral Reserve grades, while the lower portion down plunge and the D-Zone remain open. Given the lateral proximity to the C-Zone, the East Extension appears to have the potential to bring additional higher-grade reserves at a low development cost into the mine plan in the near-to mid-term."
New Afton Mine long section with target locations
New Afton Mine
Underground East Extension
The Company launched a phase-two drilling program for the upper zone of the East Extension in October 2021 as a follow-up to the drill holes completed in 2020 targeting the high-grade gold-copper intercepts discovered in 2019 (refer to the Company's February 12, 2020 press release for further information). The phase-two drilling program has been designed to define the extension and continuity of the mineralization to support a Mineral Resource estimate and evaluate the potential addition to the current life of mine plan. The Company advanced a 55 metre exploration drift to allow three diamond drills to intercept mineralization at appropriate angles to properly infill the interpreted target area (refer to Figures 2 and 3). The drilling program totaled 38,084 metres in 115 drill holes planned on 20 metre centers, the results of which will be incorporated in the 2022 year-end New Afton Mineral Resource estimate with the potential to add valuable resources at above current Mineral Reserve grades.
Results to date show continuous mineralization, within an interpreted 1% copper grade shell, averaging 300 x 30 metres in plan and 250 metres down dip with higher gold and copper grades compared with the average grade of the current New Afton Mineral Reserve estimate of 0.67g/t gold and 0.74% copper (refer to Figures 2 and 3). The upper zone of the East Extension is characterized by disseminated and fracture filled sulphide mineralization as bornite and chalcopyrite associated with potassic dominant alteration hosted in volcanic fragmental and intrusive lithologies controlled by cross-cutting faults often on lithological contacts.
Geological interpretations show additional targets for higher-grade mineralization down plunge and vertically below the upper portion of East Extension where drilling is ongoing (refer to Figure 1). Both targets have the potential to host additional mineralization similar to the upper portion of the East Extension.
Additional Underground Targets
An additional 5,000 metres of underground drilling is planned upon completion of the required infrastructure at the base of C-Zone development to follow up on the Artificial Intelligence (AI) target areas previously defined in 2020 and is expected to be completed by the end of 2022. The program has been designed to explore the AI Southeast and AI North target areas and to assess potential higher-grade mineralization within the D-Zone ore body (refer to Figure 1).
Regional Exploration
The Company completed the exploration drilling program at the Cherry Creek Trend area and is progressing the data interpretation to assess if a follow-up drilling phase is warranted. Additional drill ready targets have been defined upon geophysical and geochemical surveys completed within the priority areas of the Company's landholdings. The most prospective target is located approximately eight kilometres southwest of the New Afton Mine, where a 5,000 metre reconnaissance drilling program started in August 2022 and is expected to be completed in the fourth quarter of 2022. Additional field activities, inclusive of geological mapping and geochemical survey are in progress for drill ready target definition within the broader landholdings focused on gold-copper porphyry style mineralization.
Rainy River Mine
At Rainy River, the Company is now focusing on potential additional underground mineralization in proximity to the actual operation footprint. Compilation and interpretation of the project dataset is centered approximately 500 metres from the southern limit of the ultimate open pit (refer to Figure 4), where a broader alteration halo hosting gold mineralization has been intersected along strike of historical drill hole intervals with similar alteration/mineralization. A follow-up drilling program for a total of 2,000 metres is planned to begin in the fourth quarter of 2022 and completed by year end. Additional exploration activities inclusive of geological mapping and rock and soil sampling are progressing within the broader Rainy River mineral tenures, with the objective to define prospective areas for gold mineralization and further define new drill ready targets.
About New Gold
New Gold is a Canadian-focused intermediate mining company with a portfolio of two core producing assets in Canada, the Rainy River gold mine and the New Afton copper-gold mine. The Company also holds approximately 5% equity stake in Artemis Gold Inc., and other Canadian-focused investments. New Gold's vision is to build a leading diversified intermediate gold company based in Canada that is committed to the environment and social responsibility. For further information on the Company, visit www.newgold.com.
Certain information contained in this news release, including any information relating to New Gold's future financial or operating performance are "forward-looking". All statements in this news release, other than statements of historical fact, which address events, results, outcomes or developments that New Gold expects to occur are "forward-looking statements". Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the use of forward-looking terminology such as "plans", "expects", "is expected", "budget", "scheduled", "targeted", "estimates", "forecasts", "intends", "anticipates", "projects", "potential", "believes" or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "should", "might" or "will be taken", "occur" or "be achieved" or the negative connotation of such terms. Forward-looking statements in this news release include, among others, statements with respect to: planned focus areas and initiatives regarding New Afton's underground exploration program; the continued return from the East Extension of gold and copper assay results above current grades and the potential to bring additional higher-grade reserves into the mine plan in the near-to mid-term; the intention to incorporate drilling program results into the 2022 year-end New Afton Mineral Resource estimate; the intended plans for and potential opportunities relating to resources, grades and mineralization resulting from the underground East Extension; planned additional underground drilling at New Afton and expected timing for completion; anticipated timing for completion of the reconnaissance drilling program at New Afton; the planned follow-up drilling program at Rainy River and expected timing for completion; and proposed exploration activities at New Afton and Rainy River and the objectives thereof.
All forward-looking statements in this news release are based on the opinions and estimates of management that, while considered reasonable as at the date of this press release in light of management's experience and perception of current conditions and expected developments, are inherently subject to important risk factors and uncertainties, many of which are beyond New Gold's ability to control or predict. Certain material assumptions regarding such forward-looking statements are discussed in this news release, New Gold's latest annual MD&A, its most recent annual information form and technical reports on the Rainy River Mine and New Afton Mine filed on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. In addition to, and subject to, such assumptions discussed in more detail elsewhere, the forward-looking statements in this news release are also subject to the following assumptions: (1) there being no significant disruptions affecting New Gold's operations other than as set out herein; (2) political and legal developments in jurisdictions where New Gold operates, or may in the future operate, being consistent with New Gold's current expectations; (3) the accuracy of New Gold's current Mineral Reserve and Mineral Resource estimates and the grade of gold, silver and copper expected to be mined and the grade of gold, copper and silver expected to be mined; (4) the exchange rate between the Canadian dollar and U.S. dollar, and to a lesser extent, the Mexican Peso, and commodity prices being approximately consistent with current levels and expectations for the purposes of 2022 guidance and otherwise; (5) prices for diesel, natural gas, fuel oil, electricity and other key supplies being approximately consistent with current levels; (6) equipment, labour and materials costs increasing on a basis consistent with New Gold's current expectations; (7) arrangements with First Nations and other Aboriginal groups in respect of the New Afton Mine and Rainy River Mine being consistent with New Gold's current expectations; (8) all required permits, licenses and authorizations being obtained from the relevant governments and other relevant stakeholders within the expected timelines and the absence of material negative comments or obstacles during any applicable regulatory processes; (9) there being no significant disruptions to the Company's workforce at either the Rainy River Mine or New Afton Mine due to cases of COVID-19 (including any required self-isolation requirements due to cross-border travel to the United States or any other country or any other reason) or otherwise; (10) the responses of the relevant governments to the COVID-19 outbreak being sufficient to contain the impact of the COVID-19 outbreak; (11) there being no material disruption to the Company's supply chains and workforce that would interfere with the Company's anticipated course of action at the Rainy River Mine and the New Afton Mine; and (12) the long-term economic effects of the COVID-19 outbreak not having a material adverse impact on the Company's operations or liquidity position.
Forward-looking statements are necessarily based on estimates and assumptions that are inherently subject to known and unknown risks, uncertainties and other factors that may cause actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. Such factors include, without limitation: price volatility in the spot and forward markets for metals and other commodities; discrepancies between actual and estimated production, between actual and estimated costs, between actual and estimated Mineral Reserves and Mineral Resources and between actual and estimated metallurgical recoveries; equipment malfunction, failure or unavailability; accidents; risks related to early production at the Rainy River Mine, including failure of equipment, machinery, the process circuit or other processes to perform as designed or intended; the speculative nature of mineral exploration and development, including the risks of obtaining and maintaining the validity and enforceability of the necessary licenses and permits and complying with the permitting requirements of each jurisdiction in which New Gold operates, including, but not limited to: obtaining the necessary permits for the New Afton C-Zone; uncertainties and unanticipated delays associated with obtaining and maintaining necessary licenses, permits and authorizations and complying with permitting requirements, including those associated with the C-Zone permitting process; changes in project parameters as plans continue to be refined; changing costs, timelines and development schedules as it relates to construction; the Company not being able to complete its construction projects at the Rainy River Mine or the New Afton Mine on the anticipated timeline or at all; volatility in the market price of the Company's securities; changes in national and local government legislation in the countries in which New Gold does or may in the future carry on business; controls, regulations and political or economic developments in the countries in which New Gold does or may in the future carry on business; the Company's dependence on the Rainy River Mine and New Afton Mine; the Company not being able to complete its exploration drilling programs on the anticipated timeline or at all; disruptions to the Company's workforce at either the Rainy River Mine or the New Afton Mine, or both, due to cases of COVID-19 or any required self-isolation (due to cross-border travel, exposure to a case of COVID-19 or otherwise); the responses of the relevant governments to the COVID-19 outbreak not being sufficient to contain the impact of the COVID-19 outbreak; disruptions to the Company's supply chain and workforce due to the COVID-19 outbreak; an economic recession or downturn as a result of the COVID-19 outbreak that materially adversely affects the Company's operations or liquidity position; there being further shutdowns at the Rainy River Mine or New Afton Mine; significant capital requirements and the availability and management of capital resources; additional funding requirements; diminishing quantities or grades of Mineral Reserves and Mineral Resources; actual results of current exploration or reclamation activities; uncertainties inherent to mining economic studies including the Technical Reports for the Rainy River Mine and New Afton Mine; impairment; unexpected delays and costs inherent to consulting and accommodating rights of First Nations and other indigenous groups; climate change, environmental risks and hazards and the Company's response thereto; tailings dam and structure failures; actual results of current exploration or reclamation activities; fluctuations in the international currency markets and in the rates of exchange of the currencies of Canada, the United States and, to a lesser extent, Mexico; global economic and financial conditions and any global or local natural events that may impede the economy or New Gold's ability to carry on business in the normal course; compliance with debt obligations and maintaining sufficient liquidity; taxation; fluctuation in treatment and refining charges; transportation and processing of unrefined products; rising costs or availability of labour, supplies, fuel and equipment; adequate infrastructure; relationships with communities, governments and other stakeholders; geotechnical instability and conditions; labour disputes; the uncertainties inherent in current and future legal challenges to which New Gold is or may become a party; defective title to mineral claims or property or contests over claims to mineral properties; competition; loss of, or inability to attract, key employees; use of derivative products and hedging transactions; counterparty risk and the performance of third party service providers; investment risks and uncertainty relating to the value of equity investments in public companies held by the Company from time to time; the adequacy of internal and disclosure controls; conflicts of interest; the lack of certainty with respect to foreign operations and legal systems, which may not be immune from the influence of political pressure, corruption or other factors that are inconsistent with the rule of law; the successful acquisitions and integration of business arrangements and realizing the intended benefits therefrom; and information systems security threats. In addition, there are risks and hazards associated with the business of mineral exploration, development, construction, operation and mining, including environmental events and hazards, industrial accidents, unusual or unexpected formations, pressures, cave-ins, flooding and gold bullion losses (and the risk of inadequate insurance or inability to obtain insurance to cover these risks) as well as "Risk Factors" included in New Gold's most recent annual information form, MD&A and other disclosure documents filed on and available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Forward looking statements are not guarantees of future performance, and actual results and future events could materially differ from those anticipated in such statements. All forward-looking statements contained in this news release are qualified by these cautionary statements. New Gold expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, events or otherwise, except in accordance with applicable securities laws.
QA/QC Procedure
New Gold maintains a Quality Assurance / Quality Control ("QA/QC") program at its New Afton Mine operation using industry best practices and is consistent with the QA/QC protocols in use at all of the Company's exploration and development projects. Key elements of New Gold's QA/QC program include chain of custody of samples, regular insertion of certified reference standards and blanks, and duplicate check assays. Drill core is sampled at regular two metre intervals, halved and shipped in sealed bags to Activation Laboratories Ltd. in Kamloops, British Columbia. Additional information regarding the Company's data verification and quality assurance processes is set out in the February 28, 2020 New Afton National Instrument 43-101 Technical Report titled "Technical Report on the New Afton Mine, British Columbia, Canada" available on SEDAR at www.sedar.com.
Technical Information
The scientific and technical information relating to the Mineral Resources contained herein has been reviewed and approved by Michele Della Libera, Director, Exploration for the Company. All other scientific and technical information contained in this news release has been reviewed and approved by Patrick Godin, Executive Vice President and Chief Operating Officer of New Gold. Mr. Della Libera is a Professional Geologist and a member of the Association of Professional Geoscientists of Ontario and the Engineers and Geoscientists British Columbia. Mr. Godin is a Professional Engineer and member of the Ordre des ingénieurs du Québec. Mr. Della Libera and Mr. Godin are each a "Qualified Person" for the purposes of National Instrument 43-101 – Standards of Disclosure for Mineral Projects.
For additional technical information on New Gold's material properties, including a detailed breakdown of Mineral Reserves and Mineral Resources by category, as well as key assumptions, parameters, and risks, refer to New Gold's most recent annual information form filed and available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.
Figure 1: New Afton Mine long section with target locations and complete drill hole traces
Figure 2: New Afton Mine planview showing infill drill holes completed and copper and gold value intercepts within the East Extension higher-grade target area
Figure 3: Isometric view looking northeast across the New Afton Mine East Extension target areas
Figure 4: Rainy River Exploration – Pinewood South Target Location on Geology map with ultimate pit boundary and surface projective of known ore lenses
Table 2: New Afton Mine East Extension Drill Assay Summary
Table 3: New Afton Mine East Extension Drill Hole Collar Coordinates (total depth rounded to closest metre)
The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc. | https://www.whsv.com/prnewswire/2022/09/07/drilling-new-aftons-east-extension-continues-deliver-high-grade-mineralization/ | 2022-09-07T11:53:31Z |
PHILADELPHIA, Sept. 7, 2022 /PRNewswire/ -- R7 energy drink today announced the signing of Lynch Hunt to its national ambassador team. Based in North Carolina, Lynch is the founder of AWOL Fitness and cofounder of Resultz Nutritional Supplements.
"I am proud to represent the R7 brand. The company has formulated a product that delivers high-performance key ingredients to consumers in and out of the gym, keeping them energized and focused without harmful chemicals," said Hunt.
The decision to team up with Hunt was based on his natural fit for the R7 central market: consumers who value their health and overall wellness. Hunt is a proven motivational speaker and life coach focused on helping people achieve their greatest potential. That core group is the heart and soul of the R7 brand — pushing boundaries to excel in all areas of life.
R7 wants to get the word out about "better-for-you" options within the energy drink category. The brand knows that general consumers, not just athletes, are looking for healthier and more sustainable energy drinks as health and wellness trends continue to arise.
R7 is specially formulated using a combination of unique ingredients: green coffee beans, L-theanine, adaptogens, L-carnitine, select B vitamins, and pure electrolytes. This premium, high-efficiency product is positioned as a "better-for-you" option in the energy drink market, worth $30 billion.
R7 is available in three robust flavors: Lightning Lemon Lime, Orbit Orange, and Midnight Rush (grape). All three flavors are on sale now at www.DrinkR7.com.
R7 is a healthy energy drink brand developed by veteran entrepreneurs and professional athlete management executives. They wanted to create a more sustainable, healthier energy drink for professional athletes and everyday, high-achieving individuals.
R7 is uniquely crafted, delivering a quick energy boost and sustained, clean energy powered by L-theanine and adaptogens that improve cognitive function. R7 focuses on providing consumers with a delightful-tasting beverage that will not make them crash or experience jitters. It is designed to repair, replenish, and restore your body so that you are ready for your next exertion. Follow R7 online at https://drinkr7.com/.
View original content to download multimedia:
SOURCE R7 Energy | https://www.whsv.com/prnewswire/2022/09/07/drink-r7-signs-transformation-specialist-life-coach-lynch-hunt-r7-national-ambassador-team/ | 2022-09-07T11:53:39Z |
RYE, N.Y., Sept. 7, 2022 /PRNewswire/ -- Dunes Point Capital, LP ("DPC") has made a controlling investment in NextGen Security, LLC ("NextGen"). Located in Exton, PA, NextGen is an electronic security integration company that provides technology solutions such as access control and video surveillance to commercial and industrial clients in diverse and complex end markets. NextGen has facilities in Exton, PA and Houston, TX and serves clients across the United States. The Company employs approximately 125 people. For more information, please visit www.nextgensecured.com.
Dunes Point Capital Fund II, LP provided the controlling equity for the transaction. The debt for the transaction was provided by M&T Bank.
Polsinelli served as legal advisor to DPC.
About DPC: DPC is a family office and private investment firm, pursuing control investments in companies operating in the general industrial and business services sectors. DPC targets companies with enterprise values of up to $1 billion. For more information, please visit www.dunespointcapital.com.
About NextGen: Located in Exton, PA, NextGen is an electronic security integration company that provides technology solutions such as access control and video surveillance to commercial and industrial clients in diverse and complex end markets. NextGen's comprehensive suite of services encompasses all facets of a facility's security system, including consultation, design, installation, integration, training, and aftermarket support. NextGen has facilities in Exton, PA and Houston, TX and serves clients across the United States. The Company employs approximately 125 people. For more information, please visit www.nextgensecured.com.
View original content:
SOURCE Dunes Point Capital, LP | https://www.whsv.com/prnewswire/2022/09/07/dunes-point-capital-lp-announces-control-investment-nextgen-security-llc/ | 2022-09-07T11:53:46Z |
LEXINGTON, Mass., Sept. 7, 2022 /PRNewswire/ -- Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, today announced that it has initiated the rollout of its Hemanext ONE® RBC (Red Blood Cell) Processing and Storage System in Europe.
Doctors have begun transfusing patients suffering from hematological malignancies using RBCs processed and stored with the Hemanext ONE® system, as part of a post-market clinical study in Bergen, Norway. This is a study designed to assess the initial safety effects of transfusing hypoxic RBCs in patients with acute burns and hematological malignancies, including MDS.
Hemanext received CE Mark Certification for its RBC Processing & Storage System in April 2021 and plans to roll out Hemanext ONE® across additional European markets in the coming months. As part of this commercialization and sales ramp program, Hemanext has been strengthening its relationship with distributors, healthcare institutions and blood establishments across Europe.
The Company has recently submitted a De Novo classification request to the US FDA. The De Novo submission is currently pending, and the product is not commercially available in the United States at this time.
Martin Cannon, Co-Founder and CEO of Hemanext, said: "Successfully beginning the treatment of patients in Europe with hypoxically stored RBCs is a tremendous milestone, both for our company and for transfusion patients globally. We believe the road to improved patient transfusions begins with storing RBCs under hypoxic conditions to limit oxidative damage and storage lesions. Our technology has the potential to facilitate efficient treatment of patients in need. We look forward to continuing to expand our presence into additional European markets over the course of 2022."
Geir Hetland, MD, PhD, group leader, Department of Immunology and Transfusion Medicine, Oslo University Hospital said: "As a physician, it is thrilling to have a powerful new tool available that could improve transfusions. We look forward to seeing the data that results from this clinical study, as we believe these real-world improvements in technology have the potential to transform blood and transfusion therapy."
Janice Frey-Angel, CEO of Aplastic Anemia & MDS International Foundation (AAMDSIF), said: "This announcement marks a concrete step forward for transfusion patients everywhere. AAMDSIF is proud to partner with companies like Hemanext that work tirelessly with the mission to improve the quality of life for patients who are burdened by chronic blood disorders. We are eager to learn more about the data from the study, as we look to further our support for patients searching for tools to navigate their chronic illnesses."
Håkon Reikvam, MD, PhD, Professor, Department of Clinical Science, University of Bergen in Norway, and a study investigator, said: "The commencement of this study marks an important step forward in the journey to innovate on behalf of patients suffering from severe blood disorders. As a clinician, I am well-aligned with Hemanext's mission to provide safer transfusions. I believe this study represents a key stride towards a world with fewer and better transfusions."
About Hemanext
Hemanext is a privately held medical technology company based in Lexington, MA that is dedicated to improving the quality, safety, efficacy, and cost of transfusion therapy. The company's research and development efforts center on the study of hypoxically stored red blood cells (RBCs). The company's aim is to significantly improve the quality of stored RBCs by limiting oxygen and carbon dioxide levels in the storage environment.
Since its founding in 2008, Hemanext has envisioned a world with fewer and better transfusions. In its early years, multiple grants from the U.S. National Institutes of Health (NIH) enabled the company to demonstrate the feasibility of hypoxic RBC storage, develop its first prototype system, and conduct in vivo research. To date, the company has raised more than $100 million in private equity capital from major US and international investors.
On April 13, 2021, Hemanext announced that it had received CE Mark certification for Hemanext ONE® system, clearing the way for the medical device to be sold in European markets.
About Hemanext ONE®
In Europe, the system is CE Marked for the processing and storage CPD/PAGGSM Red Blood Cells, Leukocytes Reduced (LR RBC) that have been prepared and processed with the HEMANEXT ONE® system within 24hours of collection. The HEMANEXT ONE® system limits the O2 and CO2 levels in the storage environment. Red Blood Cells Leukocytes Reduced, O2 /CO2 Reduced may be stored for up to 42 days at 1-6°C. HEMANEXT ONE® is used for volumes no greater than 350 ml of LR RBC.1
In the United States, the product remains available for investigational use only, pending marketing authorization from the FDA.
Preclinical data show that the medical device can maintain RBCs at or below 20% oxygen saturation for up to 42 days2, thereby creating hypoxic RBCs. Clinical studies are underway to measure the impact of hypoxic RBCs on patient outcomes and the potential cost savings.3,4
Visit Hemanext.com to learn more about the Company.
Hemanext Media Contact:
Nathan Riggs / Hallie Wolff
nathan.riggs@kekstcnc.com / Hallie.Wolff@kekstcnc.com
Stacy Smith
Associate Director Marketing Communications
stacy.smith@hemanext.com
1 Hemanext ONE®, Instructions for Use for the European Union (April 2021), DOF
2 Brouard, D et al. Vox Sang 2018; 113: 153.2018.
3 Frank, S et al. Anesthesiology 2017;127(5):754-764.
4 DOF. Document.Calculation.2021
View original content:
SOURCE Hemanext Inc. | https://www.whsv.com/prnewswire/2022/09/07/european-patients-have-begun-receiving-transfusions-with-hemanext-one-rbc-processing-storage-system/ | 2022-09-07T11:53:57Z |
The world's most highly rated BPO, based on employee ratings, aims to hire 3,000 people in Bogota over the next 3 years.
BOGOTA, Colombia, Sept. 7, 2022 /PRNewswire/ -- Everise, one of the fastest growing outsourced customer experience companies in the world, announced today that it has officially entered the Colombian market. The company plans to hire 1,000 people in Bogota over the next 12 months, and over 3,000 by 2025.
A ribbon-cutting ceremony was attended by Bogota's Undersecretary of Economic Development of Bogotá, Sebastián Marulanda, representing of the Mayor's Office of Bogota; Elsa Aurora Bohórquez, coordinator of the National Employment Agency of SENA; and Sudhir Agarwal, CEO and founder of Everise.
At the event, Marulanda said, "Everise's arrival is proof that when the public and private sectors come together, they achieve great results. We celebrate the start of its operations that will not only boost economic development in Bogotá but will also open up new and better job opportunities for all."
"We have followed Colombia for years. Government support and a well-prepared population make the BPO environment here very favorable. This is a strategic and valuable territory through which we will continue to offer premium support to our valued clients and their customers," says Sudhir Agarwal. He adds, "The central location, market size, and availability of bilingual, educated labor in Colombia are additional reasons Everise chose the country for its Latin American expansion."
Everise is not new to Latin America. In 2012, the company launched operations in Guatemala City, Guatemala. In Colombia, the company hopes to replicate its success in building teams in and for the region.
Agarwal says, "At Everise, we specialize in quickly recruiting quality people to staff and scale support programs, even in challenging labor markets. Our expansion into Colombia is an important part of our plan to maintain and grow that ability, and with the quality of talent in this country, we are confident we will assemble a great group of champions that can help us evolve the customer experience for our present and future clients."
Everise, headquartered in Florida, USA, employs over 15,000 people across 4 continents and has won multiple awards for its training and treatment of staff. These include being named one of Newsweek's 100 Most Loved Workplaces in America in 2021 and earning the Gold Stevie Award for Employer of the Year – Consumer Services in 2022. Everise also has the highest Glassdoor and Indeed ratings in the entire outsourcing sector, making it the best BPO in the world, based on employee opinions.
How to take part?
For instructions on how to apply, candidates can follow Everise Colombia on Facebook. Everise welcomes applications from recent graduates with strong English skills as well as professionals with experience. The company offers various benefits, including connectivity aid, food vouchers, health payments and a base salary of $2,400,000 Colombian pesos.
Everise is committed to inclusivity and diversity, and does not consider racial, sexual, religious, or creedal factors.
About Everise:
Everise is a technology-enabled outsourcing firm with expertise in transforming healthcare and technology customer experiences globally. The Company's unique approach combines customer and technical support services with AI, robotic process automation, analytics, and secure cloud-based technology. Some of the world's most loved brands have products and services that are perfected, protected, supported, and sold by Everise.
Our innovative digital outsourcing services are high performing, scalable, secure, agile, and have fluent proficiency in 32 languages, which helps brands to create seamless customer, product, digital, and home experiences. We strategically operate in seven markets to enable our partners to economically reach their customers across the globe. Learn more at www.weareeverise.com.
Images:
- For images of the Everise leadership team: ELT portraits
- For images of Everise champions at work: Bogota site and staff photos
- For images from the 7 September ribbon-cutting: Ribbon-cutting 6 Sep
Press contacts
Coral Gotay
Everise Public Relations & Brand Communications, Americas
E: coral.gotay@weareeverise.com
View original content to download multimedia:
SOURCE Everise | https://www.whsv.com/prnewswire/2022/09/07/everise-launches-operations-colombia-celebrates-official-opening-bogota-office/ | 2022-09-07T11:54:03Z |
REHOVOT, Israel, Sept. 7, 2022 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) (the "Company", "Evogene"), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today that Ofer Haviv, Evogene's President and CEO, will attend virtually and present at the H.C. Wainwright 24th Annual Global Investment Hybrid Conference, 2022, taking place from September 12-14, 2022, in New York and also in a virtual format.
Mr. Haviv's presentation will focus on Evogene's disruptive technologies, its AI engines for biologic product discovery and development, and the ecosystem of product-focused subsidiaries and partnerships it has built around its technologies. The presentation will be available from the H.C. Wainwright conference website from 7am ET on Monday, September 12, 2022.
Mr. Haviv will also be available for 1-1 meetings with current and prospective investors via video conference on Tuesday, September 13, 2022. Interested investors are welcome to contact Evogene's Investor Relations team whose contact details are below, or for H.C. Wainwright clients, schedule meetings directly via the conference's online meeting platform.
About Evogene Ltd.:
Evogene (Nasdaq: EVGN) (TASE: EVGN) is a computational biology company aiming to revolutionize the development of life-science based products by utilizing cutting edge technologies to increase probability of success while reducing development time and cost. Evogene established three unique technological engines - MicroBoost AI, ChemPass AI and GeneRator AI – leveraging Big Data and Artificial Intelligence and incorporating deep multidisciplinary understanding in life sciences. Each technological engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI). Evogene uses its technological engines to develop products through subsidiaries and with strategic partners. Currently, Evogene's main subsidiaries utilize the technological engines to develop human microbiome-based therapeutics by Biomica Ltd., medical cannabis products by Canonic Ltd., ag-chemicals by Ag Plenus Ltd. and ag-biologicals by Lavie Bio Ltd. For more information, please visit: www.evogene.com.
Evogene Investor Contact:
Kenny Green
Email: kenny.green@evogene.com
Tel: +1 212 378 8040
Logo - https://mma.prnewswire.com/media/890385/Evogene_Logo.jpg
View original content:
SOURCE Evogene | https://www.whsv.com/prnewswire/2022/09/07/evogene-present-hc-wainwright-24th-annual-global-investment-conference/ | 2022-09-07T11:54:10Z |
– Four leading pediatric infectious disease institutions will study M2SR vaccine response in pediatric subjects, a population in which infection rates are often highest –
– Collaborative study led by National Institute of Allergy and Infectious Diseases' "Collaborative Influenza Vaccine Innovation Centers" program –
MADISON, Wis., Sept. 7, 2022 /PRNewswire/ -- FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced the completion of enrollment of the first cohort in an age de-escalation clinical trial of M2SR (M2 Deficient Single Replication) live virus vaccine, the company's investigational supra-seasonal intranasal influenza (flu) vaccine, in volunteers ages 6 months to 17 years old. This study is the first of its kind to evaluate M2SR in children under 9 years old, a population with the greatest rates of flu infection each year and who are at higher risk of serious complications or death. The study, funded by the National Institute of Allergy and Infectious Diseases (NIAID) Collaborative Influenza Vaccine Innovation Centers (CIVICs) program will assess safety, tolerability, and immunological response to M2SR.
"Influenza can have serious complications in young children, a particularly vulnerable patient population, and there is a demonstrated need for improved vaccines that can mitigate the impact of the flu," said Dr. James Campbell, Professor of Pediatrics at the University of Maryland School of Medicine and Principal Investigator of the study. "The M2SR vaccine candidate has already shown a robust safety profile in adults, and we look forward to advancing scientific understanding of the potential benefits of M2SR in children."
The randomized, double-blind, dose-escalating, age de-escalating, placebo-controlled, Phase 1b study, (clinicaltrials.gov NCT04960397) is designed to evaluate a monovalent Singapore 2016 H3N2 M2SR influenza A vaccine in children. The primary endpoint is to measure the safety and tolerability of M2SR. The secondary endpoint is to assess the humoral immunogenicity (serum antibody and mucosal antibody responses) directed against the matched virus strain. The study will enroll 220 participants in three cohorts: 9-17 years old (n=45); 2-8 years old (n=115); and 6-23 months old (n=60); and will occur over two flu seasons. Participants will be randomized to receive either one or two doses of a monovalent M2SR vaccine (at increasing doses of 107, 108, or 109 TCID50) or placebo delivered intranasally. All participants will be offered the seasonal influenza vaccine at the end of the study period.
"The rate of influenza infection is highest in pediatric patients, and the current standard-of-care does not meet the needs of this unprotected population," said Paul Radspinner, President and Chief Executive Officer of FluGen. "We are pleased that the NIH has selected our M2SR flu vaccine candidate to be studied as part of its CIVICs program, and look forward to sharing further updates, and the initial results of the study, which are expected in the first half of 2023."
FluGen's novel supra-seasonal, intranasal M2SR flu vaccine has already been studied in more than 200 subjects aged 9 to 55 years and has shown a strong safety and immunogenicity profile. It is also being studied in a separate ongoing study in adults 55 to 85 years old. The study in pediatric subjects is supported by NIH CIVICs under contract numbers 75N93019C00055 to University of Maryland School of Medicine and 75N93019C00054 to Duke University. In addition to James Campbell, M.D. at the University of Maryland, Emmanuel Walter, M.D. at Duke University, Clarence Creech at Vanderbilt University and Patricia Winokur, M.D. at the University of Iowa will serve as investigators for the study.
The content of this announcement is the responsibility solely of FluGen, Inc. and does not necessarily represent the official views of NIH.
FluGen, Inc. is a clinical-stage vaccine company transforming vaccine efficacy in respiratory diseases. The company's lead candidate is M2SR, a supra-seasonal, live, single-replication, intranasal flu vaccine. Unlike standard of care flu vaccines, M2SR stimulates mucosal, humoral, and cellular immunity. In an unprecedented challenge trial, M2SR demonstrated protection against infection and illness across seven years of virus drift; and M2SR induces a durable antibody response with potential to cover an entire flu season and beyond. M2SR also has shown activity as a vaccine vector for other respiratory vaccines and infectious diseases, including a COVID-19/flu combination. For more information about FluGen, Inc., please visit http://www.FluGen.com/.
The M2 Deleted Single Replication Live Virus Vaccine (M2SR) offers a potentially differentiating clinical value proposition. FluGen's flu vaccine candidate works differently, stimulating mucosal, humoral, and cellular immunity, and offering unprecedented efficacy against infection and illness across seven years of virus drift, and documented immune response for at least six months.
View original content to download multimedia:
SOURCE FluGen, Inc. | https://www.whsv.com/prnewswire/2022/09/07/flugen-announces-completion-first-cohort-age-de-escalation-clinical-trial-m2sr-flu-vaccine-candidate-pediatric-subjects-ages-6-months-17-years/ | 2022-09-07T11:54:16Z |
SHANGHAI and PARIS, Sept. 7, 2022 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the results from phase I study of GFH018 (TGF-β R1 inhibitor) monotherapy (NCT05051241) for treatment of advanced solid tumor will be presented as a poster at the 2022 European Society for Medical Oncology Meeting in Paris on September 12th.
Through an open-label, multicenter study, GFH018 demonstrated a favorable safety/tolerability profile and preliminary efficacy signal among advanced solid tumor patients that failed to respond to prior standard therapies. No dose-limiting toxicities were observed and over 20% patients with different types of cancer achieved stable disease. Two phase II combination studies of GFH018 with PD-1 inhibitor are ongoing with additional data to be presented at medical meetings in the future.
"We are delighted to collaborate with GenFleet in the clinical research of GFH018 as an innovative small-molecule kinase inhibitor designed to specifically target and inhibit TGF-β R1. We are pleased to report the preliminary efficacy signal and good safety/tolerability profile of GFH018 monotherapy and look forward to the further trials in combination studies." said Professor Ye Guo of Shanghai Oriental Hospital.
"It is the first time for GenFleet to present clinical data at ESMO, which represents a significant milestone in the company's multi-regional clinical research and global development. We have recently determined the recommended phase II dose and hope to confirm the response of combination therapies in patients with advanced tumors. Moreover, we expect to release more data related to GFH018 in future academic conferences." said Yu Wang, M.D./Ph.D., Chief Medical Officer of GenFleet.
Phase I study of GFH018, a small molecular TGF-β R1 inhibitor, in patients with advanced solid tumor
Poster 437p, Abstract：#1623, Poster Area: Hall 4
This is an open-label, multicenter study comprising of a modified 3 + 3 dose escalation part followed by an expansion part and the starting dose was 5 mg. Eligible patients with advanced solid tumors failed to standard therapies were administrated with GFH018 BID, 14d on/14d off in 28-day cycles. As of Jan. 25, 2022, 39 patients were sequentially enrolled in the dose escalation part. The median lines of prior therapy were≥3. No dose-limiting toxicities were observed, the maximum tolerated dose was not reached, and no patients discontinued the study treatment due to adverse events.
PK of GFH018 was linear and dose-independent with mean half-life in the range of 3.11 hours to 8.30 hours. Of 24 evaluable patients, 5 achieved stable disease. A patient with thymic carcinoma receiving 50 mg achieved a durable stable disease with tumor shrinkage (maximum lesion decreased by 18.4% and has stayed on treatment for 185 days as of the data cut-off date.
About GFH018 and TGF-β R1
Developed by GenFleet Therapeutics, GFH018 is an orally administered TGF-β R1 inhibitor and entered into phase I clinical trial in 2019. Preclinical data showed evidence of GFH018's good anti-tumor properties against cancer cells in vivo and in vitro. Besides, translational and mechanistic studies confirmed it effectively acts on TGF-β signaling pathway and synergizes with checkpoint inhibitors.
In the microenvironment of advanced solid tumors, TGF-β signaling pathway can promote epithelial mesenchymal transition (EMT) & metastasis, induce the formation of cancer stem cells and their functional maintenance, inhibit anti-tumor immunity, enhance vasculature and fibrosis, and ultimately result in tumor progression. Among patients of hepatocellular carcinoma, glioma, colorectal cancer, lung cancer, pancreatic cancer, urothelial cancer and other solid tumors, high expression of genes related to TGF-β signaling pathway is frequently discovered in their blood and tumor tissues. The expression level is positively correlated to the malignancy & poor differentiation of tumor and unfavorable prognosis in patients.
About GenFleet Therapeutics
GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies, is dedicated to serving significant global unmet medical needs in oncology and immunology. Based on the deep understanding of disease biology and translational medicine, GenFleet's proprietary and fully integrated R&D platform highlights multiple cutting-edge products with novel mechanisms and global IP.
Since its inception in 2017, GenFleet has built up industry-leading capabilities and expertise in developing novel drug candidates - both small molecules and biologics. Its pipeline includes over 10 programs, many of which have entered multi-regional clinical trials across China (including Taiwan), the United States and Australia. To date, GenFleet has over 5 clinical studies encompassing IND stage to phase II studies and completed co-development partnerships with 3 publicly listed companies in China or US.
GenFleet is expected to progress additional programs into the clinic, as well as transition from a clinical stage biotech company into a commercial stage biopharmaceutical company in the next 3-5 years.
Yun Zeng
+86-13482182145
yzeng@genfleet.com
View original content:
SOURCE GenFleet Therapeutics | https://www.whsv.com/prnewswire/2022/09/07/genfleet-therapeutics-present-data-phase-i-trial-gfh018-monotherapy-2022-european-society-medical-oncology-annual-meeting/ | 2022-09-07T11:54:23Z |
Shares Outstanding: 295,518,506
Trading Symbols: TSX: GGD
OTCQX: GLGDF
1,625 g/t AgEq over 1.1m within 47.6m of 147 g/t AgEq at El Favor East
HALIFAX, NS, Sept. 7, 2022 /PRNewswire/ - GoGold Resources Inc. (TSX: GGD) (OTCQX: GLGDF) ("GoGold", "the Company") is pleased to release the results of 7 drill holes from the El Favor East deposit within Los Ricos North property. Hole LRGF-22-136 intersected 1.1m of 1,625 g/t silver equivalent ("AgEq") contained within 47.6m of 147 g/t AgEq, and hole LRGF-22-124 intersected 0.9m of 1,835 g/t AgEq contained within 22.0m of 134 g/t AgEq.
"Further holes from El Favor East show both wider bulk tonnage potential and very high grade portions included within. They show extension of the zone to the east and additional high grade infill," said Brad Langille, President and CEO. "Throughout the Los Ricos district, we continue to see drill intercepts that have both the potential for bulk open pit mining and/or bulk underground mining. Both of these mining methods will be fully evaluated for best economics while keeping in mind our high ESG standards."
Table 1: Drill Hole Intersections
In early 2022, the exploration team began a systematic stepout drilling program to test the eastern strike extension of the El Favor deposit in the area between Discovery Hole 48 and the underground workings at the Constancia Mine. This area is known as the El Favor East zone, and the mapping and drilling program has extended the presence of mineralization 900m to the east of hole 48 (El Favor East zone discovery hole), as shown in Figure 1. To date, approximately 800m of El Favor East has been drilled showing the strong mineralization. The drill holes in this release were not included in the initial Mineral Resource Estimate for Los Ricos North released on December 7, 2021, hole LRGF-21-094 was the final drill hole included in that resource.
Table 2: Drill Hole Locations
In September, the company commissioned TMC Exploracion to complete an IP survey using the Pole:Dipole array on the El Favor property. The grid consists of a network of 28 N/S profiles spaced every 100 m from L-2W to L-25E ranging in length from 0.85 to 2.0 km. The survey outlined several high chargeability anomalies representative of the sulphide mineralization along the El Favor – El Favor East zone. A geophysical map showing anomalies and drilling targets is included as Figure 2 below.
El Favor is located approximately 800 meters along strike to the east of the El Orito deposit. The combined systems cover approximately 2.9km in mineralized strike length over a 3.7km distance. At El Orito, wide zones of precious and base metal mineralization were cut by drill holes at El Orito at elevations between 600 to 900m. The drill holes at El Favor have cut primarily silver-gold mineralization with trace to minor amounts of base metals at a higher elevation in the system, between 1,050m to 1,400m, compared to the semi-massive to massive base metal sulphide mineralization seen deeper in the El Orito deposit.
VRIFY is a platform being used by companies to communicate with investors using 360° virtual tours of remote mining assets, 3D models and interactive presentations. VRIFY can be accessed by website and with the VRIFY iOS and Android apps.
The VRIFY Slide Deck and 3D Presentation for GoGold can be viewed at: https://vrify.com/decks/10437 and on the Company's website at: www.gogoldresources.com.
The Company's two exploration projects at its Los Ricos Property are in Jalisco state, Mexico. The Los Ricos South Project began in March 2019 and an initial Mineral Resource was announced on July 29, 2020 which disclosed a Measured & Indicated Mineral Resource of 63.7 million ounces AgEq grading 199 g/t AgEq contained in 10.0 million tonnes, and an Inferred Mineral Resource of 19.9 million ounces AgEq grading 190 g/t AgEq contained in 3.3 million tonnes. An initial PEA on the project was announced on January 20, 2021 indicating an NPV5% of US$295M.
The Los Ricos North Project was launched in March 2020 and an initial Mineral Resource was announced on December 7, 2021, which disclosed an Indicated Mineral Resource of 87.8 million ounces AgEq grading 122 g/t AgEq contained in 22.3 million tonnes, and an Inferred Mineral Resource of 73.2 million ounces AgEq grading 111 g/t AgEq contained in 20.5 million tonnes. The Company has a drill program for an additional 100,000 metres of drilling for 2022 in place.
The diamond drill core (HQ size) is geologically logged, photographed and marked for sampling. When the sample lengths are determined, the full core is sawn with a diamond blade core saw with one half of the core being bagged and tagged for assay. The remaining half portion is returned to the core trays for storage and/or for metallurgical test work.
The sealed and tagged sample bags are transported to the ActLabs facility in Zacatecas, Mexico. ActLabs crushes the samples and prepares 200-300 gram pulp samples with ninety percent passing Tyler 150 mesh (106μm). The pulps are assayed for gold using a 50-gram charge by fire assay (Code 1A2-50) and over limits greater than 10 grams per tonne are re-assayed using a gravimetric finish (Code 1A3-50). Silver and multi-element analysis is completed using total digestion (Code 1F2 Total Digestion ICP). Over limits greater than 100 grams per tonne silver are re-assayed using a gravimetric finish (Code 8-Ag FA-GRAV Ag).
Quality assurance and quality control ("QA/QC") procedures monitor the chain-of-custody of the samples and includes the systematic insertion and monitoring of appropriate reference materials (certified standards, blanks and duplicates) into the sample strings. The results of the assaying of the QA/QC material included in each batch are tracked to ensure the integrity of the assay data. All results stated in this announcement have passed GoGold's QA/QC protocols.
Mr. David Duncan, P. Geo. is the qualified person as defined by National Instrument 43-101 and is responsible for the technical information of this release.
GoGold Resources (TSX: GGD) is a Canadian-based silver and gold producer focused on operating, developing, exploring and acquiring high quality projects in Mexico. The Company operates the Parral Tailings mine in the state of Chihuahua and has the Los Ricos South and Los Ricos North exploration projects in the state of Jalisco. Headquartered in Halifax, NS, GoGold is building a portfolio of low cost, high margin projects. For more information visit gogoldresources.com.
The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States or to, or for the benefit of, U.S. persons (as defined in Regulation S under the U.S. Securities Act) except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to exemptions therefrom. This release does not constitute an offer to sell or a solicitation of an offer to buy of any of GoGold's securities in the United States.
This news release may contain "forward-looking information" as defined in applicable Canadian securities legislation. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Los Ricos South and North projects, and future plans and objectives of GoGold, including the intention to undertake further exploration at Los Ricos North, and the prospect of further discoveries there, constitute forward looking information that involve various risks and uncertainties. Forward-looking information is based on a number of factors and assumptions which have been used to develop such information but which may prove to be incorrect, including, but not limited to, assumptions in connection with the continuance of GoGold and its subsidiaries as a going concern, general economic and market conditions, mineral prices, the accuracy of mineral resource estimates, and the performance of the Parral project. There can be no assurance that such information will prove to be accurate and actual results and future events could differ materially from those anticipated in such forward-looking information.
Important factors that could cause actual results to differ materially from GoGold's expectations include exploration and development risks associated with GoGold's projects, the failure to establish estimated mineral resources or mineral reserves, volatility of commodity prices, variations of recovery rates, and global economic conditions. For additional information with respect to risk factors applicable to GoGold, reference should be made to GoGold's continuous disclosure materials filed from time to time with securities regulators, including, but not limited to, GoGold's Annual Information Form. The forward-looking information contained in this release is made as of the date of this release.
View original content to download multimedia:
SOURCE GoGold Resources Inc. | https://www.whsv.com/prnewswire/2022/09/07/gogold-announces-additional-positive-drilling-el-favor-east/ | 2022-09-07T11:54:30Z |
NEW YORK, Sept. 7, 2022 /PRNewswire/ -- Gradian Health Systems (Gradian) is proud to announce a strategic relationship with Canon Virginia Inc. (CVI). This announcement marks the collaboration of two mission driven organizations, with a common goal of addressing disparities within healthcare globally.
This collaboration builds on Gradian's decade plus work developing and supporting medical technology in resource-limited settings and CVI's 37 years of established manufacturing excellence and medical device expertise. CVI will assume manufacturing operations for Gradian's flagship product, the UAM, an anesthesia machine designed to work in the absence of electricity and medical oxygen and establish manufacturing operations for Gradian's newest product – the K-O2. CVI plans to be in full scale production of both products by the end of 2022. The UAM and K-O2 are specifically designed to better enable access to anesthesia and oxygen therapy, respectively, by addressing resource constraints that often prevent medical providers from being able to deliver continuous care for patients.
"We are very excited to partner with Canon," said Lina Sayed, Chief Executive Officer, Gradian Health Systems. "At Gradian, we know how important it is to work with partners whose missions align with ours. Canon's proven expertise is unmatched – both in manufacturing and as a partner to work side-by-side with us to build a better future in healthcare. We are looking forward to what we hope will be a longstanding relationship with Canon."
Years of industry and manufacturing experience make both Gradian and CVI uniquely qualified to embark on a collaboration designed to deliver top of the line solutions that enable providers to offer premier care for their patients. By combining their excellence in manufacturing and product quality, the two organizations aim to create world-class products that address some of the biggest healthcare challenges to date.
"CVI and Gradian share many of the same values – a commitment to our customers, quality, and efficient manufacturing services to name a few," said Ronald Kurz, Sr. Director and General Manager, Business Operations Group / Medical, Canon Virginia, Inc. Our corporate philosophy, is driven by the Japanese principle, 'Kyosei,' the concept that all people, regardless of race, religion, or culture, are harmoniously living and working together into the future,' and we are proud to be working with a partner who is equally committed to this mission. We pride ourselves on providing exceptional service and resources to our partners and are very excited to see what the future holds for healthcare world-wide."
Today's announcement marks the beginning of a relationship that aims to build on both companies' commitment to addressing inequities in healthcare and helping to ensure that everyone has access to the best health services possible.
Gradian Health Systems is a nonprofit medical technology company that works in partnership with healthcare providers to design and introduce user-centric solutions that address gaps in technology solutions, training, and customer service. With innovations in anesthesia, critical care, and oxygen therapy, Gradian has enabled healthcare teams to provide high-quality, safe care to more than 2.2 million patients across Africa, Asia, and Latin America. Working in partnership with health facilities, national governments, global NGOs, and medical technology partners, Gradian is also revolutionizing the way that life-changing innovations are introduced by ensuring that healthcare providers are fully equipped to use their products with a hands-on training and reliable customer support model. Learn more at: gradianhealth.org
Located in Newport News, Va., Canon Virginia, Inc. serves as the Canon manufacturing, engineering, recycling, and technical support center for the Americas. Canon Virginia produces new products using advanced manufacturing methodologies while also serving as a factory service center providing expert customer service in the repair and refurbishment of Canon products. Canon Virginia's manufacturing services extend to injection mold making, contract manufacturing, medical contract manufacturing and aftermarket services. For more information, call 1-866-99-CANON or visit https://www.cvi.canon.com/manufacturing-services/.
Media Contacts:
Gradian Health Systems
Mariam Khan
Senior Communications Manager
Email: mkhan@gradianhealth.org
Phone: +1-917-445-1774
Canon Virginia, Inc.
Lindsey Wagner-Jones
Senior Communications Specialist
Email: lwagner@cvi.canon.com
Phone: +1-757-881-6267
View original content to download multimedia:
SOURCE Gradian Health Systems | https://www.whsv.com/prnewswire/2022/09/07/gradian-health-systems-announces-partnership-with-canon-virginia-inc-cvi/ | 2022-09-07T11:54:36Z |
TSX: GPR | NYSE American: GPL
This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated October 15, 2021, to its short form base shelf prospectus dated September 10, 2021.
VANCOUVER, BC, Sept. 7, 2022 /PRNewswire/ - Great Panther Mining Limited (TSX: GPR) (NYSE-A: GPL) ("Great Panther" or the "Company"), reports a corporate update following the announcement on September 6, 2022, regarding the filing of a notice of intention to seek creditor protection (the "NOI").
Great Panther's Brazilian subsidiary, Mina Tucano Ltda. ("Mina Tucano") and its two shareholders, Beadell (Brazil) Pty Ltd and Beadell (Brazil 2) Pty Ltd, has filed a judicial reorganization proceeding in the judicial district of Rio de Janeiro, State of Rio de Janeiro, Brazil. The judicial reorganization proceeding is a court-supervised arrangement between debtors and their creditors to allow the debtors to attempt to restructure their operations and liabilities and in order to address a situation of financial distress.
Under the judicial reorganization proceeding, Mina Tucano and its shareholders will remain in possession of their assets and will continue to control and manage the business as a going concern. They will obtain protection against collection and enforcement actions in order to preserve their liquidity and assets and to effectively negotiate with their creditors a judicial reorganization plan intended to maximize stakeholder value.
A list of frequently asked questions related to the filing of the NOI and the judicial reorganization can be found on the Company's website at www.greatpanther.com/corporate/restructuring.
On September 6, 2022, as a result of the Company filing a notice of intention to make a proposal (the under the Bankruptcy and Insolvency Act ( Canada ), the Toronto Stock Exchange ("TSX") suspended trading of the Company's common shares and advised the Company that a delisting review would be required by the TSX. The TSX is reviewing the eligibility for continued listing on the TSX of the common shares of the Company pursuant to an expedited review process. The delisting review is expected to take place on September 16, 2022.
On September 6, 2022, the Company also received notice that the NYSE American (the "NYSE-A") has determined to commence proceedings to delist the Company's common shares from the NYSE-A. The NYSE-A notified the Company that it no longer complies with the continued listing standards set forth in the NYSE American Company Guide. If the Company elects not to appeal the delisting determination within seven calendar days, the delisting determination will become final. The Company is evaluating its options related to the delisting notice.
Great Panther Mining is a precious metals producer focused on the operation of the Tucano Gold Mine in Brazil where the Company controls a land package covering nearly 200,000 hectares in the prospective Vila Nova Greenstone belt. Great Panther is listed on the Toronto Stock Exchange under the symbol GPR and on the NYSE American under the symbol GPL.
This news release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and forward-looking information within the meaning of Canadian securities laws (together, "forward-looking statements"). Such forward-looking statements include but are not limited to the effects of the judicial reorganization proceeding in Brazil, including the ability of Mina Tucano and its shareholders to remain in possession of their assets, to continue to control and manage the business as a going concern, and to obtain protection against collection and enforcement actions in order to preserve their liquidity and assets and to effectively negotiate with their creditors a judicial reorganization plan intended to maximize stakeholder value.
These forward-looking statements and information reflect the Company's current views with respect to future events and are necessarily based upon a number of assumptions that, while considered reasonable by the Company, are inherently subject to significant procedural, operational, business, economic and regulatory risks and uncertainties, including risks related to the restructuring process and its impact on the Company's operations and financial conditions, uncertainty regarding the ability to obtain protection against all collection and enforcement actions during the judicial reorganization proceedings, uncertainty regarding the Company's ability to identify and pursue strategic alternatives that will maximize stakeholder value, and the risks described in respect of Great Panther in its most recent annual information form and management's discussion and analysis filed with the Canadian Securities Administrators and available at www.sedar.com and its most recent annual report on Form 40-F and management's discussion and analysis on Form 6-K filed with the Securities and Exchange Commission and available at www.sec.gov.
There is no assurance that these forward-looking statements will prove accurate or that actual results will not vary materially from these forward-looking statements. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated, described, or intended. Accordingly, readers are cautioned not to place undue reliance on forward looking statements. Forward-looking statements and information are designed to help readers understand management's current views of our near- and longer-term prospects and may not be appropriate for other purposes. The Company does not intend, nor does it assume any obligation to update or revise forward-looking statements or information, whether as a result of new information, changes in assumptions, future events or otherwise, except to the extent required by applicable law.
View original content to download multimedia:
SOURCE Great Panther Mining Limited | https://www.whsv.com/prnewswire/2022/09/07/great-panther-mining-provides-corporate-update/ | 2022-09-07T11:54:43Z |
Leading Single-Family Rental Operator and U.S. Homebuilder Recognized on Debut Real Estate List
LAS VEGAS, Sept. 7, 2022 /PRNewswire/ -- American Homes 4 Rent (NYSE: AMH) ("American Homes 4 Rent" or the "Company"), a leading provider of high-quality, single-family homes for rent, has been honored by Great Place to Work® and Fortune as one of the 2022 Best Workplaces in Real Estate™. American Homes 4 Rent placed 24th on this year's inaugural real estate list.
The Best Workplaces in Real Estate award is based on analysis of survey responses from over 23,000 employees from Great Place to Work-Certified™ companies in the real estate industry. In that survey, 87% of AMH's employees said the company is a great place to work. This number is 50% higher than the average U.S. company.
"Earning this coveted recognition means that AMH is one of the best companies to work for in the country and we owe this ranking to our dedicated team members who drive our values-based culture," said Lisa Phelps, Senior Vice President of Human Resources of American Homes 4 Rent. "We've built a team that represents the diverse residents we serve and works to provide them peace of mind in their homes. We take care of each other, so that together we can take care of the people who make their home with us."
The Best Workplaces in Real Estate is highly competitive. Great Place to Work, the global authority on workplace culture, selected the list using rigorous analytics and confidential employee feedback. Companies were only considered if they had been a Great Place to Work-Certified™ organization.
Great Place to Work is the only company culture award in America that selects winners based on how fairly employees are treated. Companies are assessed on how well they are creating a great employee experience that cuts across race, gender, age, disability status, or any aspect of who employees are or what their role is.
"These companies have adapted to the challenges of an ever-changing workplace by their commitment to inclusive, high-trust cultures where employees are treated as human beings first and foremost," said Michael C. Bush, Chief Executive Officer of Great Place to Work. "Congratulations to the Best Workplaces in Real Estate."
American Homes 4 Rent (NYSE: AMH) is a leading single-family property owner, leasing operator, and build-to-rent developer. Recent achievements include being named a 2022 Great Place to Work®, a 2022 Top U.S. Homebuilder by Builder100, one of America's Most Responsible Companies 2022 and America's Most Trusted Companies 2022 by Newsweek and Statista, and a Top ESG Regional Performer by Sustainalytics. We are an internally managed Maryland real estate investment trust (REIT) focused on acquiring, developing, renovating, leasing, and managing homes as rental properties. As of March 31, 2022, we owned 57,984 single-family properties in select submarkets in 22 states. Additional information about American Homes 4 Rent is available on our website at www.americanhomes4rent.com.
Great Place to Work selected the Best Workplaces in Real Estate by gathering and analyzing confidential survey responses from over 23,000 employees from Great Place to Work-Certified™ companies in the real estate industry. Company rankings are derived from 60 employee experience questions within the Great Place to Work® Trust Index™ survey. Great Place to Work determines its lists using its proprietary For All™ methodology to evaluate and certify thousands of organizations in America's largest ongoing annual workforce study, based on over 1 million survey responses and data from companies representing more than 6.1 million employees, this year alone. Read the full methodology.
To get on this list next year, start here.
Great Place to Work® is the global authority on workplace culture. Since 1992, they have surveyed more than 100 million employees worldwide and used those deep insights to define what makes a great workplace: trust. Their employee survey platform empowers leaders with the feedback, real-time reporting and insights they need to make data-driven people decisions. Everything they do is driven by the mission to build a better world by helping every organization become a great place to work For All™.
Learn more at greatplacetowork.com and on LinkedIn, Twitter, Facebook and Instagram.
Contacts:
American Homes 4 Rent
Megan Grabos
Media Relations
Phone: (805) 413-5088
Email: media@ah4r.com
American Homes 4 Rent
Nicholas Fromm
Investor Relations
Phone: (855) 794-2447
Email: investors@ah4r.com
View original content to download multimedia:
SOURCE American Homes 4 Rent | https://www.whsv.com/prnewswire/2022/09/07/great-place-work-fortune-name-american-homes-4-rent-one-2022-best-workplaces-real-estate/ | 2022-09-07T11:54:52Z |
Experienced Private Equity Executive Joins Growing Team of Professionals
CHICAGO, Sept. 7, 2022 /PRNewswire/ -- GTCR, a leading private equity firm, announced today that Don McDonough has joined the firm as Managing Director, Business Development. In this role, he will lead business development efforts for the firm's Strategic Growth Fund and work with members of the GTCR investment teams to identify and develop investment opportunities for the fund. He will also have responsibility for building and maintaining relationships with investment banking organizations and other advisors across GTCR's investment domains. Mr. McDonough comes to GTCR with over 20 years of experience in the financial services industry and over a decade spent in business development for private equity.
GTCR closed its first Strategic Growth Fund in January 2022 with $2.0 billion of limited partner capital commitments. The fund supports GTCR's Leaders Strategy™ investment approach for smaller opportunities than those pursued by its most recent flagship fund, GTCR Fund XIII, which closed in 2020 with $7.5 billion in limited partner capital commitments. The firm's Leaders Strategy™ approach involves partnering with exceptional management leaders in its core domains to identify, acquire and build market-leading companies through transformational acquisitions and organic growth. GTCR has successfully applied the Leaders Strategy™ for several decades and maintains a culture of partnership with management teams as they build strategically attractive businesses over time.
To date, the Strategic Growth Fund has made several investments in partnership with experienced executives in its core industry sectors. Investment opportunities appropriate for the Strategic Growth Fund range from $50 million to $200 million of equity capital over time. GTCR's investment strategy typically involves multiple add-on acquisitions for each platform company, and those often involve the commitment of incremental equity capital in support of acquisitions and other growth initiatives.
"The Strategic Growth Fund allows GTCR to apply our investment approach and domain expertise at different points in the lifecycle of a growing business," said Sean Cunningham, Managing Director and Co-Head of Healthcare at GTCR. "Adding a seasoned business development professional like Don will help us manage the fund's new investment opportunity set and support our management teams' efforts to identify and complete attractive platform and add-on acquisitions."
Mr. McDonough joins GTCR from private equity firm JLL Partners where he served as Managing Director and Head of Business Development for the past 10 years. While in this role, he led deal generation efforts across the firm's aerospace & defense, business services, healthcare and industrial sector verticals. Mr. McDonough has also served as Principal and Director of Business Development for international private equity firm 3i Group plc. Earlier in his career, he worked at Sentinel Partners and JP Morgan Securities. He holds an MBA from Columbia Business School and a BA in Politics and Economics from Princeton University.
Investment opportunities for the Strategic Growth Fund are managed both by investment professionals in the firm's industry groups in conjunction with a dedicated team of investment professionals who primarily focus on the Strategic Growth Fund. Mr. McDonough joins a growing team of professionals committed to the Strategic Growth Fund. Senior leaders of the dedicated team include Managing Director John D. Kos, who has fourteen years of experience at GTCR where he has contributed to a number of impactful healthcare investments for the firm, as well as new Principal Kirk Smith who joined earlier this year to focus on financial technology. Mr. Smith was most recently a Principal at private equity firm Bregal Sagemount and previously he was an Associate in the Special Situations Group at Goldman, Sachs & Co. Mr. Smith holds an MBA from Harvard Business School and a BS in Finance with honors from the University of Kansas.
"As a firm, we continue to invest in key resources to sustain the quality of our growing franchise. Our Strategic Growth Fund is focused on the four industry sectors we have invested in for many years, and this fund applies our investment approach of partnering with management leaders to execute transformational change. Don joins a talented, experienced team of dedicated professionals that work with investment teams from across the firm to support GTCR's priority of providing superior investment performance to limited partners of the Strategic Growth Fund," said Aaron Cohen, Managing Director and Head of Financial Services & Technology at GTCR.
About GTCR
Founded in 1980, GTCR is a leading private equity firm that pioneered The Leaders Strategy™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through organic growth and strategic acquisitions. GTCR is focused on investing in transformative growth in companies in the Business & Consumer Services, Financial Services & Technology, Healthcare and Technology, Media & Telecommunications sectors. Since its inception, GTCR has invested more than $24 billion in over 270 companies, and the firm currently manages over $27 billion in equity capital. GTCR is based in Chicago with offices in New York and West Palm Beach. For more information, please visit www.gtcr.com. Follow us on LinkedIn.
GTCR Contact
(212) 835-7042
View original content to download multimedia:
SOURCE GTCR | https://www.whsv.com/prnewswire/2022/09/07/gtcr-appoints-don-mcdonough-lead-business-development-its-strategic-growth-fund/ | 2022-09-07T11:54:58Z |
STOCKHOLM, Sept. 7, 2022 /PRNewswire/ -- Hosting provider Internet Vikings are now able to go above and beyond and offer a broader range of customizable hosting services in the prominent iGaming state of New Jersey. The global supplier has been operating in New Jersey for over a year and has plans to continue developing partnerships.
Industry experts consider New Jersey to be one of the most favored markets in the US for iGaming, especially with the rise in iGaming popularity and its continuous increase in revenue outperforming land-based casinos since the pandemic.
Global iGaming hosting provider Internet Vikings started its U.S. expansion with vigor, following the industry trends and providing solutions that suit each state's unique requirements. Developing custom tech solutions that cater to clients across the U.S. has proved highly successful for Internet Vikings, whose solutions are available in several states.
With the full force of U.S. market insights and industry professionals in their team, it is no surprise that Internet Vikings, who have been successfully operating in New Jersey for over a year, continue to reach for new heights. The hosting solutions experts have secured the necessary approvals to offer an even wider range of their customizable hosting services to New Jersey iGaming and online sports betting businesses.
Internet Vikings' CEO, Rickard Vikström, adds, "Entering the New Jersey market was a top priority, and the latest advancements are set to be a huge gain for us. Our experts are already busy preparing the next steps to offer the full suite of Infrastructure-as-a-Service."
Hosting provider Internet Vikings plans to expand in even more states and continue to offer its services nationwide.
"We want to continue adding value to iGaming businesses across the U.S. with our extensive understanding of the market and reliable cloud hosting options. Entering New Jersey is a big step forward for us, and the team looks forward to welcoming new clients and partnerships." - Victor Jerlin, Internet Vikings, Founder, and CTO, concluded.
CONTACT:
For press inquiries please contact Julija Lavosnik
+35699998020
julija.lavosnik@internetvikings.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content:
SOURCE Internet Vikings International AB | https://www.whsv.com/prnewswire/2022/09/07/internet-vikings-expand-their-offerings-new-jersey/ | 2022-09-07T11:55:05Z |
GOTHENBURG, Sweden, Sept. 7, 2022 /PRNewswire/ -- Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL) today reported data from the AGENT study that formed the basis for its assessment that it was not justified to continue the study. Isofol will continue to collect and review data related to, among other areas, subgroups and gene expression, in order to identify possible commercial value. Data has so far failed to show any concrete results of value, which means severely limited commercial potential. The AGENT study will be terminated in accordance with applicable ethical considerations and regulatory requirements, which will occur during the autumn. Parallel to this, Isofol's Board of Directors will evaluate possible courses of action to secure the greatest possible value for Isofol's shareholders.
The information in this press release is intended for investors.
On August 3, 2022 Isofol presented top-line results showing that the AGENT study met neither its primary endpoint nor its key secondary endpoints. On August 31, 2022 the company announced that based on available data[1], it was not justified to continue conducting the AGENT study further. Today, Isofol is able to present data from the AGENT study that formed the basis for this assessment and that indicate a severely limited clinical and commercial value for Isofol:
- The P-value[2] for the primary endpoint of objective response rate (ORR) was approximately 0.85 and the study arms displayed no difference in outcome. Data for this endpoint is deemed to be final.
- Progression-free survival (PFS) was approximately 12.8 months for the arfolitixorin arm and 11.6 months for the control arm, with a P-value of 0.76. Data for this endpoint is not final but it is not deemed to change significantly moving forward.
- Analysis of overall survival (OS), one of the AGENT study's safety endpoints, showed a preliminary indication of a non-significant detrimental trend for the experimental arm of the study compared with the control arm.
- There was no difference between the study arms with regards to key safety data.
- No significant differences between the study arms in any subgroups have been identified so far.
Isofol will continue to collect and analyze study data throughout the autumn so that the final study report can be compiled. This work will cover final analysis of subgroups, gene expression and additional safety data to identify possible clinical and commercial value. Parallel to this, work continues to close down the AGENT study in line with applicable ethical aspects and regulatory requirements for termination of phase III studies. This process will require both company time and resources during the autumn. Moreover, Isofol must take into consideration patients who are still undergoing treatment and follow up and this process must be completed in an ethically sound way. The AGENT study will be concluded when all patients have been taken care of, all data is available, and all analyses are finalized.
"The clinical results that we have access to right now point to a severely limited clinical and commercial value. This is a huge disappointment given the large medical need for new treatments of advanced colorectal cancer. Even if the opportunities of finding results that indicate commercial value are limited, we will continue to analyze the AGENT study's data as it becomes available. At the same time, we are focusing on closing down the study appropriately with regards to ethics and regulations, as well as optimizing the company's resources as new information becomes available," said Ulf Jungnelius, CEO of Isofol.
Isofol is actively implementing measures to decrease costs and thereby protect the company's financial position. Isofol's current assessment is that additional in-house studies cannot be justified.
As communicated on August 31, Isofol's Board of Directors has taken the decision to investigate potential courses of action to secure the greatest possible value for Isofol's shareholders. These options can consist of, among others, structural deals such as clinical collaborations or a potential merger with another company. The Board of Directors will consider additional options should they arise.
[1] Final clinical data is not yet available but Isofol's assessment is that the current data will not change significantly moving forward.
[2] The P-value describes the probability that the result is a matter of chance. Values close to 1 do not indicate statistical difference, while a low value (often below 0.05) indicates a statistically significant difference.
Isofol Medical AB (publ)
Jarl Ulf Jungnelius, M.D., Chief Executive Officer
E-mail: jungnelius@isofolmedical.com
Phone: +46 (0) 709 16 89 55
Roger Tell, M.D., PhD, Chief Medical Officer
E-mail: roger.tell@isofolmedical.com
Phone: +46 (0) 760 293 911
The information was submitted for publication, through the agency of the contact person set out above, at 12.00 CEST on September 7, 2022.
The Phase III AGENT Study is the first to evaluate a meaningful alternative to the standard of care for most patients with metastatic colorectal cancer (mCRC) in 20 years and involves approximately 90 clinics in the U.S., Canada, Europe, Australia, and Japan. The Phase III randomized, controlled, multi-center study of 490 patients assessed the efficacy and safety of arfolitixorin, [6R]-5,10 methylene-THF (MTHF), compared to leucovorin, both used in combination with 5-U, oxaliplatin, and bevacizumab, in first line mCRC patients.
The study was designed to show that arfolitixorin was better than leucovorin and that the results would be statistically significant. Patients were randomized in a 1:1 ratio with the primary endpoint being an overall response rate (ORR) >10 percent improvement vs. the control arm. The key secondary endpoint is a clinically meaningful positive trend in progression free survival (PFS). Other secondary endpoints include duration of response (DOR), number of curative metastasis resections, safety, and patient reported outcomes such as quality of life (QoL). Exploratory endpoints include pharmacokinetic (PK) measurements and level of gene expression of folate relevant genes in tumor cells.
In the AGENT study, patients with non-resectable mCRC treated with arfolitixorin in combination with 5-FU, oxaliplatin and bevacizumab did not achieve a statistically significant overall response rate of ≥ 10% as compared to patients treated with the standard of care (leucovorin + 5-FU, oxaliplatin and bevacizumab).
About Isofol Medical AB (publ)
Isofol Medical AB (publ) is a clinical stage biotech company that is developing and progressing the current standard of care for patients suffering from cancer by working to improve the efficacy of the current chemotherapeutic standards of care. Isofol is focused on developing a first line treatment of metastatic colorectal cancer (mCRC) and seeks to elevate current clinical practice by unlocking the full strength of 5-FU with the addition of arfolitixorin. Isofol holds a worldwide exclusive licensing agreement with Merck & Cie, Darmstadt, Germany to develop and commercialize arfolitixorin for use in oncology. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content:
SOURCE Isofol Medical AB (publ) | https://www.whsv.com/prnewswire/2022/09/07/isofol-reports-data-agent-study/ | 2022-09-07T11:55:11Z |
As public interest in the war wanes, four leaders commit to help Ukrainian youth and remind Americans to stay engaged in the fight for freedom
NEW YORK, Sept. 7, 2022 /PRNewswire/ -- As American public interest in the war in Ukraine wanes, chef and humanitarian José Andrés; global human rights and pro-democracy activist Garry Kasparov; social entrepreneur and KIND Snacks Founder Daniel Lubetzky; and Retired U.S. Army Lieutenant Colonel Alexander Vindman have announced a scholarship program and global democracy ambassadorship to help displaced Ukrainian students continue their studies, educate global peers on the fragility and importance of democracy, and inspire the world to stay engaged.
Andrés, Kasparov, Lubetzky, and Vindman, who have proudly made the United States home after emigrating or seeking asylum (Vindman and Kasparov came to America from Soviet Ukraine and Russia respectively), aim to go beyond their direct impact on Ukrainian scholars and their classmates to also remind Americans, and the world, not to take our freedom for granted.
According to the United Nations, the Russian invasion of Ukraine has forced over twelve million Ukrainians to flee their homes. The World Bank reports that 700,000 Ukrainian students have been displaced and 2,000 schools have been destroyed in Ukraine. Among those Ukrainians whose lives have been upended are college- and university-aged youth challenged with forging their futures as their nation battles for the future of the free world.
In response, the program will grant $1 million to support an initial group of Ukrainian scholars with financial and wraparound support to study at a US-based post-secondary institution for one academic year. The Lubetzky Family Foundation (LFF) is leading the initiative by activating its resources and team to launch the program and raise awareness for the critical role of citizens in defending democracy.
Says Lubetzky, "Young Ukrainians have a powerful role to play in waking up our world to our shared responsibility to defend values like freedom and democracy that we cannot take for granted. We want this program to put a spotlight on the fact that the fight for freedom is ongoing, and that every one of us has the power to make a difference."
To ensure that their lessons for our world do not go untold, scholarship recipients will be empowered to act as campus ambassadors for democracy. Kasparov, who has long used his platform to educate the world on the global interconnectivity of democracy, will mobilize his Renew Democracy Initiative to provide scholars with educational programming designed to encourage all students to build strong global alliances in support of democratic values like those that Ukraine is bravely defending.
Says Kasparov, "It's not just that we are offering Ukrainian scholars a chance to continue their education, but also that they can educate us by their example. They represent the Frontlines of Freedom and can remind American students, who are their roommates and classmates, that democracy is worth fighting for. That could have a phenomenal impact on reinstating a culture of defending democratic institutions and recognizing the invaluable importance of democracy for human progress."
Andrés, whose nonprofit organization World Central Kitchen has provided over 120 million meals to Ukrainians, has committed to lending his public support to the initiative, and to connecting with participating scholars to express his gratitude and instill hope.
Says Andrés, "It's been nearly six months since the invasion started and World Central Kitchen's work to support Ukrainians began. Despite incredible hardship, every single day, thousands of Ukrainian Food Fighters show up to provide nourishing meals and food aid to families. It is the young Ukrainians who are leading the way! They are the future, and we must invest in supporting them to rebuild and thrive."
Vindman, who continues to advocate strongly for increased US government action to support Ukraine, including better efforts to aid refugees, is working to bring on increased resources to scale the program's impact for more Ukrainian scholars.
Says Vindman, "Reconstruction in Ukraine is going to be a decades-long effort that will require the participation of passionate young students with the capabilities to take on this project. We are trying to generate some of that capability and passion through this program, so that scholars can return home to help rebuild a new Ukraine – one that pays tribute to the enormous sacrifice of its people, who are defending not only their homes but also democracy and freedom."
The scholarship's application and selection processes are being led by the Institute of International Education (IIE), which oversees multiple leading international scholarship programs and student and scholar rescue initiatives. Recognizing the trauma that accompanies experiences of war, the program will take into consideration the holistic needs of all participants. To deliver immediate support and impact, the scholarship will kick off during the 2022 fall semester, serving eligible Ukrainians already studying in the US before expanding internationally in Spring 2023. For more information and to apply, visit www.iie.org/Programs/Ukraine-Democracy.
About José Andrés
Named one of Time Magazine's "100 Most Influential People" in both 2012 and 2018, and awarded "Outstanding Chef" and "Humanitarian of the Year" by the James Beard Foundation, José Andrés is an internationally-recognized humanitarian, culinary innovator, New York Times bestselling author, and educator. In 2010, Andrés founded World Central Kitchen, a non-profit which uses the power of food to nourish communities and strengthen economies in times of crisis and beyond. Andrés' work has earned awards and distinctions including the 2017 Lifetime Achievement Award from the International Association of Culinary Professionals and the 2015 National Humanities Medal from President Barack Obama. Andrés was awarded the Princesa de Asturias Foundation's 2021 Concordia Prize for his humanitarian work. As a naturalized citizen originally from Spain, Andrés has been a tireless advocate for immigration reform.
About Garry Kasparov
Garry Kasparov is the chairman and founder of the Renew Democracy Initiative (RDI). He is widely considered the greatest chess-player of all time. His famous matches against the IBM supercomputer Deep Blue in 1996-97 were key to bringing artificial intelligence and chess into the mainstream. Today he is a prominent human rights activist as well as an author and speaker on politics, human rights, decision-making, and artificial intelligence. He is the author of the 2015 book: Winter is Coming: Why Vladimir Putin and the Enemies of the Free World Must be Stopped.
About Daniel Lubetzky
Daniel Lubetzky is a social entrepreneur working to build bridges between people and increase appreciation for our shared humanity. The son of a Holocaust survivor, he has made it his life's work to help prevent what happened to his father from happening again. While best known as the founder of KIND Snacks, Daniel's foray into food was the unexpected outcome of his work to use business to bring neighbors in Middle Eastern conflict regions together. He conceived of civic initiatives OneVoice, Empatico, and Starts With Us to foster empathy and empower individuals to practice daily habits that move our culture away from extreme, divisive, and hateful positions. Daniel is a member of the Anti-Defamation League's Inaugural Board of Directors. He has received awards from The King Center, World Economic Forum, Skoll Foundation, Conscious Capitalism, Hispanic Heritage Foundation, and Horatio Alger Association. Daniel was named a Presidential Ambassador for Global Entrepreneurship by President Obama. He is the author of The New York Times bestseller Do the KIND Thing.
About Colonel Alexander Vindman
Alexander Vindman, a retired U.S. Army Lieutenant Colonel, was most recently the director for Eastern Europe, the Caucasus, and Russia on the White House's National Security Council. Previously, he served as the Political-Military Affairs Officer for Russia for the Chairman of the Joint Chiefs of Staff and as an attaché at the U.S. Embassy in Moscow, Russia. While on the Joint Staff, he co-authored the National Military Strategy Russia Annex and was the principal author for the Global Campaign for Russia. He is currently a doctoral student and senior fellow for the Foreign Policy Institute at the Johns Hopkins School of Advanced International Studies (SAIS), Pritzker Military Fellow at the Lawfare Institute, executive board member for the Renew Democracy Initiative, senior advisor for VoteVets, and the author of the New York Times bestselling memoir, Here, Right Matters.
View original content:
SOURCE Lubetzky Family Foundation | https://www.whsv.com/prnewswire/2022/09/07/jos-andrs-garry-kasparov-daniel-lubetzky-alexander-vindman-team-up-launch-ukrainian-scholarship-program-student-ambassadorship-global-democracy/ | 2022-09-07T11:55:17Z |
NEWTON, Mass., Sept. 7, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the following investor conferences in September:
Morgan Stanley 20th Annual Global Healthcare Conference
Format: Fireside chat
Date: Monday, September 12, 2022
Time: 12:30 p.m. ET
Baird 2022 Global Healthcare Conference
Format: Fireside chat
Date: Tuesday, September 13, 2022
Time: 12:50 p.m. ET
A live webcast of the fireside chats, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations, and will be available for replay for 90 days following each fireside chat.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation. Karyopharm's lead SINE compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications and has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China, Singapore, Canada, Israel, South Korea and Australia. Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in multiple myeloma, endometrial cancer, myelodysplastic syndromes and myelofibrosis. For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on Twitter at @Karyopharm and LinkedIn.
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.
View original content to download multimedia:
SOURCE Karyopharm Therapeutics Inc. | https://www.whsv.com/prnewswire/2022/09/07/karyopharm-participate-upcoming-investor-conferences/ | 2022-09-07T11:55:24Z |
Sports Invigorate the City
BEIJING, Sept. 7, 2022 /PRNewswire/ -- On the morning of September 1st, the Sports Services Section of the China International Fair for Trade in Services 2022 (hereinafter referred to as the CIFTIS) was officially opened in Shougang Park, Beijing. As one of the nine themed sections of the CIFTIS, this Sports Services Section, themed as "Sports Invigorate the City", aims to promote the cooperation of sports services trade and build a bridge for international sports industry. The section consists of exhibitions, forums, trade matching and supporting activities around four highlights of internationalization, professionalization, marketization, and technologization. The 2022 CIFTIS Sports Services Section Fair will be hosted by the Beijing Municipal Bureau of Sports and organized by ADG Exhibition.
As the largest themed exhibition of this CIFTIS, the Sports Services Exhibition is located in the indoor halls 6 and 7 and outdoor halls 14 and 15 of Shougang Park, with a total area of 22,200 square meters. It is composed of eight sub-exhibitions including services for international sports, Olympic achievements promotion, sports events, sports consumption, smart sports, sports integration, fitness for all and outdoor life. A total of 347 enterprises and institutions get involved in the exhibition online or offline, including 151 offline exhibitors, 101 offline international institutions and enterprises and 59 offline industry leading enterprises. The internationalization rate and industry leading enterprise ratio are 67% and 39% respectively, and raw space booths account for 94%.
This section includes one main forum and five parallel forums. On the morning of September 1st, the Main Forum of the International Sports Services Trade Conference & the World Winter Sports (Beijing) Expo was held at the No.3 Blast Furnace, Shougang Park, addressed by Li Yingchuan, deputy head of the General Administration of Sport of China (GASC), and Zhang Jiandong, vice mayor of Beijing and executive vice president of the Beijing Organizing Committee for the 2022 Olympic and Paralympic Winter Games (BOCOG).
The Sports Economy Department of the GASC and Asia Digital Group have successively released the Report on China's Sports Services Trade (2021) and the Research Report on China's Winter Sports Industry Development (2022). Five parallel forums including the Olympic City Development Forum, the Digital Sports Development Forum, the International Sports, Culture and Tourism Development Forum, the International Ice and Snow Industry Development Forum, and the Outdoor Living Forum was held one after another, together with the release of such reports as the Digital Sports Development Report (2022), the Report on International Sports, Culture and Tourism Industry (2022) and the Bulletin of Main Data on Beijing Sports Venues (2021).
Meanwhile, the Sports Science and Technology Entrepreneurship Competition, the Industry TOP Awards and the Fashion Show were staged. Besides, the experience area has been set up for emerging fashion sports such as camping, recreational vehicles, Frisbees and standup paddleboards in the outdoor exhibition halls 14 and 15. Visitors are welcome to get involved.
In order to facilitate more transaction for sports services projects, the Sports Services Section has made every effort to build a supply and demand docking platform with offline exhibitions, forums and related supporting activities.
Main Forum of the International Sports Services Trade Conference & the World Winter Sports (Beijing) Expo Held at the No.3 Blast Furnace, Shougang Park.
The Sports Services Section of the China International Fair for Trade in Services 2022 (hereinafter referred to as the CIFTIS) was officially opened in Shougang Park, Beijing on September 1st. This section includes one main forum and five parallel forums. On the morning of September 1st, the Main Forum of the International Sports Services Trade Conference & the World Winter Sports (Beijing) Expo, also the Main Forum of the Sports Services Section, was held at the No.3 Blast Furnace, Shougang Park, addressed by Li Yingchuan, deputy head of the General Administration of Sport of China (GASC), and Zhang Jiandong, vice mayor of Beijing and executive vice president of the Beijing Organizing Committee for the 2022 Olympic and Paralympic Winter Games (BOCOG).
According to Li Yingchuan, with the theme of "Sports Invigorate the City", the Sports Services Section of this CIFTIS, highlighting internationalization, professionalization, marketization, and technologization, is of great significance to the development of sports services trade and ice and snow industry in the post-Winter Olympics era. Let us take this Sports Services Section as an opportunity to jointly build a bridge of communication for international sports industry, promote the docking and cooperation of sports services trade, accelerate the release of the potential of this kind of trade, and contribute new strength to the high-quality development of the sports industry and ice and snow industry in the new era.
Zhang Jiandong pointed out that the Sports Services Section, a vital part of the CIFTIS, is a specific measure to promote the high-quality development of Beijing's sports. Since 2012, it has attracted over 400 sports services institutions in and out of China, guests and businessmen from more than 70 countries and regions, and 40,000 some professional visitors. Therefore, it has played a positive role in disseminating ideas, connecting supply and demand, and sharing business opportunities. The section went further this year, attracting more than 300 Chinese and foreign exhibitors, and becoming the largest themed exhibition of this CIFTIS. Furthermore, featuring internationalization, professionalization, marketization, and technologization, it will surely create more fruitful results with richer content and more novel form.
Zhao Wen, director of the Beijing Municipal Bureau of Sports, introduced the sports services industry in 2022. The Report on China's Sports Services Trade (2021) and the Research Report on China's Winter Sports Industry Development (2022) were released respectively by Peng Weiyong, deputy director of the Sports Economy Department at the GASC and Zhang Li, executive vice president of Asia Digital Group. British Trade Commissioner for China John Edwards gave an outlook on China-UK sports cooperation in a video.
In addition, focusing on hot topics of the sports industry, guests who "came" to the site offline or via online videos to jointly explore new trends of the sports industry include Minister Counsellor of the Department for International Trade at the British Embassy Beijing Sohail Shaikh, President of the World Professional Billiards and Snooker Association Jason Ferguson, President of the International Sports Press Association Gianni Merlo, Executive Director of the Olympic Games at the International Olympic Committee Christophe Dubi, President of the International Biathlon Union Olle Dahlin and Former Secretary-General of the International Ski Federation Sarah Lewis.
A round-table dialogue, themed as "Focus on the 'Post-Winter Olympics': China's Ice and Snow-the Future Can Be Expected" was held. Suggestions for the Olympic heritage, fitness for all and sustainable development of ice and snow industry were offered by such guests as Zhao Yinggang, chairman of the China Sled Association and deputy director of the Sustainable Development Committee at the BOCOG, Michael Berger, counsellor of the Commercial Office at the Austrian Embassy in China, Nico H. Schiettekatte, counsellor for Health, Welfare and Sports at the Embassy of Kingdom of the Netherlands in Beijing, Zeng Dechao, chairman of the Yulin City Committee of the CPPCC of Shaanxi Province, Li Yanqiu, general manager of Doppelmayr China and Shen Yumei, director of the Engo Division at TechnoAlpin Group.
Five parallel forums, including the Olympic City Development Forum and the Digital Sports Development Forum, were held on September 2nd-4th.
View original content:
SOURCE ADG Expo Group Co., Ltd. | https://www.whsv.com/prnewswire/2022/09/07/largest-themed-exhibition-ciftis-opens/ | 2022-09-07T11:55:30Z |
L'ATTITUDE Live Presented by LaMusica Will Feature World Renowned Superstars Juanes, Farruko and Alex Sensation Who Will Take the Stage at the Waterfront Concert Event in Downtown San Diego, CA
-Tickets are currently on sale at ticketmaster.com
MIAMI, Sept. 7, 2022 /PRNewswire/ -- L'ATTITUDE, a top-tier business and media event, is excited to announce their first ever concert taking place this year that will celebrate the power of Latin music in popular culture with a star-studded slate of performances at San Diego's premier music venue, the Rady Shell. The highly anticipated concert will feature a headlining performance by multiple GRAMMY and LATIN GRAMMY winning Colombian superstar Juanes, along with opening performances from reggaeton superstar Farruko and one of the most beloved radio personalities and DJs in the Latin community, Alex Sensation. On September 24th, the breakout event will be a new addition to the four-day conference that hosts world class CEO's, celebrities, economists, business leaders, educators, entrepreneurs, journalists, and politicians.
"As part of our 5 Year Anniversary Celebration we are proud to introduce the L' ATTITUDE LIVE Presented by LaMusica concert event to showcase this dynamic lineup of incredible musical talent," said Emilio Estefan, L'ATTITUDE partner. "Music is an incredible passion in the Latin community and this concert is the perfect way to bring legendary artists together to celebrate our accomplishments this year both economically and artistically."
"Today, the New Mainstream Economy is powered by Latino consumers, entrepreneurs and artists who together are helping drive U.S. economic growth. We are proud to drive purposeful conversations that connect and inspire leaders to reinforce the continued growth and advancements of The New Mainstream Economy," says Sol Trujillo, founder of L'ATTITUDE.
"Partnering with L'ATTITUDE is an exciting opportunity to strengthen LaMusica's continued dialogue with business leaders that recognize the importance of the Hispanic voice. We are also looking forward to producing an amazing show in San Diego at such a beautiful venue," said Alessandra Alarcon, President of SBS Entertainment.
"As a gathering that is designed to foster greater opportunity for Latinos across the United States in many crucial fields, I'm very happy to continue my relationship with L'ATTITUDE and look forward to a very special night of music," said Juanes.
Juanes is unquestionably Latin Rock's most globally recognized ambassador, known for his distinctive sound fusing a love of guitar-driven rock with smartly crafted, multi-layered songwriting and a deep reverence for the traditional folkloric and other indigenous rhythms from his native Colombia and throughout Latin America. Hailed by TIME as "one of the 100 Most-Influential People in the World," and The New York Times as "Latin America's hottest singer-songwriter," Juanes is the only artist holding TWO of Billboard's "Top-5 Latin Pop Songs of All-Time," has 12 #1 U.S. singles, millions of album sales, and has made dozens of groundbreaking television appearances bringing Spanish language music to wider audiences around the world. Recognition from his musical peers has also seen Juanes collect a staggering TWENTY-SEVEN combined GRAMMY & Latin Grammy, awards, including latest wins of both this past year for ORIGEN- a return to roots collection that reimagines some of the most important songs and artists that shaped Juanes' early musical vision. Simultaneously, Juanes has become a leading advocate for global peace and other positive social change through the tireless work of his Mi Sangre Foundation.
Farruko is recognized as an important musical phenomenon in the Latin music industry. Thanks to his fantastic artistic versatility and his excellence on stage, the multi-platinum artist and two-time Latin GRAMMY Award Winner has managed to conquer massive audiences around the world, becoming one of the most innovative exponents of the reggaeton genre. With eight successful studio albums and multiple collaborations with international artists of different genres, his success has impacted the Hispanic American community, in such a way that his career has been recognized by HBO with a documentary focused on his career, "Farruko: En Letra de Otro."
Alex Sensation is the most influential DJ and radio personality in Spanish-language radio in the United States, and an international Universal Music Recording artist. His radio show is broadcasted live, daily on the stations, Mega 97.9 FM in New York, El Zol 106.7, in Miami, 96.5 FM in Puerto Rico, and 96.3 FM in Los Angeles, reaching the highest ratings within its markets. With more than 3 million listeners weekly, Alex Sensation's radio show is notably top in the country for Latin music for 15 years. Alex Sensation is credited for his successful sold-out arena shows called "Mega Mezcla" in Prudential Center and "Miami Bash" in the FTX Arena (formerly known as American Airlines Arena}, with national endorsements and presentations for top brands. These shows have included appearances by top talent such as Maluma, Marc Anthony, J Balvin, Don Omar, Ozuna, Prince Royce, Nicky Jam, and many more.
About L'ATTITUDE
L'ATTITUDE is the only event of its kind in the country focused on how U.S. Latinos are sustaining the economic growth of America. A world-class slate of CEOs, celebrities, economists, business leaders, educators, entrepreneurs, journalists, and politicians gather annually to discuss the economic opportunities in the U.S. being made possible by The New Mainstream Economy. Many of America's most influential leaders across all sectors of the economy gather in San Diego to better understand how our economy is being driven by U.S. Latinos, our country's youngest cohort, representing nearly 1 in 5 Americans, and accounting for over $2.13 Trillion in GDP, roughly the size of India. L'ATTITUDE features presentations, panel discussions, interactive sessions, and entertainment featuring leading celebrities. It is the source of facts and data gathered specifically about U.S. Latinos and the New Mainstream Economy.
L'ATTITUDE's mission is to celebrate Latinx contributions and provide a platform for burgeoning leaders, change-makers and aspiring Hispanic visionaries, from all backgrounds, to unite and discover how to create a world ready for greater possibilities. Some of the country's most influential people will be participating because they have already recognized how critical it is for everyone to understand our economy is being driven by U.S. Latinos, the youngest cohort representing nearly 1 in 5 Americans.
About Spanish Broadcasting System, Inc.
Spanish Broadcasting System, Inc. (SBS) owns and operates radio stations located in the top U.S. Hispanic markets of New York, Los Angeles, Miami, Chicago, San Francisco and Puerto Rico, airing the Tropical, Regional Mexican, Spanish Adult Contemporary, Top 40 and Urbano format genres, including the global leader in Hispanic radio, WSKQ-FM in New York City. SBS also operates AIRE Radio Networks, a national radio platform of over 275 affiliated stations reaching 95% of the U.S. Hispanic audience. SBS also owns MegaTV, a network television operation with over-the-air, cable and satellite distribution and affiliates throughout the U.S. and Puerto Rico, produces a nationwide roster of live concerts and events, and owns a stable of digital properties, including LaMusica, a mobile app providing Latino-themed audio and video streaming content and HitzMaker, a new-talent destination for aspiring artists. For more information, visit us online at www.spanishbroadcasting.com.
Contact: Jessica Meisels
Fingerprint Communications
jessica@fingerprintcom.net
View original content to download multimedia:
SOURCE Spanish Broadcasting System, Inc. | https://www.whsv.com/prnewswire/2022/09/07/lattitude-announces-its-first-ever-concert-presented-by-lamusica/ | 2022-09-07T11:55:37Z |
NGT's fund will invest $100 million in breakthrough early-stage biotech and medical technologies
TEL AVIV, Israel, Sept. 7, 2022 /PRNewswire/ -- Arieli Capital joins NGT Healthcare2 ("NGT"), a health-tech venture capital fund based in Nazareth, as a Partner. The second fund will allow NGT to invest around $100 million in breakthrough technologies from academic and medical institutions, with an emphasis on promoting entrepreneurship within the Arab community.
"We at Arieli Capital believe in promoting technologies that have the potential to improve the lives of millions of people around the world," said Or Haviv, Partner and Head of Global Innovation at Arieli Capital. "We are confident that our past performance in biotechnology investments, successful track-record of licensing and commercialization of therapeutics and leading multiple global innovation programs will add unique value to NGT and to its portfolio companies."
"Arieli's investment along with others will allow us to invest in approximately 25 additional early-stage start-up companies and 16 'year zero' projects (pre-incubator, academic projects). We will continue to provide significant support for our portfolio companies after the initial investment period to lead their success," said Nizar Mishael, a Managing Partner at NGT. "We are happy to have Arieli Capital join us as a Partner, which expands our extensive network of connections. Together with Arieli, the fund will aim to be active in all future funding rounds of the companies, which will provide significant added value to the entire portfolio after the incubator period."
About Arieli Capital:
Arieli Capital is a US-based holding and investment company with offices in New York, Tel Aviv and London. Arieli Capital's hands on and holistic ability along with a growth strategy provides technology companies with a wide spectrum of resources and services. Ariel Capital identifies, develops and commercializes selected technology assets and platforms. Additionally, Arieli Capital is a trusted partner of governments, financial institutions, industry brands and funds to lead cutting-edge global start-up acceleration programs, investment bootcamps and innovation centers across the globe.
About NGT Healthcare2:
Established in August 2021, NGT aims to invest and assist in the growing of cutting-edge start-up companies in the field of bio convergence, biotechnology and medical devices whilst creating social impact focusing on Arab entrepreneurship. NGT's first fund established 23 groundbreaking medical companies. The second fund with $100 million will invest in approximately 25 additional early-stage start-up companies and 16 'year zero' projects.
View original content:
SOURCE Arieli Capital | https://www.whsv.com/prnewswire/2022/09/07/leading-healthcare-venture-capital-fund-ngt-healthcare2-welcomes-arieli-capital-partner/ | 2022-09-07T11:55:44Z |
CAMBRIDGE, Mass., Sept. 7, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in a fireside chat at the Baird 2022 Global Healthcare Conference, being held in New York on September 13-14, 2022.
Baird 2022 Global Healthcare Conference
Date: Tuesday, September 13th, 2022
Time: 3:10 p.m. Eastern Time
The fireside chat will be webcast live and may be accessed on the Investors page of the company's website at https://investors.leaptx.com/, where a replay of the event will also be available for a limited time.
Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is in clinical trials in patients with esophagogastric, colorectal, and gynecologic cancers. Leap has entered into a strategic collaboration with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand. For more information about Leap Therapeutics, visit http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via https://investors.leaptx.com/.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements include Leap's expectations with respect to the development and advancement of DKN-01, including the initiation, timing and design of future studies, enrollment in clinical studies, potential for the receipt of future option exercise, milestone, or royalty payments from BeiGene, financial runway, and other future expectations, plans and prospects. Although Leap believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from our expectations. Such risks and uncertainties include, but are not limited to: that the initiation, conduct, and completion of clinical trials, laboratory operations, manufacturing campaigns, and other studies may be delayed, adversely affected, or impacted by COVID-19, global conflict or supply chain related issues; unstable global market and economic conditions; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; the outcome, cost, and timing of our product development activities and clinical trials; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; our ability to obtain and maintain regulatory approval of our drug product candidates; the size and growth potential of the markets for our drug product candidates; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; and other risks. Detailed information regarding factors that may cause actual results to differ materially is included in Leap Therapeutics' periodic filings with the SEC, including Leap's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on March 11, 2022 and as may be updated by Leap's Quarterly Reports on Form 10-Q and the other reports Leap files from time to time with the SEC. Any forward-looking statement contained in this release speaks only as of its date. Leap undertakes no obligation to update any forward-looking statement contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
CONTACT:
Douglas E. Onsi
President & Chief Executive Officer
Leap Therapeutics, Inc.
617-714-0360
donsi@leaptx.com
Matthew DeYoung
Investor Relations
Argot Partners
212-600-1902
matthew@argotpartners.com
View original content to download multimedia:
SOURCE Leap Therapeutics, Inc. | https://www.whsv.com/prnewswire/2022/09/07/leap-therapeutics-participate-baird-2022-global-healthcare-conference/ | 2022-09-07T11:55:50Z |
HOUSTON, Sept. 7, 2022 /PRNewswire/ -- McDermott International, together with its storage business, CB&I, has been awarded a Front-End Engineering Design (FEED) contract from Gunvor Petroleum Rotterdam B.V. for the Green Hydrogen Import Terminal project. The project is part of Gunvor's program to transform their Rotterdam facility into a green energy hub.
Under the contract scope, CB&I will provide the FEED of the ammonia tank and associated Inside Battery Limits (ISBL) equipment. McDermott will support with FEED activities for the interconnecting pipeline, tie-ins and other Outside Battery Limits (OSBL) scope. As part of the FEED, a project execution cost estimate will be developed as basis for a potential conversion into an engineering, construction and procurement (EPC) contract for the implementation phase.
"After successfully completing the feasibility study in 2021, we are well positioned to execute the next phase of this important green energy project," said Tareq Kawash, Senior Vice President, Onshore of McDermott. "Our ability to bring together McDermott's decades of project execution experience with CB&I's expertise in design, engineering and construction of ammonia tanks make us the ideal partner for Gunvor."
"This project represents a vital contribution to ensuring a reliable logistical chain for the growing green hydrogen market and ultimately meeting the Netherlands 2030 climate goals," said Cesar Canals, Senior Vice President, of CB&I. "As a world leader in the design and build of storage terminals, CB&I, together with McDermott, bring safety, quality and assurance."
Work on the project will be executed from McDermott's office in The Hague, the Netherlands and CB&I's office in Plainfield, Illinois.
McDermott is a premier, fully-integrated provider of engineering and construction solutions to the energy industry. Our customers trust our technology-driven approach engineered to responsibly harness and transform global energy resources into the products the world needs. From concept to commissioning, McDermott's innovative expertise and capabilities advance the next generation of global energy infrastructure—empowering a brighter, more sustainable future for us all. Operating in over 54 countries, McDermott's locally-focused and globally-integrated resources include more than 30,000 employees, a diversified fleet of specialty marine construction vessels and fabrication facilities around the world. To learn more, visit www.mcdermott.com.
CB&I is the world's leading designer and builder of storage facilities, tanks and terminals. With more than 60,000 structures completed throughout its 130-year history, CB&I has the global expertise and strategically located operations to provide its customers world-class storage solutions for even the most complex energy infrastructure projects. To learn more, visit www.cbi.com.
McDermott cautions that statements in this communication which are forward-looking, and provide other than historical information, involve risks, contingencies and uncertainties. These forward-looking statements include, among other things, statements about the expected scope, execution and benefits of the project discussed in this press release. Although we believe that the expectations reflected in those forward-looking statements are reasonable, we can give no assurance that those expectations will prove to have been correct. Those statements are made by using various underlying assumptions and are subject to numerous risks, contingencies and uncertainties, including, among others: adverse changes in the markets in which we operate or credit or capital markets; our inability to successfully execute on contracts in backlog; changes in project design or schedules; the availability of qualified personnel; changes in the terms, scope or timing of contracts, contract cancellations, change orders and other modifications and actions by our customers and other business counterparties; changes in industry norms; actions by lenders, other creditors, customers and other business counterparties of McDermott and adverse outcomes in legal or other dispute resolution proceedings. If one or more of these risks materialize, or if underlying assumptions prove incorrect, actual results may vary materially from those expected. You should not place undue reliance on forward-looking statements. This communication reflects the views of McDermott's management as of the date hereof. Except to the extent required by applicable law, McDermott undertakes no obligation to update or revise any forward-looking statement.
Contacts:
Global Media Relations
Reba Reid
Senior Director, Global Communications and Marketing
+1 281 588 5636
RReid@McDermott.com
Local Media Relations
Barbara Knight
Senior Director, Business Line Communications and Marketing
+971 56 403 2903
BBKnight@McDermott.com
View original content to download multimedia:
SOURCE McDermott International, Ltd | https://www.whsv.com/prnewswire/2022/09/07/mcdermott-awarded-feed-contract-gunvor-petroleum/ | 2022-09-07T11:55:57Z |
NEW YORK, Sept. 7, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it will participate virtually at the H.C. Wainwright 24th Annual Global Investment Conference, and its presentation will be available beginning at 7:00 a.m. ET on September 12, 2022.
For details or to register to attend please visit https://hcwevents.com/annualconference/. A replay of the webcast will be available in the "News & Media" section of MindMed's website.
MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.
MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
For Media: media@mindmed.co
For Investors: ir@mindmed.co
View original content to download multimedia:
SOURCE Mind Medicine (MindMed) Inc. | https://www.whsv.com/prnewswire/2022/09/07/mindmed-participate-hc-wainwright-global-investment-conference/ | 2022-09-07T11:56:03Z |
Join Minelab Metal Detectors at their test beds at the UK metal detecting festival September 10 and 11.
CAMBRIDGE, United Kingdom, Sept. 7, 2022 /PRNewswire/ -- In the UK's largest metal detecting event, Minelab will be joining top metal detector brands at Detectival Sept. 10 and 11, 2022. The two-day festival will give detectorists a wonderful opportunity to explore the expansive properties with enthusiasts from across the globe. Attendees can visit the Minelab testing area and test beds to experience some of the detecting technology in the industry first-hand and learn from international Minelab experts.
"We are so proud to be a part of Detectival this year and are excited for a weekend full of detecting activities. Hosted over sprawling grounds, this event allows all detector enthusiasts to truly focus on their craft, while experiencing the top technology of Minelab's products and the fun social side of this hobby," said Minelab Vice President of Global Marketing Michelle Meyers.
With a team of over 60 engineers, Minelab's hand-held metal detection technology has been hailed as the best in the world and offers a range of products for beginners and experienced detectorists. Magnetic minerals, iron-rich soil, deep water and snow are no match Minelab products, making them adaptable to any season. Minelab is affordable considering its high military-grade quality—after all, you want a metal detector that's easy-to-use while offering you the best return on your investment: undiscovered treasures!
Minelab also has a partnering IOS/Google application, making it more accessible for younger consumers. Minelab also has a global community network so when you get one of their detectors, you're also part of a new family of explorers. Through Minelab's app and blog, you can share your discovery stories, connect with other detectorists, and learn about new places you might not have explored before.
To purchase Minelab, visit them online and check with your local detector dealer.
For more information about Minelab, visit minelab.com and follow on Facebook, Instagram, and Twitter.
View original content to download multimedia:
SOURCE Minelab Electronics | https://www.whsv.com/prnewswire/2022/09/07/minelab-joins-detectival-2022/ | 2022-09-07T11:56:10Z |
LOS ANGELES and NEW YORK, Sept. 7, 2022 /PRNewswire/ -- MPLC (Motion Picture Licensing Corporation) today announced that MPLC has become a Patron-Level Member of the Copyright Society.
"We are excited to be members of the Copyright Society," said Ron Wheeler, EVP, Business & Legal Affairs at MPLC. "Like us, they are deeply committed to copyright education and to fostering creativity and the arts. We look forward to collaborating with them and with our fellow members to advance these worthy causes."
MPLC licenses film and television rights for public performances on behalf of more than 1,000 producers, ranging from Hollywood majors to small independent producers. For businesses that display audiovisual content in public spaces, MPLC's Umbrella License® provides the most coverage commercially available to ensure copyright compliance.
Since its founding in 1986, MPLC has taken an educational approach to the licensing of television, movies, and other audiovisual content, forging partnerships with a variety of associations to educate businesses about copyright compliance.
According to the US Copyright Act, Title 17 of the United States Code, copyrighted movies, television, and other audiovisual content originally intended for personal, private use, require a public performance license when exhibited in public. Showing audiovisual content in public spaces via broadcast, cable, or satellite television; DVDs, downloads, or streaming services requires a public performance license.
"As a leader in the licensing of copyright-protected audiovisual content, MPLC shares the Copyright Society's goal of promoting awareness and understanding of copyright law," said Casey Chisick, President of the Copyright Society. "We are delighted to welcome MPLC to the Copyright Society community."
About MPLC:
MPLC is the global leader in non-theatrical licensing, supporting legal public performances of film, television, and other audiovisual content in more than 40 countries around the world. Under the Umbrella License®, a blanket license for public performance, MPLC represents rights holders ranging from major Hollywood studios to independent producers. MPLC licensees include government, corporations, and non-profit organizations. Hundreds of thousands of locations around the world publicly perform content legally with the Umbrella License. Learn more at www.mplc.org.
The Copyright Society, a non-profit organization established in 1953, is devoted to copyright law awareness and education. With more than 1,000 members worldwide, regional chapters in over a dozen major U.S. cities, as well as two international chapters, in Canada, and Europe, the Copyright Society's mission is to promote and advance the study and understanding of copyright law and its role in fostering creativity and the arts, copyright industries, and the use and distribution of copyrighted materials through traditional and new media. Learn more at www.copyrightsociety.org.
View original content to download multimedia:
SOURCE MPLC | https://www.whsv.com/prnewswire/2022/09/07/mplc-joins-copyright-society/ | 2022-09-07T11:56:16Z |
DALLAS, Sept. 7, 2022 /PRNewswire/ -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that management will present at Baird's 2022 Global Healthcare Conference on Wednesday, September 14, 2022, in New York.
Chief Executive Officer, Sulagna Bhattacharya, and Chief Medical Officer, Aaron Osborne will present a company update on Nanoscope clinical and corporate activities on Wednesday, September 14, at 12:15 PM Eastern Time in the Morgan Suite (Mezzanine Level). Nanoscope leadership will be available for in-person meetings at the event on both Tuesday, September 13, and Wednesday, September 14.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company's lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top-line data expected H1 2023. The company has also initiated a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy.
Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com
View original content to download multimedia:
SOURCE Nanoscope Therapeutics | https://www.whsv.com/prnewswire/2022/09/07/nanoscope-therapeutics-present-bairds-2022-global-healthcare-conference/ | 2022-09-07T11:56:23Z |
- Three-year data from the BE BRIGHT open-label extension study are being presented at the 31st EADV Congress
- Over eight out of 10 patients who achieved complete skin clearance (PASI 100) at week 16 maintained PASI 100 responses and health-related quality of life outcomes through to three years
- Analysis of pooled safety data from up to three years of treatment in Phase 2 and 3 clinical trials showed bimekizumab was generally well tolerated with no new safety signals identified over three years
BRUSSELS and ATLANTA, Sept. 7, 2022 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced new three-year results from the BE BRIGHT open-label extension (OLE) study evaluating the long-term safety, tolerability and efficacy of bimekizumab in adults with moderate to severe plaque psoriasis who completed one of three pivotal Phase 3 studies.1 These data, together with a three-year safety analysis of pooled data from Phase 2 and Phase 3 studies,2 are being presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress in Milan, Italy, September 7-10. A total of 11 abstracts highlighting data related to bimekizumab in psoriasis are being presented at the congress.
Data presented from the BE BRIGHT OLE study showed that over eight out of 10 patients who achieved complete skin clearance (PASI 100) following 16 weeks of bimekizumab treatment maintained PASI 100 response and health-related quality of life outcomes through to three years with continuous maintenance dosing. In addition, approximately nine out of 10 patients who achieved absolute PASI (PASI ≤2) at week 16 maintained this response through to three years.1 Pooled data from up to three years of treatment in Phase 2 and 3 clinical trials showed that bimekizumab was generally well-tolerated over this period with no safety signals identified.2 Bimekizumab is an investigational product; its efficacy and safety have not been established for any indication in the U.S. and it is not approved by the U.S. Food and Drug Administration (FDA).
"These positive results highlight the deep and long-lasting skin clearance achieved with bimekizumab, along with a consistent safety and tolerability profile, and reinforce the positive relationship clearing skin has on patients' quality of life. These new data add to the growing body of evidence supporting longer-term use of bimekizumab in moderate to severe plaque psoriasis," said Emmanuel Caeymaex, Executive Vice President, Immunology Solutions and Head of U.S., UCB.
"The findings presented today show that bimekizumab provided maintenance of completely clear skin and health-related quality of life outcomes in the majority of patients with moderate to severe plaque psoriasis over a three year period," said Dr. Bruce Strober, Clinical Professor of Dermatology at Yale University, New Haven, Conn. "The goal of psoriasis treatment often is complete clearance of skin symptoms, and the availability of long-term data across treatment options is important since it supports healthcare providers and patients to be more informed when making treatment decisions."
All patients who had completed one of the pivotal Phase 3 studies (BE SURE, BE VIVID and BE READY) were eligible to enter the BE BRIGHT OLE study.1 On OLE entry, patients were assigned to bimekizumab 320 mg every four weeks (Q4W) or every eight weeks (Q8W) based on PASI 90 response at the end of the respective Phase 3 study.
In all bimekizumab-randomized patients: 1¥
- Among week 16 PASI 100 responders (N=503), 89.3 percent achieved PASI 100 at year one (week 52) and 82.0 percent at year three (OLE week 96)
- Among week 16 PASI ≤2 responders (N=694), 96.5 percent achieved PASI ≤2 at year one (week 52) and 94.2 percent at year three (OLE week 96)
- Among week 16 PASI 100 responders in BE SURE and BE READY only (N=330), 92.0 percent achieved the Dermatology Life Quality Index (DLQI) 0/1 at year one (week 56), and 88.0 percent at year three (OLE week 96)
In bimekizumab-randomized patients (320 mg Q4W for 16 weeks, and then every eight weeks [Q8W] through three years, BE SURE and BE READY only):1¥
- Among week 16 PASI 100 responders (N=147), 93.6 percent achieved PASI 100 at year one (week 52) and 84.4 percent at year three (OLE week 96)
- Among week 16 PASI ≤2 responders (N=189), 98.9 percent achieved PASI ≤2 at year one (week 52) and 96.8 percent at year three (OLE week 96)
- Among week 16 PASI 100 responders (N=147), 95.8 percent achieved DLQI 0/1 at year one (week 56) and 92.5 percent at year three (OLE week 96)
Total bimekizumab exposure was 4245.3 patient-years (PY; N=1789) across the Phase 2 and 3 trials, and 3876.4 PY (N=1495; Q4W: 1965.6 PY; Q8W: 1914.5 PY) in the Phase 3 trials.2 Treatment emergent adverse events (TEAEs) occurred at an exposure-adjusted incidence rate (EAIR) of 186.1 per 100 PY: serious TEAEs were seen at an EAIR of 5.6 new cases per 100 PY and TEAEs leading to discontinuation at 3.5 new cases per 100 PY.2
The most common TEAEs in the Phase 2 and 3 trials with bimekizumab were nasopharyngitis, oral candidiasis and upper respiratory tract infection at EAIRs of 15.3, 10.2 and 7.1 new cases per 100 PY, respectively.2 The EAIR for oral candidiasis showed a decrease compared with two years of bimekizumab treatment (10.2 versus 12.6 new cases per 100 PY) and was lower with bimekizumab dosed Q8W compared with Q4W (7.1 and 15.9 per 100 PY, respectively).2 The vast majority of oral candidiasis events were mild to moderate (99.4 percent), and none were serious.2 Serious infections occurred at a rate of 1.2/100 PY. The most frequently reported were serious coronavirus infections (0.2 per 100 PY).2
¥ Modified non-responder imputation analyses
Notes to editors :
BE BRIGHT (NCT03598790) is an ongoing, multicenter, open-label extension study assessing the long-term safety, tolerability and efficacy of bimekizumab in adult patients with moderate to severe chronic plaque psoriasis.3 Patients who completed one of three bimekizumab Phase 3 studies, BE READY, BE VIVID and BE SURE, were eligible to enroll in the BE BRIGHT study.4 More details on BE BRIGHT can be found at ClinicalTrials.gov.3
BE VIVID, BE READY and BE SURE evaluated the efficacy and safety of bimekizumab in the treatment of adults with moderate to severe plaque psoriasis versus placebo and ustekinumab, versus placebo, and versus adalimumab, respectively.4,5,6
Psoriasis is a chronic inflammatory disease with primary involvement of the skin.7 Psoriasis signs and symptoms can vary but may include red patches of skin covered with silvery scales; dry, cracked skin that may bleed; and thickened, pitted or ridged nails.8 Psoriasis also has a considerable psychological and quality-of-life impact, potentially affecting work, recreation, relationships, sexual functioning, family and social life.9 This skin condition affects men and women of all ages and ethnicities.7
Bimekizumab is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines driving inflammatory processes.10,11
In August 2021, bimekizumab was approved in the European Union (EU)/European Economic Area (EEA) and in Great Britain, for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.10,12 In January 2022, bimekizumab received marketing authorization in Japan for the treatment of plaque psoriasis, generalized pustular psoriasis and psoriatic erythroderma in patients who are not sufficiently responding to existing treatments.13 In February and March 2022, bimekizumab was approved in Canada and Australia, respectively, for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.14,15
Bimekizumab is an investigational product; its efficacy and safety have not been established for any indication in the U.S. and it is not approved by the U.S. Food and Drug Administration (FDA).
For further information, contact UCB:
Investor Relations
Antje Witte
T +32.2.559.94.14
email antje.witte@ucb.com
U.S. Immunology Communications
Nicole Herga
T +1.404.226.7591
email nicole.herga@ucb.com
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8,600 people in approximately 40 countries, the company generated revenue of €5.8 billion in 2021. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news.
This press release may contain forward-looking statements including, without limitation, statements containing the words "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to differ materially from those that may be expressed or implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: the global spread and impact of COVID-19, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, will progress to product approval or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products, which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB's efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB's products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems.
Given these uncertainties, you should not place undue reliance on any of such forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labelling in any market, or at any particular time, nor can there be any guarantee that such products will be or will continue to be commercially successful in the future.
UCB is providing this information, including forward-looking statements, only as of the date of this press release and it does not reflect any potential impact from the evolving COVID-19 pandemic, unless indicated otherwise. UCB is following the worldwide developments diligently to assess the financial significance of this pandemic to UCB. UCB expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.
Additionally, information contained in this document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction.
View original content to download multimedia:
SOURCE UCB, Inc. | https://www.whsv.com/prnewswire/2022/09/07/new-three-year-bimekizumab-data-reinforce-long-term-maintenance-complete-skin-clearance-moderate-severe-plaque-psoriasis/ | 2022-09-07T11:56:30Z |
The BrandSpark/Newsweek Most Trusted by Pharmacists Awards were earned across 86 OTC product categories and based on a survey of 1,682 U.S. Pharmacists
NEW YORK, Sept. 7, 2022 /PRNewswire/ - Leading market research firm BrandSpark International today announced the inaugural winners of the BrandSpark/Newsweek Most Trusted by Pharmacists Awards ("BMTPA") for over-the-counter ("OTC") consumer product brands. The winners were selected based on the BrandSpark American Pharmacists Trust Study, a survey of 1,682 pharmacists currently practicing in the United States who gave their top-of-mind, unaided opinions on which brands they trust the most in 86 categories.
Americans turn to over-the-counter products to address a multitude of common health-related issues and many of these purchases are made with the help of pharmacists. They provide their opinions to consumers based on their deep knowledge of which brands they have seen to be most effective in delivering relief, treatment and care, and therefore trust the most. BrandSpark has made it easier for shoppers to navigate OTC brands by providing a 100% pharmacist-voted seal to look for when you want to know which OTC brands pharmacists trust the most.
BrandSpark researchers identified key OTC categories where trust is important to consumers, based on a review of the most common ailments consumers face and where pharmacists believe in the superiority of specific brands. Opinions of pharmacists were gathered and BrandSpark calculated which brands had the highest volume of unaided mentions. All respondents were confirmed to be currently practicing licensed pharmacists and standard research best practices were applied to ensure accuracy.
"When health is a factor, consumers actively seek the most effective and trusted products, which inspired us to expand our program to pharmacists, the premier OTC health experts. Our goal is to make healthcare professionals' opinions about the brands they most trust accessible to the everyday shopper", said Robert Levy, President of BrandSpark. "Shoppers already recognize our purple seal as a reputable and research-backed mark that helps them make better purchase decisions, and this value is amplified in OTC categories with a pharmacist-backed trust mark".
The BrandSpark American Shopper Study ("BASS") found that OTC health consumers rely on the opinions of healthcare professionals more than any other driver of trust. Pharmacists' suggestions of the brands they trust are the second most influential factor after doctors' opinions according to the study and strongly influence shoppers' purchases across major OTC categories. The study showed that establishing consumer trust is crucial to promote brand purchase over competitive options. The BASS also revealed that the importance shoppers place on pricing and recommendations of other consumers when buying OTC products slightly weakened in the last year, while the importance they place on opinions from medical professionals and pharmacists has remained stable, which speaks to the longevity of the impact of these opinions. The BrandSpark/Newsweek Most Trusted by Pharmacists Awards list of winning OTC brands meets this consumer need by providing an accessible and extensive overview of the OTC brands that pharmacists trust most.
4 Notable Winners from the 2022 BrandSpark/Newsweek Most Trusted by Pharmacists Awards:
- Sensitivity toothpaste brand, Sensodyne, earned the highest trust share of any brand among pharmacists, at 72%.
- Nature Made took home 5 awards, the most wins out of any brand in the survey, proving deep trust and authority in the supplement segment.
- Coppertone led all brands in Sunscreen for Kids while Neutrogena was most trusted for Adult Sunscreen.
- Consumer health & wellness company i-Health won in 3 categories: Probiotic Supplement (Culturelle), UTI Prevention (AZO), and Menopause Supplement (Estroven).
The BrandSpark/Newsweek Most Trusted by Pharmacists Awards 2022 winners are listed below (brands in a tie are presented in alphabetical order). See details at www.BrandSparkMostTrusted.com, and contact us for more information on any category.
Newsweek and Pharmacy Today will be publishing the results from the BrandSpark/Newsweek Most Trusted by Pharmacists Awards, helping support winners by reaching consumers and pharmacists.
1,682 pharmacists practicing in the United States determined the BrandSpark/Newsweek Most Trusted by Pharmacists Awards winners for 2022 through their unaided write-in citations, as if they were giving their suggestions in the pharmacy. The highest share of citations as Most Trusted in the category determined the winner. If the margin of citation share between the leading brands did not exceed the estimate of sampling error at 90% statistical confidence, then a tie was declared.
Founded in 2001, BrandSpark International is a research and consulting firm that provides brands with the insights they need to understand the omnichannel shopper, refine their strategic brand positioning, build consumer trust, and improve the success of their new product launches. Best New Product Awards Inc. runs two research-backed, highly accredited awards programs: the BrandSpark Most Trusted Awards, in its 10th year of helping consumers shop smarter by determining which brands they trust most; and the Best New Product Awards, in their 15th year of recognizing and rewarding brands for R&D and product innovation.
Permission and authorization from Best New Product Awards Inc. are required to reference the BrandSpark/Newsweek Most Trusted by Pharmacists Awards win or use the claim or logo in any communication.
View original content to download multimedia:
SOURCE BrandSpark International | https://www.whsv.com/prnewswire/2022/09/07/newsweek-brandspark-international-announce-1st-annual-most-trusted-by-pharmacists-otc-brands-america/ | 2022-09-07T11:56:34Z |
Preliminary Dose Escalation Data on ROS1-selective Inhibitor NVL-520 to be Presented in the "New Drugs on the Horizon" Oral Plenary Session
New Preclinical Data to be Presented on Parallel-lead, Clinical-stage Candidate NVL-655, an ALK-selective Inhibitor
Selection of Third Development Candidate NVL-330, a Potential Best-in-Class HER2-selective Inhibitor for Patients with HER2 Exon 20 Insertion-Positive Cancers, and Preclinical Characterization to be Presented
Company Plans to Host Conference Call in Conjunction with Data Presentation on October 28, 2022
CAMBRIDGE, Mass., Sept. 7, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced it will present preliminary dose escalation data from its ongoing ARROS-1 Phase 1/2 clinical trial of NVL-520 for patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) and other solid tumors during an oral plenary session at the 34th EORTC-NCI-AACR (ENA) Symposium taking place October 26-28, 2022 in Barcelona, Spain. In addition, new preclinical data will be presented in poster sessions for its ALK-selective inhibitor NVL-655 and its recently nominated HER2-selective inhibitor, NVL-330.
The NVL-520 oral presentation represents the first report of preliminary safety and clinical activity data from the dose-escalation portion of the company's ongoing Phase 1/2 ARROS-1 study, evaluating NVL-520 in patients with advanced ROS1-positive NSCLC and other solid tumors. NVL-520 has been designed to address the clinical challenges of emergent treatment resistance, off-target central nervous system (CNS) adverse events, and brain metastases that may limit the use of currently available ROS1 kinase inhibitors. The ARROS-1 clinical trial is continuing to enroll patients in the Phase 1 portion of the study.
The NVL-655 poster presentation will describe new preclinical data demonstrating activity of NVL-655 in additional models derived from patients who have progressed on treatment with earlier-generation ALK inhibitors. NVL-655 has previously demonstrated the potential for a best-in-class profile through broad preclinical activity across diverse ALK oncoproteins, single and compound resistance mutations, and tumor types while maintaining strong selectivity for ALK over TRKB and CNS penetrance.
Clinical investigation of NVL-655 is currently ongoing in the Phase 1 portion of the ALKOVE-1 Phase 1/2 study of NVL-655 for patients with advanced ALK-positive NSCLC and other solid tumors. Nuvalent also continues to advance a discovery program for ALK IXDN compound mutations and plans to leverage insights from the ALKOVE-1 clinical trial to guide development candidate selection, which is no longer planned for 2022.
Nuvalent recently selected NVL-330 as the development candidate from its HER2 exon 20 insertion discovery program. Preclinical characterization of NVL-330 as a HER2-selective, brain-penetrant, small molecule inhibitor with activity against HER2 exon 20 insertion mutations will be shared in a poster presentation.
Nuvalent plans to host a conference call and webcast in conjunction with the data presentation on October 28, 2022. Details for the conference call will be provided at a future date, and, once available, presentation and poster information will be archived on the Nuvalent website at www.nuvalent.com.
Title: Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors
Abstract Number: ENA22-0275
Session Topic: Molecular Targeted Agents
Session Title: New Drugs on the Horizon, Plenary Session 6
Session Date and Time: October 28, 2022, 1:00 p.m. - 1:10 p.m. CEST
Presenter: Alexander Drilon, M.D. (Memorial Sloan Kettering Cancer Center, New York, USA)
Title: Preclinical activity of NVL-655 in patient-derived models of ALK cancers, including those with lorlatinib-resistant G1202R/L1196M compound mutation
Abstract Number: ENA22-0105
Session Title: Poster Session, Molecular Targeted Agents 2
Session Date and Time: October 27, 2022, 10:00 a.m. - 5:00 p.m. CEST
Presenter: Anupong Tangpeerachaikul, Ph.D. (Nuvalent, Cambridge, USA)
Title: NVL-330 is a selective, brain-penetrant inhibitor of oncogenic HER2 exon 20 insertion mutations in preclinical models
Abstract Number: ENA22-0150
Session Title: Poster Session, Molecular Targeted Agents 2
Session Date and Time: October 27, 2022, 10:00 a.m. - 5:00 p.m. CEST
Presenter: Kristin L. Andrews, Ph.D. (Nuvalent, Cambridge, USA)
NVL-520 is a novel brain-penetrant ROS1-selective inhibitor designed to remain active in tumors that have developed resistance to currently available ROS1 inhibitors, including tumors with the prevalent G2032R resistance mutation and those with the S1986Y/F, L2026M, or D2033N resistance mutations. NVL-520 has been optimized for brain penetrance to potentially improve treatment options for patients with brain metastases. NVL-520 has been observed in preclinical studies to selectively inhibit wild-type ROS1 and its resistance variants over the structurally related tropomyosin receptor kinase (TRK) family to potentially avoid TRK-related CNS adverse events seen with dual TRK/ROS1 inhibitors and drive more durable responses for patients. NVL-520 is currently being investigated in the ARROS-1 study (NCT05118789), a first-in-human Phase 1/2 clinical trial for patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors.
NVL-655 is a novel brain-penetrant ALK-selective inhibitor created to overcome limitations observed with currently available ALK inhibitors. NVL-655 is designed to remain active in tumors that have developed resistance to first-, second-, and third-generation ALK inhibitors, including tumors with the solvent front G1202R mutation or compound mutations G1202R / L1196M ("GRLM"), G1202R / G1269A ("GRGA"), or G1202R/L1198F ("GRLF"). NVL-655 has been optimized for CNS penetrance to improve treatment options for patients with brain metastases. NVL-655 has been observed in preclinical studies to selectively inhibit wild-type ALK and its resistance variants over the structurally related tropomyosin receptor kinase (TRK) family to potentially avoid TRK-related CNS adverse events seen with dual TRK/ALK inhibitors and drive more durable responses for patients. NVL-655 is currently being investigated in the ALKOVE-1 study (NCT05384626), a first-in-human Phase 1/2 clinical trial for patients with advanced ALK-positive non-small cell lung cancer (NSCLC) and other solid tumors.
NVL-330 is a novel, selective, brain-penetrant HER2 inhibitor designed to treat patients with HER2 exon 20 insertion-positive tumors, including those with brain metastases, and to minimize adverse events and dose-limiting toxicities related to off-target inhibition of epidermal growth factor receptor ("EGFR" or "ErbB1"), a HER2 family member.
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC), along with multiple discovery-stage research programs. We routinely post information that may be important to investors on our website at www.nuvalent.com. Follow us on Twitter (@nuvalent) and LinkedIn.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Nuvalent's strategy, business plans, and focus; the preclinical and clinical development programs for NVL-520, NVL-655 and NVL-330 the potential clinical effect of NVL-520 and NVL-655; the design and enrollment of the ARROS-1 and ALKOVE-1 studies; the potential of Nuvalent's pipeline programs, including NVL-520, NVL-655 and NVL-330; Nuvalent's plans for ALK IXDN; data readouts and presentations; Nuvalent's research and development programs for the treatment of cancer; and risks and uncertainties associated with drug development. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "aim," "goal," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target" or the negative of these terms and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. You should not place undue reliance on these statements or the scientific data presented. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties, and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation: risks that Nuvalent may not fully enroll the ARROS-1 or ALKOVE-1 studies or that enrollment will take longer than expected; unexpected concerns that may arise from additional data, analysis, or results obtained during clinical trials; the occurrence of adverse safety events; risks of unexpected costs, delays, or other unexpected hurdles; risks that Nuvalent may not be able to nominate drug candidates from its ALK IXDN and other discovery programs; the direct or indirect impact of COVID-19 or other global geopolitical circumstances on the timing and anticipated timing and results of Nuvalent's clinical trials, strategy, and future operations, including the ARROS-1 and ALKOVE-1 studies; the timing and outcome of Nuvalent's planned interactions with regulatory authorities; and obtaining, maintaining, and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2022, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Nuvalent's views only as of today and should not be relied upon as representing its views as of any subsequent date. Nuvalent explicitly disclaims any obligation to update any forward-looking statements.
View original content to download multimedia:
SOURCE Nuvalent, Inc. | https://www.whsv.com/prnewswire/2022/09/07/nuvalent-present-preliminary-phase-1-data-arros-1-clinical-trial-nvl-520-34th-eortc-nci-aacr-symposium-announces-pipeline-updates/ | 2022-09-07T11:56:41Z |
Mr. Rigby is the Group Chief Executive Officer of Revolo Biotherapeutics and has three decades of experience in the pharmaceutical and biotechnology industries
SAN DIEGO and CALGARY, AB, Sept. 7, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the appointment of Jonathan Rigby to its Board of Directors.
"Jonathan has successfully built, financed, listed, and led several life science companies across a range of therapeutic areas, and I am thrilled to welcome him to our Board," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech Inc. "His extensive executive leadership experience, together with his business development and commercial expertise, will guide us as we advance our breast and pancreatic cancer programs towards late-stage trials and work to deepen our relationships with leading biopharmaceutical companies. His background is highly complementary with those of our other Board members, and I look forward to beginning our work together."
Mr. Rigby added, "The opportunity to join Oncolytics at this crucial stage in the Company's evolution and help forge the Company forward to treat these terrible cancers is compelling. Extensive clinical data have demonstrated pelareorep's ability to provide a statistically significant survival benefit in breast cancer, its potential to synergize with checkpoint inhibition and drive objective responses in pancreatic cancer, as well as how its multifaceted mechanism of action positions it to enhance the efficacy of additional drug classes across various indications. Upcoming data readouts in breast and pancreatic cancer will provide valuable opportunities to accelerate pelareorep's path towards registration in these indications. I am keen to lend my insights to company management and the Board as they work towards these potential catalysts and prepare for anticipated growth."
Mr. Rigby joins Oncolytics' Board with over three decades of experience in the pharmaceutical and biotechnology industries. He is currently the Group Chief Executive Officer (CEO) of Revolo Biotherapeutics, where he leads a team focused on the development of therapies for autoimmune and allergic diseases. Previously, he was the CEO of SteadyMed Ltd., which he led through a NASDAQ listing and sale to United Therapeutics Corporation. Prior to his time at SteadyMed, Mr. Rigby co-founded Zogenix, Inc., a CNS-focused specialty pharmaceutical company that was acquired by UCB earlier this year in a transaction valued at up to approximately U.S. $1.9 billion. Before co-founding Zogenix, Mr. Rigby held roles of increasing responsibility in commercial and business development functions at large pharmaceutical companies such as Merck, Bristol Myers Squibb, and Profile Therapeutics (now Phillips Medical). In addition to his Oncolytics appointment, Mr. Rigby is also a member of the Revolo Biotherapeutics and ImmunoMolecular Therapeutics Boards of Directors and the Chairman of BIOS, a Nasdaq-listed biotech acquisition company. He holds a B.S. with Honors in Biological Sciences from Sheffield University, UK, and an M.B.A. from Portsmouth University, UK.
About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards a registration study in metastatic breast cancer. For further information, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential and benefits of pelareorep as a cancer therapeutic; Oncolytics' expectations as to the purpose, design, outcomes and benefits of its current or pending clinical trials involving pelareorep; our plans to advance towards a registration study in metastatic breast cancer; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. In particular, we may be impacted by business interruptions resulting from COVID-19 coronavirus, including operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labour shortages, travel and shipping disruption, and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how Oncolytics may be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.
Logo: https://mma.prnewswire.com/media/1808285/Oncolytics_Biotech_Grey.jpg
View original content:
SOURCE Oncolytics Biotech® Inc. | https://www.whsv.com/prnewswire/2022/09/07/oncolytics-biotech-appoints-jonathan-rigby-its-board-directors/ | 2022-09-07T11:56:48Z |
- New Name to better represent Company's proprietary technology platform expanded applications beyond orthopedics
MONTREAL, Sept. 7, 2022 /PRNewswire/ - Ortho Regenerative Technologies Inc., (CSE: ORTH) (OTCQB: ORTIF) ("Ortho" or the "Company") a clinical-stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, announced today that it has changed its corporate name to ChitogenX Inc. to better reflect the Company's expanded clinical and commercial opportunities, mission, values, and core competencies.
The Company's shares are expected to begin trading on the CSE under the new name and new ticker symbol, CSE: CHGX at market open on or around September 12, 2022.
"We evaluated our Company name in light of the vast potential clinical and commercial applications for our proprietary technology platform, and it was obvious that these applications were much broader than just the orthopaedic field the previous corporate name was inferring to", said Philippe Deschamps, CEO. "We opted for a new company name that better represented our identity and expanded possibilities. ChitogenX achieves both".
The corporate name change was approved at the last Annual General and Special Meeting of Shareholders held via videoconference on July 21, 2022, following the passing of a special resolution authorizing an amendment to the Company's articles to effect the name change.
No action is required by shareholders in connection with the name change, and no change has been made to the Company's share capital. The Company encourages any shareholder with questions to contact their broker or agent.
ChitogenX Inc. (formally Ortho Regenerative Technologies Inc.) is a clinical stage regenerative medicine company dedicated to the development of novel therapeutic tissue repair technologies to improve tissue healing. The Company is committed to the clinical development of its proprietary RESTORE technology platform, a muco-adhesive CHITOSAN based biopolymer matrix, specifically designed to deliver biologics such as platelet-rich plasma (PRP) or bone marrow aspirate concentrate (BMAC), to enhance healing in various musculoskeletal conditions. ORTHO-R, its lead Chitosan-PRP hybrid biologic implant combination product, is formulated and designed to increase the healing rates of occupational and sports related injuries to tendons, ligaments, and cartilage such as the meniscus. ORTHO-R can be directly and easily applied to the site of injury by a surgeon during a routine operative procedure with minimal disruption to length of surgery. ORTHO-R is currently the object of an ongoing U.S. Phase I/II clinical trial for rotator cuff tear repair in 10 U.S. based clinical centers.
Other formulations are being developed to leverage the technology's performance characteristics such as tissue adhesion, pliability, and ability to deliver biologics or therapeutics to various tissues damaged by trauma or disease. Further information about Chitogenx is available on the Company's website at www.chitogenx.com and on SEDAR at www.sedar.com.
This news release may contain certain forward-looking statements regarding the Company's expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
View original content to download multimedia:
SOURCE Ortho Regenerative Technologies Inc. | https://www.whsv.com/prnewswire/2022/09/07/ortho-regenerative-technologies-announces-corporate-name-change-chitogenx/ | 2022-09-07T11:56:54Z |
- GR Supra evolves again with a new manual transmission (MT) option
- MT available on GR Supra 3.0, 3.0 Premium and the A91-MT Edition, which is limited to 500 units for the U.S.
- A91-MT offered in two exclusive exterior colors, Burnout and CU Later Gray, both with a unique hazelnut leather trimmed interior
- Refined handling across all GR Supra 2.0/3.0/A91 models with new steering and suspension tuning and new Hairpin+ function on 3.0/A91 models
- Premium 12-speaker JBL Audio system standard on all 3.0 Premium and A91-MT models
- Complimentary 1-year membership to the National Auto Sport Association, featuring a High-Performance Driving Event with expert instruction
SALT LAKE CITY, Sept. 7, 2022 /PRNewswire/ -- The 2023 Toyota GR Supra adds a new dimension to the driver experience thanks to a new six-speed intelligent Manual Transmission option. Already a blend of performance, power and style, the 2023 Supra's addition of a stick shift brings hands-on engagement to the mix. It also holds to Toyota GAZOO Racing's on-going tweaks to the fifth generation Supra, with yet another update to the model that continues to make its mark in the sports car segment.
"When we revealed the GR Supra back in 2019, we tapped into a heritage nameplate for Toyota," said Mike Tripp, vice president of Toyota Vehicle Marketing and Communications. "But we were regularly asked if there would be a manual version. We immediately took that feedback to heart and started developing it, and we're happy that we can now bring customers the perfect complement for Supra's high-torque, high output engine with a six-speed manual."
The Manual Transmission is available as an option on the Supra 3.0 and 3.0 Premium. Supra also adds to its head-turning looks with new colors and special editions. A limited A91-MT Edition model will also be produced for model year 2023 only. Available colors for the MT 3.0 and 3.0 Premium will include all standard Supra colors plus a new Stratosphere Blue color, which will also be available on Supra 2.0. The A91-MT Edition will be available in Burnout (matted white) and CU Later Gray.
The GR Supra MT is arriving on dealer lots now with a Manufacturer's Suggested Retail Pricing (MSRP) starting at $52,500.
Developed by Toyota GAZOO Racing Engineers in cooperation with Toyota Motor Europe and German transmission supplier ZF, the GR Supra's manual transmission was built with components designed specifically to suit the power and torque characteristics of its 3.0-liter 382-hp straight-six engine.
The engineering team combined an existing transmission housing and gear set, developed a new shift lever and removed elements that were not required, such as the acoustic package, which reduced weight, bringing the manual equipped Supra in at 3,389 pounds. At the heart of the transmission is a newly engineered large diameter clutch with a reinforced diaphragm spring. With a larger friction area and a stronger spring, this new component has the high-performance capability appropriate for use with the GR Supra's high-torque engine.
The manual gearbox also features an Intelligent Manual Transmission (iMT) programmed with new software that prioritizes sporty performance. When upshifting, the parameters are tuned to optimize engine torque at the moment of clutch engagement and release; on downshifts, the software includes rev matching for consistent performance. The iMT is set as the default, but, if the driver prefers, it can be switched off in Individual Mode.
To support take-off, the final drive ratio has been shortened, from 3.15 (in the GR Supra automatic) to 3.46 (in the GR Supra MT). The result is response and gearing appropriate for sports car performance and a manufacturer estimated zero-to-sixty time of 4.2 seconds.
Close attention was also paid to how a manual shifter could be accommodated in the driver's cockpit. The lever ratio was specifically set to minimize the effort required to make shifts and engage reverse gear. While the weight and shape of the shift knob, along with the quality of shift engagement, have all been precisely defined. Ergonomics were also considered, as the console unit and position of the drive mode selector were adjusted to provide a 1.7-inch clearance between the shift knob and the control panel.
The GR Supra was Toyota's first global GAZOO Racing (GR) model and the dream of Toyota President Akio Toyoda to deliver a car that is purely about the joy of driving.
Subsequently, the introduction of models, like the GR Corolla and the GR86 coupe, have reinforced the special qualities that define the GR brand – cars that are born out of a passion for driving and draw directly on the world championship-winning expertise and experience of TOYOTA GAZOO Racing.
At launch, the 2020 GR Supra was offered with a straight-six 3.0-liter engine with 335 hp and 365 lb.-ft. of torque matched to an eight-speed automatic transmission. In 2021, the GR team increased the 3.0 Supra to 382 hp and 367 lb.-ft. of torque and introduced a turbocharged four-cylinder GR Supra 2.0 with 255 horsepower and a stout 295 lb.-ft. of torque.
While the car and its performance have received high praise worldwide from media and fans alike, inevitably, the question of whether a manual gearbox would be available persisted. Now that it's official, the addition of a manual transmission option to the Supra lineup means Toyota will offer all three of its U.S. GR models with a stick, which is standard on the GR Corolla and available as an option on GR86.
The GR Supra's traction and braking have been optimized for operation with a manual transmission.
With the automatic, it's possible to use second gear when pulling away uphill when opposite wheels are on surfaces with different grip levels – for example, when the car is parked on a partly icy road, progress is smooth with virtually no rolling back or wheel slip. With a manual gearbox, first gear must be used and releasing the clutch brings a greater risk of wheel spin. To address the issue, Toyota engineers have tuned the car's TRAction Control (TRAC) system to achieve smooth operation similar to the automatic. The system is also optimized for the GR Supra's characteristic high engine torque, wide tires and rear-wheel drive.
The car's character when accelerating out of a corner is a key element in the "Fun to Drive" quality Toyota has developed for the GR Supra. For the new manual version, the traction control has again been the focus to ensure an ideal balance of agility and stability when exiting a corner on the throttle. TRAC intervention has been calibrated to help maintain stability – so the car can keep faithfully to the driver's intended line – while allowing the right amount of power for a sporty experience.
The ambition to make the GR Supra fun to drive in the most demanding scenarios has helped inspire the introduction of a new Hairpin+ function. This is designed to allow more freedom and reward when taking tight bends on an uphill gradient (more than 5%) with a high-friction road surface. More "freewheel" spin can make such routes more enjoyable to drive, so Toyota has optimized engine torque control to allow a greater difference in wheel spin between the left and right-side tires.
To counter the possibility of "snap-off" oversteer – something that may be hard to control with the car's Vehicle Stability Control (VSC) alone – an Anti-Roll Program (ARP) has been adopted for both the manual and automatic versions of the GR Supra. This intervenes at an earlier point with the VSC to counter any sudden loss of grip when the car's high-response suspension setting is used.
On all grades, drivers can select from Normal, Sport and Individual modes that adjust throttle response, suspension damping and power steering settings. Additionally, 3.0 grade and up include an Adaptative Variable Suspension (AVS) with sensors that constantly detect changes in the driving operations and road surface conditions, and solenoid valves finely control the damping force of the shock absorbers. In 3.0 grade and higher, NORMAL mode provides a high-level balance between vehicle stability and supple ride comfort, enabling sports driving without sacrificing comfort. SPORT mode realizes a reassuring and flat vehicle posture with suppressed roll and driving with a more agile steering response.
The A91-MT special edition will be a 500 unit limited-run model that comes equipped with exclusive hazelnut-colored leather-trimmed seats, GR logoed shift knob and a 12-speaker acoustically tuned premium JBL sound system. On the outside, a red "Supra" Badge and red GR Supra emblazoned calipers punctuate its extreme, condensed design. It will be offered in two exclusive colors, Burnout and CU Later Gray, and comes equipped with unique forged 19-inch Frozen Gunmetal Gray wheels. Under the hood, red strut tower braces add one more accent to the already bold Supra.
All 2023 GR Supra 3.0 models, both AT and MT versions, will benefit from a retuned suspension with revised shock absorbers for improved roll balance and ride comfort. The mechanical components in the electric power steering and the system's operating parameters have also been retuned. All 3.0 models will have an active rear sport differential standard.
The 3.0 MT will come equipped with new 19-inch forged aluminum wheels and be available in previously available standard and premium colors plus the new Stratosphere Blue color. On the inside, heated black leather-trimmed seats are now standard. The 3.0 Premium has everything you will find on the 3.0, plus a red and black leather-trimmed interior, full color heads up display, acoustically tuned 12-speaker JBL sound system and Qi Wireless charger standard.
Supra Connect1 is also available. This advanced technology suite is designed to help you get more from your GR Supra 2.0 and 3.0 with Safety and Technology Package as well as the 3.0 Premium and A91-MT Edition and includes features like Automatic Emergency Call, Real-Time Traffic Information, Roadside Assistance and the available Supra Connect iPhone® app to lock/unlock the doors and activate Ventilation Now and Ventilation Timer features.
1 Available on GR Supra 2.0 and 3.0 w/Safety and Technology Package, 3.0 Premium and A91-MT Edition. 4G network dependent. Includes a 4-year trial period, except Enhanced Roadside Assistance, which is a 2-year period. Enrollment in a paid subscription required upon expiration of applicable trial period.
Toyota (NYSE: TM) has been a part of the cultural fabric in the U.S. for more than 60 years, and is committed to advancing sustainable, next-generation mobility through our Toyota and Lexus brands, plus our nearly 1,500 dealerships.
Toyota directly employs more than 39,000 people in the U.S. who have contributed to the design, engineering, and assembly of nearly 32 million cars and trucks at our nine manufacturing plants. By 2025, Toyota's 10th plant, in North Carolina, will begin to manufacture automotive batteries for electrified vehicles. With the more electrified vehicles on the road than any other automaker, a quarter of the company's 2021 U.S. sales were electrified.
To help inspire the next generation for a career in STEM-based fields, including mobility, Toyota launched its virtual education hub at www.TourToyota.com with an immersive experience and chance to virtually visit many of our U.S. manufacturing facilities. The hub also includes a series of free STEM-based lessons and curriculum through Toyota USA Foundation partners, virtual field trips and more. For more information about Toyota, visit www.ToyotaNewsroom.com..
TOYOTA GAZOO Racing embodies Toyota's commitment to overcoming every limit to make 'ever-better' cars, to forge new technologies and solutions under the extreme conditions of motorsports, and to never stop innovating. TOYOTA GAZOO Racing races its cars to push the limits for better and to learn from the toughest challenges. Competing on every kind of road, no matter what the challenge, inspires TOYOTA GAZOO Racing to build 'ever-better' cars and engineer Toyota's future DNA to bring freedom, adventure, and joy of driving to everyone. For more information, visit www.toyotagazooracing.com.
Photos and B-Roll Available at pressroom.toyota.com
For customer inquiries, please call: 800-331-4331
Media Contacts:
Paul Hogard
469-292-6791
paul.hogard@toyota.com
View original content to download multimedia:
SOURCE Toyota Motor North America | https://www.whsv.com/prnewswire/2022/09/07/power-shift-gr-supra-manual-transmission-now-sale-us-toyota-dealerships/ | 2022-09-07T11:57:01Z |
Proggio Receives First-time Gartner Recognition for its 'Ability to Execute' and 'Completeness of Vision' in Adaptive Project Management and Reporting
SALT LAKE CITY and TEL AVIV, Israel, Sept. 7, 2022 /PRNewswire/ -- Proggio, a next-generation solution that brings clarity and simplicity to Project and Portfolio Management (PPM), today announced it has been named as a Challenger in the 2022 Gartner Magic Quadrant for Adaptive Project Management and Reporting (APMR).
Proggio received the recognition based on its 'Ability to Execute' and 'Completeness of Vision.'
"We believe this Gartner recognition validates what we've heard from customers over the last few years: Proggio brings real-time visibility, clarity and simplicity to a market that's hungry for dynamic solutions that can keep pace with modern PPM," said Proggio CEO Yaniv Shor. "I'm extremely proud of our team and grateful for our customers whose feedback has enabled us to execute on our vision for providing a truly user-centric solution for project portfolio management."
According to Gartner, "By 2024, 80% of digital businesses will integrate strategic portfolio management and adaptive project management and reporting technologies, and adopt new frameworks and standards to achieve valued business outcomes." The firm also acknowledges that, "Prospective APMR buyers, PMO leaders and project managers require far more than task management solutions. They demand the right tools for managing the complexities of today's dynamically changing business conditions."
Proggio delivers on those needs by providing a holistic approach to project portfolio management, focusing on managerial and team alignment and on connecting delivery targets with project plans and execution to help teams understand real-time project status and work with confidence. Its interactive, dynamic views allow every stakeholder to get a visual on project status and help project management teams identify and act on issues and opportunities quickly, analyze scenarios and optimize resources when timelines or objectives change, and maintain alignment across teams to boost focus and synergy.
To learn more about Proggio, visit Proggio.com or click here to read more about its Challenger position and capabilities in the Gartner, Magic Quadrant for Adaptive Project Management and Reporting, Lorri Callahan, Sarah Davies, 22 August 2022.
Disclaimer:
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
GARTNER and Magic Quadrant are registered trademarks and service marks of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.
About Proggio
Proggio™ is a next-generation, adaptive project portfolio management solution for enterprises and mid-market companies. By bringing clarity and simplicity to project portfolio management, Proggio accelerates digital transformation in a segment that is primarily using spreadsheets and presentations. With its patented, agile solution, Proggio provides dynamic high-level views for executive managers, project managers, and other stakeholders. The solution was designed to quickly adapt to a change-driven environment, with an unprecedented level of user interface simplicity. To learn more, visit www.Proggio.com.
View original content:
SOURCE Proggio | https://www.whsv.com/prnewswire/2022/09/07/proggio-named-challenger-2022-gartner-magic-quadrant-adaptive-project-management-reporting/ | 2022-09-07T11:57:09Z |
JACKSONVILLE, Fla., Sept. 7, 2022 /PRNewswire/ -- Retail for the People, a retail consulting firm, has announced today its partnership with Endear, the leading retail CRM software company, to provide an in-store and online clienteling solution to retailers globally.
Endear's all-in-one clienteling tool integrates seamlessly with a retailer's POS or E-Commerce platform to deliver a retail CRM that is fully equipped with the data brands need to drive more sales.
Clienteling is the age-old retail retention strategy that enables retailers to create personalized experiences through the utilization of customer information. What was once a cumbersome process for sales associates has now been transformed thanks to Endear's intuitive digital dashboard focused entirely on building relationships with customers and increasing lifetime value through personalization, data, and loyalty building.
Krista Boyer Starratt, Founder at Retail for the People, said: "Clienteling is an important part of retail and something we believe to be a top priority. Through this partnership, we are thrilled to offer a solution that makes it easier for retailers."
Leigh Sevin, Co-Founder at Endear, said: "Such a fan of Retail for the People and the support they give brands ready to take on physical retail."
Together, Retail for the People and Endear will empower retailers with fully omnichannel clienteling solutions that include customer relationship management, personalized messaging, Shoppable Stories, and sales tracking. Users will be able to leverage customer data that spans the physical and digital retail presence, including customer order history and purchase behavior.
About Endear
Endear is changing the way omnichannel brands around the globe are clienteling with customers. With a fully integrated solution like Endear, brands can access numerous key customer data points to see a holistic view of their customers and connect accordingly. Endear is on a mission to create true cohesion between online shopping and brick-and-mortar making a more positive shopping experience for everyone.
To learn more, visit www.endearhq.com.
About Retail for the People
Retail for the People® is a leading full-service retail consultancy for fashion and lifestyle brands. Working with innovative partners to utilize cutting-edge technology to humanize the retail experience and meet their evolving needs. Retailers from over ten countries trust Retail for the People to help them navigate their business from Pop-Up Shop Openings to Point-of-Sale/E-Commerce optimization, Visual Merchandising, CRM, and Business Advisory.
To learn more, visit www.retailforthepeople.com.
Contact: hello@retailforthepeople.com
View original content to download multimedia:
SOURCE Retail for the People | https://www.whsv.com/prnewswire/2022/09/07/retail-people-partners-with-endear-provide-an-all-in-one-clienteling-solution-retailers/ | 2022-09-07T11:57:16Z |
ARLINGTON, Va., Sept. 7, 2022 /PRNewswire/ -- Risk Mitigation Consulting, the leader in mission assurance, risk management, and industrial cybersecurity solutions, today announced that it is relaunching as RMC, and unveiling a modernized brand architecture. RMC's goal is to communicate their unparalleled risk management expertise and commitment to strengthening security postures of government and commercial organizations, so they can prevail in an evolving threat environment.
Core elements of the modernized brand include:
- Assuring Tomorrow. The tagline speaks to RMC's role addressing today's risks while anticipating tomorrow's.
- The new logo is bold and contemporary, with a rising sun logomark emphasizing a forward-looking approach.
- Now at www.RMCGlobal.com, the modern website communicates RMC's global experience, ingenuity, and momentum.
"Our purpose is timeless and RMC is moving into a dynamic growth phase. This brand modernization represents the start of a new era for us," said Vince Kuchar, CEO of RMC. "We are aligning our team around the awareness, analysis, and actions needed to thwart today's bad actors from disrupting our nation's critical infrastructure and business operations. Together, we are truly united in assuring tomorrow."
As critical infrastructure assets and systems become more interconnected, vital infrastructure sectors such as utility systems, transportation, communications, health, and emergency services are facing increased risks.
"Protecting today's missions, military installations and business operations is an increasingly complex undertaking," said Brent Hyland, COO of RMC. "RMC was purpose-built for mission assurance and industrial cybersecurity solutions. Our team operates worldwide, serving clients with the experience and drive required to ensure the security of our nation's most important assets – today and tomorrow."
As part of the brand modernization, RMC's offerings will include:
- Mission Assurance
- Industrial Cybersecurity
- Intelligence and Analysis
- Critical Infrastructure Protection
Since its start in 2011, RMC has identified countless critical risks to missions, resulting in more than $2.7 billion in federal funding being reprioritized to address the most pressing risks.
RMC provides a full lifecycle of Mission Assurance and risk management solutions, with deep expertise in critical infrastructure protection and industrial cybersecurity, to protect our country's most important and vital assets. Operating worldwide, RMC provides federal government and commercial organizations the analysis, assessments, strategy and remediation required to protect personnel, facilities, networks, and critical infrastructure. Founded in 2011, RMC has offices in Destin, Florida, and Arlington, Virginia. www.RMCGlobal.com
Press Contact:
Joyce Bosc
On behalf of RMC
jbosc@boscobel.com
301-717-9529
View original content to download multimedia:
SOURCE RMC | https://www.whsv.com/prnewswire/2022/09/07/risk-mitigation-consulting-announces-brand-modernization-rmc/ | 2022-09-07T11:57:22Z |
HOUSTON, Sept. 7, 2022 /PRNewswire/ -- Riviana Foods Inc. announced today its investment of $80.6 million to expand and renovate its state-of-the-art processing and packaging plant in Memphis, Tennessee. The investment will significantly increase Riviana's production capacity for its ready to serve cup and pouch products and add approximately 80 new full-time jobs.
The investment will add approximately 65,000 square feet to the plant and include a renovation of approximately 20,000 square feet, which will increase the plant's current production capacity for its Minute® rice microwaveable cups and introduce new production capacity for ready to serve pouches lines of its Tilda®, Carolina® and Mahatma® rice brands.
"We will be in a stronger position to meet or exceed customer needs of looking for simpler, better and more nutritional food options," said Enrique Zaragoza, President and CEO of Riviana. "And, we look forward to many more years of our successful partnership between Riviana and the Memphis community with this investment."
It is the seventh expansion project at the facility since it opened in 2006. Most recently, in April 2021, Riviana invested $15 million to upgrade production and expand instant rice capacity. Demolition and construction work is expected to begin during the first quarter 2023 with new production capacity utilization starting in the first quarter 2024.
The expansion and renovation project will be supported by an 11-year payment-in-lieu-of-taxes (PILOT) incentive awarded by the Economic Development Growth Engine Industrial Development Board of the City of Memphis and County of Shelby, Tennessee. Riviana wants to thank the EDGE Board and the many other people and organizations that have provided guidance and/or financial support for this investment: The Honorable Jim Strickland, Mayor of the City of Memphis; The Honorable Lee Harris, Mayor of Shelby County; The Greater Memphis Chamber of Commerce; State of Tennessee Office of Economic and Community Development; Workforce Mid-South; Memphis Light, Gas and Water; and The Tennessee Valley Authority Office of Regional Economic Development.
Headquartered in Houston, Texas, Riviana Foods Inc. is committed to producing the cleanest, most wholesome rice products available. With more than 100 years of experience, Riviana is America's leading rice company and the world's largest marketer of wild rice. The Riviana family of well known brands includes Minute®, Success®, Mahatma®, Carolina®, Adolphus®, RiceSelect®, Tilda® and Gourmet House®.
As a wholly-owned subsidiary of Ebro Foods, the world leader in the rice sector with a leading position in fresh and premium pasta, Riviana has a truly comprehensive view of the rice business.
Based in Spain, Ebro Foods conducts business in the rice, pasta and sauces sectors across the globe through its extensive network of subsidiaries and brands in more than 80 countries spanning Europe, North America, Asia and Africa. This relationship enhances both Riviana's products and company by providing access to a worldwide network of raw material sourcing, world-class research and development centers, cutting-edge technology and product innovations.
View original content to download multimedia:
SOURCE Riviana Foods Inc. | https://www.whsv.com/prnewswire/2022/09/07/riviana-foods-invests-806-million-memphis-plant/ | 2022-09-07T11:57:29Z |
Fund I is the largest first-time real estate private equity fund raised entirely in 2022
DALLAS, Sept. 7, 2022 /PRNewswire/ -- S2 Capital ("S2"), a national value-add multifamily investor, today announced the final close of the S2 Multifamily Value-Add Fund I, LP ("Fund 1"), which closed at its hard cap of $400 million in investor and co-invest commitments in just eight months, greatly exceeding its target of $250 million. S2's debut Fund I attracted an investor base of various institutional investors, family offices, investment banks, and high net worth individuals. The firm currently has $6 billion of multifamily assets under management.
S2 focuses on value-add multifamily investing in prime Sunbelt locations. The firm has developed a vertically integrated platform which creates efficiencies in operations and construction that optimize returns.
"We are grateful for the support of our investors in raising our first fund, especially through the challenging financial markets of recent months," said Scott Everett, CEO of S2. "This year marks our firm's 10th anniversary, and we see the rapid closing of Fund I as a testament to S2's strong record of results in value-add multifamily investing and LPs' desire to invest in sector specific operator led investment vehicles."
About S2 Capital
Founded in 2012, S2 Capital is a Dallas-based national multifamily investment platform specializing in value-add properties. With approximately $10 billion in transaction volume, S2 has acquired approximately 46,000 units through 134 acquisitions, and has successfully invested over $500 million in upgrades and renovations. S2 is vertically integrated, comprised of affiliated businesses including acquisitions, construction, asset management, and operations divisions that work closely together to execute the firm's business plan. The firm concentrates its investments in the U.S. Sunbelt, including Arizona, Florida, Georgia, North Carolina, and Texas, where job and population growth is expected to outpace the national average and contribute to significant renter demand. For more information, visit www.s2cp.com.
Media Contact
Lisa Baker
Lambert
lbaker@lambert.com
(603) 868-1967
View original content:
SOURCE S2 Capital | https://www.whsv.com/prnewswire/2022/09/07/s2-capital-announces-final-close-its-multifamily-fund-i-400-million/ | 2022-09-07T11:57:36Z |
TME Is The Superbowl of Fashion Shows With Over 800 Models Set To Hit The Runway All In A Day
NEW YORK, Sept. 7, 2022 /PRNewswire/ -- The Model Experience (TME) is truly gearing up to turn their New York Fashion Week (NYFW) into a festival! With back to back shows taking place on Sunday, September 11th featuring performances from Billboard-charting raptress Coi Leray as well as Saucy Santana (who's fresh off his MTV Video Music Awards performance) rocking the runway stage! Plus a highly anticipated fashion-forward curated DJ set by artist/model Shaun Ross! "We've done many shows in Los Angeles over the years, but we're beyond excited to tap into the New York Fashion Scene," says TME founder Ashley Covarrubias.
"New York is the Mecca when it comes to Fashion. Our show is different because it's inclusive and our talent pool is unmatched. Our designers will be showing everything from streetwear to couture. 800 Models are expected to hit the Runway. Most of the models we work with are unsigned, this is their big break. When you think of NYFW, the high-fashion shows are really raw and industrial. We wanted to emulate that feeling. We're excited to bring this vision to life at our first-ever NYFW show, and the support from our New York models has been amazing, " explains the founder.
For over a decade TME has been giving up-and-coming models the chance to walk the runway. The glowing community will also bring a new element to their brand, as they manifest a New York satellite show that's been in the works for many seasons. As Ashley Covarrubias has shared about her organization, "we truly provide the model experience that aspiring talents need, and with accolades like placements in Vogue with designers who've gone on to work with stars like Cardi B, our reputation is golden." Nicknamed "the super bowl of fashion shows," the TME event will unveil dozens of designers' newest collections. In addition, TME already has a sold out 3-day Los Angeles Fashion Week (LAFW) show with soon-to-be released celebrity designers and performances, including artist Bia, starting October 7th.
For media credentials please complete this application. For further inquiries contact Echo Hattix at info@echoingsoundz.net
View original content to download multimedia:
SOURCE The Model Experience | https://www.whsv.com/prnewswire/2022/09/07/saucy-santana-coi-leray-perform-model-experience-new-york-fashion-week-nyfw-event/ | 2022-09-07T11:57:42Z |
ARLINGTON, Va, Sept. 7, 2022 /PRNewswire/ -- Science and Medicine Group Inc. (SMG), a data intelligence company providing actionable insights about hard-to-reach audiences in life sciences and healthcare, today announced that it has acquired the assets of Amplion Inc., an innovator in AI-powered data intelligence for life science marketing and sales teams seeking to identify business opportunities and accelerate sales growth.
The integration of the Amplion knowledgebase and next-generation data architecture will immediately expand SMG's capabilities to deliver more comprehensive, actionable insights to commercial organizations at life science equipment and reagent manufacturers as well as pharmaceutical services providers.
"With the Amplion acquisition, Science and Medicine Group is taking decisive action to build the premier data intelligence company serving commercial operations in the life science and healthcare industries. This is the fourth strategic acquisition we have made, and we continue to look for opportunities that expand our unique positioning in the market and accelerate our growth," said Sam Osman, CEO, Science and Medicine Group.
Amplion's machine learning-based capabilities enable commercial teams to precisely target the right accounts and most appropriate, and often hard-to-reach, decision makers in pharma, biotech and academia. The Amplion platform and intuitive browser-based user interface provides new levels of hyper-personalized targeting, prospecting, scalability, speed and automation to improve sales and marketing far beyond conventional methods and existing manually searched contact databases. The Amplion knowledgebase analyzes more than 35 million data sources in real-time to generate detailed insights using AI and machine learning on 8 million+ individual contacts across approximately 21,000 organizations globally.
Among the users of the Amplion platform is NanoCellect, a San Diego-based provider of microfluidic flow cytometry technologies who was seeking a better way to find and qualify leads. "We can describe the type of group that we would like to target, but actually finding the right name and contact that is relevant for somebody that would be interested in our product and to initiate that conversation is very challenging," said Paul DiGregorio, NanoCellect's VP Commercial. (listen to full interview in this video)
"We're now setting records in terms of our monthly lead generation activities. We have clearly been able to demonstrate that the investment in the Amplion tool for our inside sales organization has been a positive, successful investment for us and will be part of our long-term strategy," he added.
"Science and Medicine Group's customers now have access to a purpose-built, machine learning platform for life science commercial teams, while Amplion's customers are assured of continued support and long-term investment from a well-established company to further enhance the platform's capabilities," said Ed Burnham, who is the Head of Market Research & Analytics and is leading the Amplion business at SMG. "This is another step forward in our growth strategy of integrating existing and new data sources to create new intelligence-enabled products and services and building bridges between all of SMG's brands to unlock significant value for our customers."
To read more about Amplion's capabilities to support sales, marketing and business development in the commercial life sciences industry, go to www.amplion.com.
Science and Medicine Group is on a mission as a premier data intelligence company to deliver actionable insights about hard-to-reach audiences in science and medicine. The company is actively expanding its portfolio of data intelligence solutions, building on the longstanding success of its well-known market research brands, such as Bioinformatics and Kalorama, its media sites, such as auntminnie.com and LabPulse, and the Science Advisory Board, a network of scientists immersed in biological research, drug discovery and biopharmaceutical production. The company's breadth of data-driven offerings and value creation across its world-class brands is powering customer product growth and commercialization efforts to create competitive advantages for its customers. The company is based in Arlington, VA. For more information, visit www.scienceandmedicinegroup.com.
View original content to download multimedia:
SOURCE Science and Medicine Group Inc | https://www.whsv.com/prnewswire/2022/09/07/science-amp-medicine-group-expands-commercial-data-insights-leader-with-amplion-acquisition/ | 2022-09-07T11:57:49Z |
BOSTON and PARIS, Sept. 7, 2022 /PRNewswire/ -- Shift Technology, a provider of AI-driven decision automation and optimization solutions for the global insurance industry today announced the formation of the company's Healthcare Advisory Board and the appointment of Seema Verma, the former administrator for Center for Medicare and Medicaid Services (CMS), as a strategic advisor to the company and the inaugural member of the Healthcare Advisory Board. The Shift Healthcare Advisory Board will help the company address the key issues facing the healthcare payor system, and support the continued development of the technology solutions required to solve these complex challenges.
According to the National Health Care Anti-Fraud Association (NHCAA), the impact of healthcare fraud in the United States could be close to $300 billion. When considering other forms of waste and abuse, the total is estimated to be over $1.5 trillion. Through the company's Healthcare Improper Payment Detection solution, Shift is working to mitigate the impact of FWA in both private and public healthcare payor organizations. Shift's AI-native improper payment detection platform leverages advanced data science techniques to allow for the discovery of a significantly higher percentage of FWA, with greater accuracy and efficiency. The platform leverages sophisticated AI and ML healthcare models, built on internal and external data, and a comprehensive health plan data model to spot hidden FWA.
"There is an amazing opportunity to drive significant bottom-line improvement for health plans and we are thrilled to collaborate with one of the best minds in the industry to help us realize our vision," said Salil Punalekar, head of U.S. healthcare, Shift Technology. "Traditional static rule-based decision models are outdated and insufficient to identify the wide scope of improper payments plaguing payors. There is a clear need for comprehensive data driven approaches and technologies to help payors dramatically reduce the impact of FWA on their organizations and their members."
"What Shift brings to the fight against health insurance FWA is truly exceptional and could help the industry save billions of dollars in improper payments," continued Verma, Healthcare Advisory Board member, Shift Technology. "I am proud to share what I have learned throughout my career with this industry pioneer to help make health insurance better for everyone involved in the process."
Verma is a national health policy expert and was the longest serving Centers for Medicare and Medicaid (CMS) Administrator in modern history. At CMS, she oversaw health insurance programs for over 140 million Americans; managed a budget of $1.3 trillion, which represents almost a third of the federal budget; and led over 6,000 employees. Further, she spearheaded the implementation of more than sixteen strategic initiatives aimed at transforming the American health care system to lower costs, improve quality, and increase access. Her leadership of federal government efforts to infuse market competition, empower patients, and unleash innovation – including efforts to require price and quality transparency while ensuring patients have ownership over their portable medical records – produced historic reforms across CSM.
"Seema's belief in the Shift platform, its ability to drive intelligent decisioning throughout payor organizations, and its potential to drive meaningful impact to our customers makes her an ideal member of our advisory board," said Jeremy Jawish, CEO and co-founder, Shift Technology. "That she decided to participate is further validation of our value proposition and the hard work that has gone into building our products."
Shift Technology delivers AI decisioning solutions to benefit the global insurance industry and its customers. Our products enable insurers to automate and optimize decisions from underwriting to claims, resulting in superior customer experiences, increased operational efficiency, and reduced costs. The future of insurance starts with Decisions Made Better. Learn more at www.shift-technology.com.
Contacts:
Rob Morton
Corporate Communications
Shift Technology
+1.617.416.9216
rob.morton@shift-technology.com
View original content to download multimedia:
SOURCE Shift Technology | https://www.whsv.com/prnewswire/2022/09/07/seema-verma-joins-shift-technologys-healthcare-advisory-board/ | 2022-09-07T11:57:55Z |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.